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Summary 
 
DNA Topoisomerases are an important family of enzymes that catalyze the 
introduction of topological changes at the level of the DNA molecule and are required for 
several vital cellular processes such as replication, transcription, DNA recombination and 
chromosome segregation. The activity of Topoisomerases type II (Topo2) relies on the 
introduction of a transient DSB in the DNA strand by formation of a covalent bond 
between the enzyme and the nucleic acid molecule. This reversible covalent interaction 
promotes unwinding of topological events by allowing the passage of another strand 
through the formed gap, followed by ligation of DNA ends. The ability of Topo2 to relax 
positively supercoiled DNA defines its role as a determinant factor in both replication and 
transcription. Topo2 is the target for several clinically relevant anti-cancer drugs, such as 
Etoposide and Idarubicin, commonly referred to as Topo2 poisons, which stabilize the 
cleavage complex formed between the enzyme and DNA during its catalytic activity, thus 
preventing religation of broken DNA ends. When a DNA-tracking system, such as 
replication and transcription complexes, collides with the cleavage complex they leave a 
permanent double-strand break (DSB) in its place. If these breaks are not properly 
repaired, they can lead to chromosome translocations, increased genomic instability and 
even trigger apoptotic cell death. Most studies focusing on DSB repair have used ionizing 
radiation (IR) as the lesion inducing agent. However, DSBs introduced by IR are 
intrinsically more complex to repair because of the base modifications and sequence 
deletions that they often involve, whereas Topo2-mediated DSBs are stabilized by an 
enzyme and cleavage is performed in a precise manner, allowing for DNA end homology 
to be preserved.    
It is known from studies using irradiation that heterochromatin (HC) and 
euchromatin (EC) represent separate entities with respect to both damage sensitivity and 
repair. The high degree of compaction present in heterochromatin is thought to protect 
DNA from damage although, when lesions do occur, this compaction further restricts the 
capability of DNA damage response proteins to access the site to properly signal and 
mediate repair. Indeed, DNA damage introduced by IR in HC has been shown to be 
refractory to repair and resolved with slower kinetics than in EC. However, not much is 
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known about how these repair kinetics are affected by the particular nature of Topo2-
induced lesions and the restrictions imposed by chromatin structure on its enzymatic 
activity.   
Eukaryotic cells have evolved two major conserved pathways to repair DSBs in order to 
prevent transmission of genomic defects to their offspring: Non-Homologous End Joining 
(NHEJ) and Homologous Recombination (HR). HR only functions in later S or G2 phases of 
the cell cycle since it requires an available sister chromatid to use as template for faithful 
repair. NHEJ is active throughout the entire cell cycle and is the only DSB repair pathway 
available in G1 when there are no twin templates for HR. However, since it joins broken 
DNA ends regardless of sequence homology, there is a risk of introducing sequence errors 
during repair, such as deletions and translocations. 
In the present thesis we aimed to characterize how each of the two main DSB 
repair pathways, NHEJ and HR, contributes to repair of Topo2-mediated DSBs. This was 
done for separate cell cycle phases using a protocol for cell cycle synchronization based 
on a double-thymidine block. Cells with DSBs introduced by a short pulse of the Topo2 
poison Etoposide were monitored for their cell cycle progression and usage of repair 
factors over a period of 24h after Etoposide exposure. We found a diverging pattern of 
DSB repair system usage between lesions introduced in different cell cycle stages. We 
also used cell lines deficient for either BRCA1, the major determinant of HR pathway 
initiation, or DNAPKcs, the catalytic core unit of the complex that initiates NHEJ, to 
investigate whether behavior of DNA damage checkpoints is dependent on the choice of 
repair system. Loss of DNAPKcs dramatically sensitized HCT116 cells to Topo2-mediated 
DSBs, whereas similar loss of BRCA1 did not induce a dose-dependent cell viability decline 
much beyond spontaneous levels, highlighting the importance of NHEJ as the system that 
handles the bulk of these lesions.  
Overall, our results highlight G2 as a critical “workstation” phase for DSB repair, 
particularly for lesions introduced in heterochromatin. These lesions were predominantly 
repaired by HR, therefore leading to an increase in Chk1 recruitment and prolongation of 
G2/M arrest.  DSBs introduced in G2, by contrast, did not induce sufficient activation of 
HR to sustain a stable checkpoint arrest, leading to slippage of cells with unrepaired DSBs 
into mitosis which is associated with an increased risk of genomic instability. We also 
found that cells damaged in late S phase, when heterochromatin is the preferential target 
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for Topo2, trigger a strong HR activation, whereas for cells damaged in early S, when 
Topo2 is focused on euchromatin, this was not observed. We conclude therefore that HR 
in G2 preferentially targets a specific subset of DSBs that are located in heterochromatin 
regions. 
We propose a model where slippage through checkpoint arrest is also a major 
determinant of repair system usage, particularly for DSBs arising in G1 and G2 phases 
since escaping arrest and passing to the following cell cycle phase will change the 
availability of repair pathways. Because of intrinsic limitations of the checkpoints 
operating at these stages, we conclude that a significant number of DSBs introduced in G1 
are repaired by HR in S and G2 phases, while DSBs induced in G2 are mostly repaired by 
NHEJ in both G2 and G1. 
In this thesis we also provide evidence that generalized disruption of heterochromatin 
epigenetic marks sensitizes cells to the DNA damaging action of Etoposide-bound Topo2. 
By using an inhibitor of histone methylation, DZNep, prior to Etoposide, we could robustly 
determine synergistic interactions between these two drugs. This highlights the potential 
for use of DZNep in combination with existing drugs targeting Topo2 in the chemotherapy 
of cancer.  
Finally, we also present a new published methodology for accurate quantification 
of cell cycle dynamics by flow cytometry yielding absolute values (in units of time) based 
on the unique stoichiometric properties of the thymidine analogue EdU (5-ethynyl-2’-
deoxyuridine).  
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Resumo 
 
DNA Topoisomerases são uma importante família de enzimas que catalizam a 
resolução de problemas topológicos ao nível da molécula de DNA e a sua actuação é 
necessária em processos celulares essenciais, como por exemplo, na replicação, na 
transcrição, na recombinação de DNA e na segregação dos cromossomas. A actividade 
das Topoisomerases de tipo II (Topo2) é baseada na introdução de uma quebra na dupla 
cadeia (double strand break; DSB) de DNA através da formação de uma ligação covalente 
entre o enzima e o ácido nucleico. Esta interacção reversível promove o 
desembaraçamento de problemas topológicos ao permitir a passagem de outra cadeia de 
DNA pela quebra que é formada, seguida da ligação das extremidades de DNA. A 
capacidade da Topo2 de relaxar DNA na conformação supercoiled positiva define o seu 
papel como factor determinante na replicação e na transcrição. A Topo2 é alvo de várias 
drogas anti-cancro clinicamente relevantes, tais como Etoposido e Idarrubicina, 
vulgarmente designadas de venenos de Topo2, que estabilizam o complexo de clivagem 
formado entre o enzima e o DNA durante a actividade catalítica, impedindo a religação 
das extremidades de DNA quebradas. Quando um sistema que percorre o DNA, tais como 
os complexos de replicação ou transcrição, encontra o complexo de clivagem, a 
resultante excisão da enzima deixa no seu lugar um DSB permanente. Se estas quebras 
não forem propriamente reparadas podem levar a translocações cromossómicas, 
aumento da instabilidade genética e até desencadear a morte celular por apoptose. A 
maioria dos estudos realizados sobre reparação de DNA usaram radiação ionizante como 
o agente indutor de lesões. Contudo, os DSBs introduzidos por IR são intrinsecamente 
mais complexos de reparar devido às bases modificadas e à deleção de sequências que 
eles normalmente envolvem, enquanto que DSBs mediados por Topo2 são estabilizados 
por um enzima e a clivagem é realizada de maneira precisa, permitindo que a homologia 
entre as extremidades seja preservada.  
Estudos usando radiação permitiram estabelecer que a heterocromatina (HC) e a 
eucromatina (EC) representam entidades separadas no que diz respeito à sua 
sensibilidade a danos e capacidade de reparação. Pensa-se que o elevado grau de 
compactação da heterocromatina proteja o DNA da ocorrência de lesões mas, quando 
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elas acontecem, esta compactação restringe o acesso de factores de reparação de DNA 
ao local da lesão para sinalizarem e mediarem a reparação. De facto, já foi demonstrado 
que danos de DNA introduzidos em HC por radiação ionizante (IR) são reparados com 
uma cinética mais lenta que em EC. No entanto, ainda não é conhecido como esta 
cinética de reparação é afectada pela natureza particular das lesões mediadas por Topo2 
e pelas restrições impostas pela estrutura da cromatina sobre a sua actividade 
enzimática.  
As células eucariontes desenvolveram dois mecanismos principais de reparação de 
DSBs de modo a prevenirem a transmissão de defeitos genéticos à sua descendência: a 
ligação de extremidades não homólogas (Non-Homologous End Joining; NHEJ) e a 
recombinação homóloga (Homologous Recombination; HR). A HR só pode funcionar no 
fim da fase S ou na fase G2 do ciclo celular uma vez que requer que esteja disponível um 
cromatidio irmão para ser usado como base para uma reparação fidedigna. A NHEJ está 
activa ao longo de todo o ciclo celular e é a única via de reparação de DSBs disponível em 
G1 pois nesta fase ainda não existem cromatidios irmãos para a HR. No entanto, como 
esta via simplesmente faz a junção directa de extremidades de DNA partidas sem se 
importar com a homologia das sequências, existe o risco de introduzir erros na sequência 
de DNA durante a reparação, tais como deleções e translocações.     
Na presente tese procurou-se caracterizar como cada um dos dois sistemas de 
reparação de DSBs, NHEJ e HR, contribui para a reparação de DSBs mediados por Topo2. 
Isto foi feito separadamente para cada uma das fases do ciclo através do uso de um 
protocolo de sincronização de ciclo celular baseado num duplo bloqueio com timidina. 
Células com DSBs introduzidos por um curto pulso com o veneno de Topo2 Etoposido 
foram monitorizadas quanto à sua progressão no ciclo e ao uso de factores de reparação, 
durante um período de 24h após exposição ao Etoposido. Verificou-se a existência de um 
padrão divergente quanto ao uso de sistemas de reparação entre lesões introduzidas em 
diferentes fases do ciclo. Foram também usadas linhas celulares com deficiência em 
BRCA1, o principal determinador do início da HR, ou em DNAPKcs, a subunidade catalítica 
do complexo que inicia a NHEJ, para investigar se o comportamento dos checkpoints de 
danos de DNA é dependente da escolha de sistema de reparação. A perda de DNAPKcs 
sensibilizou dramaticamente células de cancro do cólon HCT116 a DSBs mediados por 
Topo2, enquanto que a perda de BRCA1 não induziu uma perda de viabilidade celular 
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dependente da dose de Etoposido muito acima dos níveis espontâneos, realçando a 
importância da NHEJ como sistema que se encarrega da maioria destas lesões. 
Acima de tudo, os nossos resultados indicam que a fase G2 é uma “oficina” para 
reparação de DSBs, particularmente para lesões introduzidas em heterocromatina. Estas 
lesões foram predominantemente reparadas por HR, levando consequentemente a um 
aumento no recrutamento de Chk1 e prolongamento da paragem em G2/M. DSBs 
introduzidos em G2, por contrário, não induziram activação de HR suficiente para manter 
uma paragem por checkpoint, levando a passagem de células com lesão por reparar para 
mitose, o que está associado com um aumento do risco de instabilidade genómica. 
Também verificámos que células cujo DNA é danificado mais tarde dentro da fase S, 
quando a heterocromatina é o alvo preferencial da Topo2, despoletam uma forte 
activação da HR, enquanto que em células danificadas no início de S, quando a Topo2 está 
focada na eucromatina, isto não foi observado. Concluímos assim que a HR em G2 visa 
uma fracção específica de DSBs que está localizada em regiões de heterocromatina.  
Propomos então um modelo onde a fuga à paragem por checkpoint é também um 
factor que determina a escolha de sistema de reparação, particularmente para DSBs que 
surjam nas fases G1 e G2, uma vez que ao evitar a paragem e passando para a fase celular 
seguinte a disponibilidade dos factores de reparação é alterada. Devido às limitações 
intrínsecas dos checkpoints que operam nestas fases, concluímos que um número 
significante de DSBs introduzidos em G1 são reparados por HR nas fases S e G2, enquanto 
que DSBs introduzidos em G2 são reparados pela NHEJ tanto em G2 como em G1. 
Nesta tese também mostramos evidências que a disrupção generalizada de 
marcas epigenéticas de heterocromatina sensibiliza o DNA das células à acção 
danificadora da Topo2 quando esta se liga ao Etoposido. Através do uso de um inibidor de 
metilação de histonas, DZNep, antes da adição de Etoposido, conseguimos determinar 
interacções sinergéticas entre estas duas drogas. Isto realça o potencial para o uso de  
DZNep em combinação com drogas já existentes, cujo alvo é a Topo2, na terapia do 
cancro. 
Finalmente, apresentamos ainda uma nova metodologia, já em publicação, que 
permite a quantificação precisa da cinética do ciclo celular por citometria de fluxo, 
fornecendo valores absolutos (em unidades de tempo) baseada nas propriedades 
particulares do análogo de timidina EdU (5-ethynyl-2’-deoxyuridine). 
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γH2AX   Histone 2A variant X phosphorylated in serine 139 
53BP1   p53-binding protein 1 
ATM   Ataxia telangiectasia mutated 
ATR   Ataxia telangiectasia and Rad3 related 
ATP   adenosine triphosphate 
BRCA1   Breast cancer type 1 susceptibility factor  
BrdU   5-bromo-2′-deoxyuridine 
Cdc   Cell division cycle 
Cdk   Cyclin-dependent kinase 
Chk   Checkpoint kinase  
CK2   Casein kinase 2  
CPT   Camptothecin 
CT   chromosome territories 
CtIP   C-terminal binding protein (CTBP)-interacting protein 
DAPI   4',6-diamidino-2-phenylindole 
DDR   DNA damage response 
D/J/F   Dean/Jett/Fox algorithm 
DNA   Deoxyribonucleic acid 
DNAPK  DNA-dependent protein kinase 
DNAPKcs  DNA-dependent protein kinase, catalytic subunit 
DSB   double-strand break 
DZNep   3-deazaneplanocin A 
EC   Euchromatin 
E-CFI   EdU-coupled Fluorescence Intensity analysis 
EdU   5-ethynyl-2’-deoxyuridine 
Etop   Etoposide 
EZH2   Enhancer of zeste homologue 2  
FLM   Fraction-of-labelled mitosis  
GDP   guanoside triphosphate 
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H3K9me2  Histone 3 dimethylated in lysine 9 
H3K9me3  Histone 3 trimethylated in lysine 9 
H3K27me3  Histone 3 trimethylated in lysine 27 
H4K20me3  Histone 4 trimethylated in lysine 20 
HAT   Histone acethyltransferase 
HC   Heterochromatin 
HDAC   Histone deacethylase 
HDM   Histone demethylase 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HMT   Histone methyltransferase 
HP1   Heterochromatin protein 1 
HR   Homologous Recombination 
JAK2   Janus kinase 2 
K   lysine 
KAP1   KRAB domain associated protein 1 
MDC1   Mediator of DNA damage checkpoint protein 1 
MEFs   mouse embryonic fibroblasts 
mESCs   mouse embryonic stem cells 
MFI   mean fluorescence intensity 
mRNA   messenger RNA 
MRN   Mre11, Rad50 and NBS1 complex 
NHEJ   Non-Homologous End Joining 
PCNA   Proliferating cell nuclear antigene 
PI   propidium iodide 
Plk   Polo-like kinase 
pRb   phosphorylated Retinoblastoma protein 
PRC   Polycomb Repressor Complex 
PTIP   Pax transactivation-domain interacting protein 
RIF1   Regulation timing regulatory factor 1 
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1. General Introduction 
 
 
1.1 . Chromatin structure and histone modifications   
 
 
In all eukaryotes, the genetic information that comprises the genome is stored in 
the cell nucleus. Yet the entire length of genomic DNA of an organism would not be able 
be packed inside its nucleus if it was randomly folded. DNA-binding proteins called 
histones must coordinate the folding of genomic DNA into an extremely condensed DNA-
protein complex known as chromatin, which is basically a repetition of units formed by 
histones and DNA called “nucleosomes”, first described by Kornberg in 1974 (Kornberg, 
1974). Each nucleosome is an octamer of four core histones (two copies each of histones 
H2A, H2B, H3 and H4) around which are coiled approximately 146 DNA base pairs. 
Another histone, H1, acts as a physical link, along with “linker” DNA, between adjacent 
nucleosome core particles. These evolutionally conserved proteins are globular except for 
their N-terminal domains, commonly designated as histone “tails”, which are 
unstructured and protrude from the nucleosome core.  A particular characteristic of the 
tails is the vast number of post-translational covalent modifications their amino acids can 
acquire, the most common being phosphorylation, acetylation, methylation, 
ubiquitination and sumoylation. These modifications or “marks” are reversible, allowing 
cells to adjust their occurrence in chromatin by means of specific histone modifying 
enzymes (Santos-Rosa & Caldas, 2005).   
Some of the modifications to nucleosomal histone tails, particularly methylation 
and acetylation, can affect the chromatin condensation state by changing the affinity of 
histones for DNA or adjacent nucleosomes. This allows chromatin regions to be 
remodelled into two different configurations: a loosely coiled or “open” state when the 
interactions between DNA and histones are weakened that facilitates access for 
transcription factors, referred to as euchromatin (EC), and a tightly coiled or “closed” 
state when interactions are strengthened that suppresses transcription, referred to as 
heterochromatin (HC) (Fig.1). While all known histone acetylations are associated with 
relaxing chromatin structure, their presence being notably enriched at promoter regions 
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and at the 5’-end of genes, methylations can have competing effects according to the 
number of methyl groups added (either one, two or three), the amino acid residue 
targeted and internal cell signalling conditions (Kouzarides, 2007). As examples, di- and 
trimethylated histone H3 at lysine 9 (H3K9me2 and me3) and trimethylated histone H3 at 
lysine 27  (H3K27me3) are hallmarks of transcriptionally silent genes, whereas active 
genes display di- and trimethylated histone H3 at lysine 4 (H3K4me2 and me3) along with 
methylations in lysine 36 (H3K36) (Bach & Hegde, 2016). Other modifications can also 
have an impact on gene expression by stabilizing or weakening binding sites for 
regulatory proteins, either repressors or activators of transcription (e.g. sumoylations are 
typically repressive and phosphorylations activating; cf. Table 1) (Choudhuri, 2011). 
 
Figure 1. Chromatin structure and function. Chromatin is made up of repeating units of nucleosomes 
consisting of 146 base pairs of DNA wrapped around dimers of four histone proteins (H2A, H2B, H3, 
and H4). The exposed amino-terminal tails of nucleosomal histones are subjected to post-translational 
modifications. Combinatorial effects of histone modifications and DNA methylation regulate the 
chromatin structure between transcriptionally silent “heterochromatin” and active “euchromatin.” 
Enrichment of DNA methylation in promoters and histone modifications such as H3K9me3, H3K27me3, 
and H4K20me3 promote nucleosome condensation to repress transcription (heterochromatin). On the 
other hand, histone modifications H3 or H4KAc and H3K4me promote open chromatin formation and 
increase accessibility to the transcription machinery, leading to active transcription (euchromatin). 
Other histone modifications such as Ser/Thr phosphorylation, ubiquitination and SUMOylation, and 
non-coding RNAs including microRNAs also regulate chromatin structure and function (not shown). 
Genome-wide patterns of DNA methylation and histone modifications are referred to as the 
“epigenome.” Its response to internal and external signals regulates gene expression involved in 
diverse biological processes and disease conditions. KAc, lysine acetylation. From Reddy, Park, & 
Natarajan, 2012. 
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Covalent histone modifications are precisely regulated epigenetic events in which 
a vast number of enzymes can participate and  great efforts have been made since the 
beginning of the 21st century to characterize these modifications on a genome-wide scale, 
partly thanks to the development of new technologies such as chromatin 
immunoprecipitation (ChIP) that allow to globally assess the incidence of these marks 
(Barski et al., 2007). The combination of these studies led researchers to propose that 
multiple histone marks could occur sequentially to form a combination or “code” for 
distinct downstream responses, such as chromosome condensation, DNA repair and 
transcription activation or repression (Strahl & Allis, 2000). Phosphorylation of histone 3 
at serine 10 (H3S10), for example, stimulates acetylation of histone 3 lysine 14 (H3K14), 
while ubiquitination of histone H2B at lysine 120 (H2BK120) stimulates methylation of 
histone H3 at lysine 4 (H3K4), both cases contributing to transcription activation 
(Choudhuri, 2011). Understanding if there is an underlying histone code in critical 
epigenetic events and how to read it is still one of the major focuses of epigenetics to this 
day, particularly for diseases that arise due to deregulation of gene expression in relation 
to abnormal histone modification patterns.  A key example is the silencing of tumor 
suppressor genes by disturbances in histone methylation and acetylation as a result of 
mutations in histone modifying enzymes and chromatin remodelers, which consequently 
elevates chromatin structure to a decidedly relevant topic for cancer research and 
potential target for therapeutic strategies (Kelly & Issa, 2017). 
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1.2 . Chromatin modifying enzymes and cancer 
 
 
Normal histone modification states in cells are maintained through a combination 
of enzymes that place or remove those particular marks in histone tails. Alterations in the 
activity or expression of these enzymes have been associated with a variety of human 
diseases, namely many oncologic disorders (cf. Table 2) (Ma & Zhang, 2016).    
Acetylation is controlled by means of histone acetyltransferases (HATs) and 
histone deacetylases (HDACs). These classes of enzymes are considered major chromatin 
remodelling factors due to the capability of acetyl groups to neutralize the natural 
positive charge of lysine residues in nucleosomes. This reduces their electrostatic 
attraction to negatively charged DNA, resulting in the unfolding of chromatin (Kouzarides, 
2007). HDAC inhibitors are currently the largest group of epigenetic drugs being 
developed for clinical use in cancer therapy by virtue of their confirmed anti-tumor 
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effects. They are believed to act mostly by restoring expression of tumor suppressor 
genes that are silenced due to abnormal heterochromatin formation, a feature of many 
known cancers. Several of these drugs have already been approved for clinical use in T-
cell lymphomas (e.g. vorinostat, belinostat and romidepsin), although reported response 
rates do not exceed 35% indicating that HDAC inhibitors by themselves might only be 
effective on a subset of patients (Kelly & Issa, 2017). Other studies have focused on 
inhibiting proteins that “read” the acetyl modification on histones. These proteins 
recognize acetyl group through their active bromodomains and have been shown to be 
mutated in some tumors, leading to increased oncogene expression (Stathis et al., 2016). 
Histone methylation is catalysed by histone methyltransferases (HMTs) and 
removed by histone demethylases (HDMs). HMTs transfer a methyl group to histone tails 
from a high energy donor, S-adenosyl methionine, but contrary to acetyl groups this does 
not neutralize a positive charge on histones therefore not causing direct conformational 
changes in nucleosomes. However, specific histone methylations can serve as binding 
platforms for chromatin remodelling effectors. For example, trimethylation of lysine 9 of 
histone 3 (H3K9me3) by the HMT SUV39 creates a binding site for heterochromatin 
protein-1 (HP1). HP1 is a mediator of heterochromatin formation and expansion, thereby 
promoting transcription silencing (Cann & Dellaire, 2011). An example seen in yeast is 
methylation of histone H3 at lysine 4 (H3K4me) which recruits a component of the NURF 
(nucleosome remodelling factor) complex to activate expression of developmental genes, 
while at the same time disrupting the binding of the repressive NuRD  (nucleosome 
remodelling deacetylase) complex (Kouzarides, 2007). Finally, trimethylation of histone 
H3 at lysine 27 (H3K27me3) is associated with transcriptional silencing of genes involved 
in fundamental cell processes such as cell cycle regulation, cell differentiation and 
senescence, including many genes involved in tumor suppression. This mark is placed by 
the methyltransferase EZH2 (enhancer of zeste homolog 2), the catalytic core protein in 
the polycomb repressor complex 2 (PRC2). H3K27me3 subsequently recruits the 
polycomb repressor complex 1 (PRC1) to ubiquitinate lysine 119 of histone H2A 
(H2AK119ub1) to prevent transcriptional elongation. EZH2 is overexpressed in many 
forms of cancer including breast, prostate, colon, lung, sarcoma and lymphomas, which 
makes it an appealing target for inhibition. In fact, drugs that target EZH2 have shown 
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promise in clinical trials, with several EZH2 inhibitors currently being developed (C.-J. 
Chang & Hung, 2012; Kelly & Issa, 2017). 
As mentioned before, histone phosphorylation is a transcription activating 
modification catalysed by kinases and removed by phosphatases that adds a negatively 
charged phosphate, usually from ATP or GDP donors, to amino acid residues in histone 
tails. Similarly to acetylation, the negatively charged phosphate contributes to disrupting 
DNA-histone electrostatic interactions thereby allowing better accessibility of 
transcription factors to DNA. Alterations in histone phosphorylation patterns are found in 
many cancers. An example is Janus Kinase 2 (JAK2), responsible for the phosphorylation 
of histone 3 on tyrosine 41 (H3Y41ph) that inhibits binding of the HP1α isoform to 
chromatin (Dawson et al., 2009). JAK2 is mutated in the majority of myeoloproliferative 
neoplasias and inhibitors for this kinase are being used clinically (Ma & Zhang, 2016). 
Additionally, the kinase Aurora B responsible for phosphorylation of histone H3 at Serine 
10 (H3S10ph), an important activator mark associated with mitosis and repression of 
heterochromatin propagation, is overexpressed in several carcinomas and is targeted for 
inhibition (Johansen & Johansen, 2006; Ma & Zhang, 2016). Because of its role in DNA 
damage repair, it is also worth mentioning phosphorylation of histone H2AX (a variant of 
H2A) at serine 139 by Ataxia Telangiectasia Mutated (ATM), Ataxia Telangiectasia and 
Rad3-related (ATR) and DNA-dependent Protein Kinase (DNAPK) which generates gamma-
H2AX (γH2AX), a key signalling modification that accumulates at sites of major DNA 
lesions and initiates recruitment of repair factors. Since patients that suffer from 
mutations in these enzymes display decreased efficiency in repairing DNA breaks resulting 
from errors in transcription or replication, they have a high predisposition for tumors 
(Zeman & Cimprich, 2014; Awasthi, Foiani & Kumar, 2016).    
Histone modifications are thus promising targets for cancer therapy since they can 
affect chromatin condensation to not only reverse the silencing of tumor suppressor 
genes, but also to potentially allow easier access by DNA damaging agents to chromatin, 
which could result in more efficient strategies for inducing tumor cell death.   
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1.3 . The DNA damage response to double strand breaks  
 
Cellular DNA is subject to constant damage from reactive oxygen species (ROS), 
free radicals that are a by-product of endogenous metabolic processes, and from 
naturally occurring errors during DNA replication, as well as from external sources, 
predominantly UV and ionizing radiation. Of the different types of DNA lesions that can 
occur in cells (e.g. modified bases, abasic sites, intra- and interstrand crosslinks, protein-
DNA adducts, various strand breaks), DNA double strand breaks (DSBs) pose the greatest 
threat to genomic integrity since their inefficient repair may lead to mutational defects or 
culminate in cell death. Indeed, defective DSB repair is associated with several 
developmental, immunological and neurological disorders, and is a major driving force in 
cancer (Jakob et al., 2011; Iyama & Wilson, 2013). In the present work, DSBs are the type 
of DNA lesion chosen for study, for the above reasons, and any allusion to DNA damage 
and repair will predominantly refer to DSBs. 
Maintaining and ensuring a faithful inheritance of genetic information is 
imperative to all eukaryotic life. To that end, cells have evolved a complex range of 
mechanisms to sense DNA damage and initiate a stress response to restore genomic 
integrity, collectively known as the DNA damage response (DDR). In the case of DSBs, DDR 
can trigger two major repair pathways conserved in most eukaryotes in order to prevent 
propagation of genomic defects: Non-Homologous End Joining (NHEJ) and Homologous 
Recombination (HR) (Soria, Polo, & Almouzni, 2012; Raschellà, Melino, & Malewicz, 2017).  
Homologous Recombination represents the most elegant solution to DSB repair 
since it is bases itself on an undamaged template to restore any lost information on the 
damaged sequence. A downside of this system is, consequently, that it can only function 
after DNA replication has taken place and a sister chromatid is available to be used as 
template, which only occurs in S or G2 phases of the cell cycle. Non-Homologous End 
Joining, on the other hand, is active throughout the entire cell cycle and is the only DSB 
repair pathway available in G1 when there are no templates for HR. However, because it 
directly connects broken DNA ends without referring to the former sequence, there is a 
risk of introducing sequence errors during repair, such as deletions, substitutions or even 
translocations if DSBs from different regions are ligated. Nevertheless, in certain contexts 
where there is no modification to terminal nucleotides on DNA ends (“clean” breaks), 
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NHEJ is known to be error free, and there are as well exceptions where HR can be 
mutagenic (Chapman, Taylor, & Boulton, 2012; Scully & Xie, 2013).   
For the DDR to initiate, DSBs first need to be recognized and signalled to the repair 
machinery. The phosphorylation of histone variant H2AX, which constitutes 
approximately 10% of total histone H2A, at serine 139 (resulting in γH2AX) serves as the 
initiating signal for the DDR. This modification is rapidly catalysed by members of the 
phosphatidylinositide 3-kinases (PI3K) family of protein kinases (ATM, ATR and DNAPK), in 
response to DNA damage and can spread over a vast (up to 2Mb) area surrounding the 
DSB acting as a beacon that can be recognized by a multitude of proteins and be 
visualized microscopically in the form of nuclear aggregates known as “foci” (van Attikum 
& Gasser, 2009). Impairment of this phosphorylation results in loss of DDR factor 
recruitment to DNA breaks and increased radiation sensitivity, as evidenced in H2AX 
mutant mice (Celeste et al., 2003). The generation of γH2AX depends mainly on the MRN 
complex formed by the Mre11, Rad50 and NBS1 (Nijmegen breakage syndrome 1) 
proteins. MRN is the most important DDR sensor due to its ability to recognize free DNA 
ends and subsequently recruit ATM kinase (ATR and DNAPK can also be recruited but are 
not the primary kinases) through NBS1 to phosphorylate H2AX in the immediate vicinity 
of the break. γH2AX is then recognized immediately by MDC1 (Mediator of DNA Damage 
Checkpoint Protein 1), which needs to be phosphorylated by Casein Kinase 2 (CK2) to be 
active, subsequently binding to the modified histone and establishing a platform for DDR 
factor accumulation and retention at the DSB, most notably for the MRN-ATM complex. 
This complex  is then able to expand H2AX phosphorylation to an increasing number of 
nucleosomes flanking the DSB, thus creating a positive feedback loop that greatly 
amplifies the signal for recruitment of repair factors (van Attikum & Gasser, 2009; Lukas, 
Lukas, & Bartek, 2011). 
After these initial signalling steps, which are common to both HR and NHEJ, each 
pathway follows separate routes and relies on distinct sets of factors for DSB repair. 
During the first step of HR, the ends of the DSB are bound by the MRN complex which 
then, through means of the endonuclease activity of Mre11, removes nucleotides in a 5’-
3’ orientation converting both DSB ends into single strand DNA (ssDNA) 3’ overhangs, a 
process that is called “end resection”. These ssDNA overhangs are bound in turn by the 
Replication Protein A (RPA) complex, an heterodimer composed of the subunits RPA1, 
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RPA2 and RPA3. RPA in concert with Rad52 recruits Rad51 to form ssDNA-Rad51 
nucleoprotein filaments that will search for an homologous sequence in the vicinity. A 
successful search will result in strand invasion and synthesis of a complementary DNA 
strand. A ligation step then completes this predominantly error-free repair event. NHEJ, 
on the other hand, initiates by the binding of the Ku heterodimer, consisting of the Ku70 
and Ku80 proteins, to the DSB ends locking them in close proximity. DNA bound Ku 
recruits the catalytic subunit of DNAPK (DNAPKcs) to form the DNAPK holoenzyme 
complex thereby activating its kinase activity. This complex then undergoes 
autophosphorylation in serine 2056 and undertakes the recruitment and activation of 
several DNA end-modifying proteins, including DNA Ligase IV, Artemis, XRCC4, XLF, and 
the recently discovered PAXX, that together carry out the rejoining of the DNA ends (de 
Campos-Nebel, Larripa, & González-Cid, 2010; Goodarzi, Jeggo, & Lobrich, 2010; Raschellà 
et al., 2017) (Fig.2).  
Initial studies have suggested a relatively simple mechanism controlling the 
decision to employ either of the two major DSB repair systems, which consists of cyclin-
depent-kinase (Cdk) phosphorylation of CtIP, an interaction partner of the MRN complex, 
at the G1/S transition that allows it to activate DNA end resection by recruiting BRCA1, 
shifting the balance from NHEJ repair to HR (Yun & Hiom, 2009). However, in more recent 
years it has become apparent that this decision is quite complex, being subject to heavy 
regulation in order to restrict the activity of either system to specific cellular 
circumstances and involving ubiquitination and SUMOylation cascades along with several  
histone modifications (Daley & Sung, 2014). While extensive investigation into this 
particular area is still ongoing, two factors have emerged as the key regulators of DSB 
repair pathway choice: p53-binding protein 1 (53BP1) for NHEJ and breast cancer type 1 
susceptibility protein (BRCA1), along with its heterodimer partner BARD1 (BRCA1-
associated RING domain protein), for HR (Chapman et al., 2012). Both of these regulators 
act downstream of the initial γH2AX/MDC1 signal amplification response and compete for 
binding to mutually exclusive sites within the γH2AX/MDC1 chromatin domain. Knock-out 
of 53BP1 was proven to be sufficient to restore HR repair capability to cells in which it had 
been abrogated due to low BRCA1 expression (Cao et al., 2009). In fact, 53BP1 has been 
shown to inhibit end resection, and thus HR, in G1 phase with RIF1 and PTIP being 
identified as its effectors though the exact mechanism of inhibition is still unknown. In 
General Introduction 
11 
 
contrast, BRCA1 activity is able to remove 53BP1 from DSBs in S and G2 thereby 
 
Figure 2. A simplified scheme of the DNA damage response. (A) Following break induction the MRN 
complex binds the DSB. Recruitment and activation of ATM by the DSBs lead to H2AX phosphorylation, 
binding of MDC1 and amplification of the damage signal. (B) Following additional histone modifications 
facilitated by MDC1, recruitment of 53BP1 and BRCA1 and depending on the cell cycle stage and other 
factors, DSB ends are either extensively resected or not, which determine repair pathway choice. (C) To 
provide time for repair the cell cycle is blocked, as Chk2 is phosphorylated by ATM (C.1.) and 
phosphorylates and inactivates Cdc25 phosphatases (C.2.), thus blocking cyclin-dependent kinases and 
cell cycle transitions. Additionally, Chk2 phosphorylation of p53 elicits transcriptional events and may 
induce apoptosis (C.3.). (D) Non-homologous end joining is the major DSB repair mode in mammals. It is 
initiated by the binding of Ku proteins (D.1.), which in turn, bind DNA-PKcs (D.2.) and activate DNA-PKcs 
kinase activity. DNA-PK regulates limited processing of DNA ends by the Artemis nuclease (D.3.) and 
brings about the recruitment of the factors that carry out rejoining of the DNA ends (D.4.). (E) 
Homologous recombination repair requires extensive processing of the DSB ends into 3’-ssDNA 
overhangs (E.1.). Single-strand DNA overhangs are first covered by RPA, later displaced by Rad51 in an 
exchange reaction dependent on Rad51 paralogues and Rad52 (E.2.). Rad51-covered nucleoprotein 
filament searches for and invades the homologous duplex and following extension (E.3.) of the invading 
strands and Holliday junction resolution the broken double helix is restored (E.4.). From Gospodinov & 
Herceg, 2013. 
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unblocking resection (Lowndes, 2010). Importantly, loss of BRCA1 leads to 53BP1 
recruitment in G2 while depletion of 53BP1 causes accumulation of BRCA1 at damage foci 
in G1, suggesting that the potential for the engagement of HR in G1 or NHEJ in G2 exists 
but is blocked by 53BP1 and BRCA1, respectively (Daley & Sung, 2014).  
These factors are thought to respond to different sets of ubiquitination marks on 
histones H2A and H2AX generated by the E3 ubiquitin ligases RNF8 and RNF168, which 
are recruited via MDC1. The exact code is not known though it involves H2A 
ubiquitination on lysines 13 and 15 and formation of long ubiquitin chains at lysine 63 
(Stewart, 2009; Panier et al., 2012). RNF8 and RNF168 activities are believed to create a 
platform for recruitment of the RAP80 complex which in turn is required for efficient 
BRCA1 enlistment to damage foci (B. Wang et al., 2007). 53BP1, however, interacts 
directly with the histone modification introduced by RNF168, H2A ubiquitinated on lysine 
15, not requiring RAP80 activity to be recruited, as opposed to BRCA1. 53BP1 also 
requires a constitutive epigenetic mark in chromatin, histone 4 dimethylated on lysine 20 
instead ensuring its retention in chromatin surrounding the break. In addition, the 
acetylation mark H4K16 introduced by the TIP60 acetyltransferase was shown to 
negatively regulate 53BP1 persistence in damaged chromatin by reducing its affinity to 
H4K20me2, which means that at least three types of histone modifications, methylation, 
ubiquitination and acetylation, are involved in regulating 53BP1 recruitment and 
retention (Daley & Sung, 2014). Further layers of regulation are in place for each of the 
previously mentioned factors involved in regulating BRCA1 and 53BP1. Together, they 
create a very complex network of protein interactions controlling the switch from NHEJ to 
HR surrounding the Cdk-dependent formation of the CtIP-MRN-BRCA1 complex that 
removes 53BP1 and initiates resection.   
 
 
1.4 .  DNA repair in the context of chromatin structure 
 
 
DNA in eukaryotic cells exists in association with histone proteins and physically 
wrapped around nucleosomes. As a consequence, repair of DNA damage has to be 
considered in the greater context of chromatin and its structure. Efficient DNA repair 
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requires changes at the level of the chromatin structure in the vicinity of lesions to 
facilitate access of various signaling and repair complexes. These structural changes can 
take the form of remodeling of nucleosome positions, exchange of histone variants, 
removal of non-histone chromatin-associated proteins or post-translational modifications 
to histone tails (Raschellà et al., 2017).  
Nucleosome remodeling was found to involve the activity of ATP-dependent 
chromatin remodelers that operate by weakening DNA-histone interactions at the 
expense of ATP hydrolysis to slide or evict individual nucleosomes (Kruhlak et al., 2006). 
Many ATP-dependent chromatin remodelers have been involved in DNA repair including 
PARP (poly-ADP-ribose polymerase), the SWI/SNF complex, INO80 and SMARCAD1 
(Gospodinov & Herceg, 2013).  
As mentioned before, histone post-translational modifications, most prominently 
acetylation, can also weaken the bonds between histones and DNA and can affect 
chromatin condensation after damage to DNA. The TIP60 acetyltransferase complex, for 
instance, was shown to be deeply involved in DNA repair. Depletion of core subunits of 
this complex led to defects in HR repair that were overcome by forced chromatin 
relaxation, indicating its role in granting repair factors access to DNA (Murr et al., 2006). 
TIP60 activation was found to be dependent on binding to histone mark H3K9me3 on 
chromatin, after which it initiates not only chromatin relaxation but also activation of 
ATM through acetylation (Sun et al., 2009). A considerable number of additional 
acetyltransferases have been implicated in promoting recruitment and activity of NHEJ 
and HR factors (Gospodinov & Herceg, 2013). 
Over the last decades it has become apparent that heterochromatin (HC) and 
euchromatin (EC) represent separate entities with respect to both damage sensitivity and 
repair. The high degree of compaction present in heterochromatin is thought to protect 
DNA from damage although, when lesions do occur, this compaction further restricts the 
capability of DNA damage response proteins to access the site to properly signal and 
mediate repair, as evidenced by the ability of HC to block the expansion of H2AX 
phosphorylation to neighbouring nucleosomes (Kim, Kruhlak, Dotiwala, Nussenzweig, & 
Haber, 2007). Indeed, DNA damage in HC has been shown to be refractory to repair 
considering that DSBs introduced by ionizing radiation are resolved with slower kinetics 
than in EC (Cann & Dellaire, 2011). HC harbours an abundance of the repressive mark 
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H3K9me3, introduced by the methyltransferases SETDB1 (SET domain bifurcated 1) and 
SUV39 (suppressor of variegation 3-9), that acts as a binding site for non-histone proteins 
to associate with chromatin and promote its compaction. The most central of these 
proteins are the heterochromatin protein 1 variants (HP1α, β and γ, in mammals) that 
help to maintain the structure and stability of HC. Surprisingly though, these proteins 
have been shown to also contribute to DSB repair in HC. After initial dispersion following 
DNA damage, all HP1 variants are recruited to and accumulate at damage foci in HC 
regions (Luijsterburg et al., 2009). Loss of HP1 was shown to induce high sensitivity to 
ionizing radiation, defects in recruiting DDR factors such as 53BP1 and RAD51, and 
impaired DNA end resection (Baldeyron, Soria, Roche, Cook, & Almouzni, 2011). Another 
protein that affects chromatin structure is KAP1 (KRAB domain associated protein 1). 
KAP1 is recruited to HC by sequence-specific-recognizing repressor proteins, subsequently 
interacting with HP1, SETDB1, HDAC1 and HDAC2, together maintaining a compacted 
chromatin state (Watts, 2016). Following damage in HC, ATM phosphorylates KAP1 which 
causes it to disperse throughout chromatin promoting global relaxation. This requirement 
of ATM phosphorylation seems to be specific for repair in HC as knockdown of KAP-1, HP1 
or HDAC1/2 alleviates the need for ATM in DSB repair (Goodarzi et al., 2008). In sum, HC 
components are dynamic and can contribute to DSB repair in opposing ways, suggesting 
that repair does not require a DNA region empty of proteins but instead a region with 
varying levels of compaction but permissive to DDR factors.  
Furthermore, studies in Drosophila have indicated that localized HC relaxation 
occurs in the vicinity a DSB followed by rapid relocalization of the break to the periphery 
of chromatin dense regions before γH2AX foci formation and lesion repair by HR in an 
ATM-dependent fashion, indicating that there exists an additional level of modulation in 
HC in response to DSBs involving higher-order chromatin reorganization (Chiolo et al., 
2011; Goodarzi & Jeggo, 2012; Jakob et al., 2011). This movement may serve to not only 
facilitate access of repair proteins to the lesion site, but also to reduce the risk of 
illegitimate joining during HR caused by the abundance of sequence repeats found in HC. 
In yeast, it was found that this rearrangement is directed by the yeast homologue of 
histone variant H2AZ with assistance from the chromatin remodeler complex INO80 and 
Rad9 (the yeast homologue of 53BP1) along with several components of the homologous 
recombination machinery (Dion, Kalck, Horigome, Towbin, & Gasser, 2012).  
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 Taken together, these findings point to DSBs located in chromatin dense regions 
as being particularly reliant on the HR pathway for repair. As such, the state of chromatin 
condensation and the presence of HC-associated factors at DSB sites have come to light 
as additional relevant elements capable of determining usage and efficiency of repair 
systems.  
 
 
1.5.  Cell cycle checkpoint activation and reversal 
 
 
In a proper functioning cell, DSBs are quickly recognized by DDR proteins which 
prompt the cell to transiently halt cell cycle progression, initiating what is called a “cell 
cycle checkpoint”. Checkpoint activation allows cells time to repair DNA damage before it 
can compromise genomic integrity and cell viability. Furthermore, if damage is too 
extensive to be repaired, it prevents cells harbouring potential oncogenic mutations from 
proliferating by permanently halting their proliferation (a phenomenon known as cellular 
senescence) or initiating programmed cell death (apoptosis). Depending on several 
circumstances, including the complexity of DNA lesions and the cycle phase the cell finds 
itself in, different repair and checkpoint pathways can be activated which together 
function as a highly complex and interacting defence mechanism against genotoxic 
insults. Although our knowledge of how DDR and checkpoint proteins are regulated by 
post-translational modifications has greatly improved in recent decades, it is still not 
completely understood how the interaction between repair systems and checkpoint 
effectors coordinates the decision to maintain cell cycle arrest, or else to terminate 
checkpoint signaling to allow cycle progression to resume. However, it is becoming 
increasingly clear that checkpoint activation and reversal mechanisms are precisely tuned 
to each cell cycle phase (Shaltiel, Krenning, Bruinsma & Medema, 2015).  
DNA damage can be particularly harmful in certain cell cycle phases. In S phase, 
for example, DNA lesions that would be relatively mild in G1 or G2 can interfere with the 
progression of replication forks and may even lead to fork collapse, causing further DSBs 
and potential chromosome breakage (Scully & Xie, 2013). The existence of checkpoints at 
the G1/S and G/M boundaries of the cell cycle is thus thought to prevent cells from 
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undergoing replication or mitosis, respectively, in the presence of DNA damage.  An intra-
S phase checkpoint for damaged or incorrectly replicated DNA, and a mitotic spindle 
assembly checkpoint that senses incorrect alignment of chromosomes at the equatorial 
plane or impaired attachment of spindle fibers at kinetochores are also in place (Deckbar 
et al, 2011).   
The essential step for checkpoint activation is the recruitment of ATM kinase by 
the MRN complex once it recognizes DSBs, a requirement that is common to all cycle 
stages. Afterwards, the downstream effectors of checkpoint activation vary according to 
each phase. Cycle progression in G1 is mediated by the cyclinD/Cdk4/6 complex, whose 
rising levels in G1 are responsible for phosphorylation (and inactivation) of the 
retinoblastoma protein pRb, an inhibitor of transcription factors of the E2F family which 
are required for cell cycle progression. E2F promotes expression of cyclin E that, together 
with Cdk2, will coordinate entry into S phase (Deckbar et al., 2011). Detection of DSBs 
leads to ATM activating Checkpoint Kinase 2 (Chk2), and together they stabilize the key 
transcription activator p53, which in turn results in expression of a large variety of 
transcriptional targets including the major Cdk-inhibitor protein p21 that binds to cyclin-
Cdk complexes blocking cell cycle progression. ATM and Chk2 activities also promote the 
degradation of cyclin D and Cdc25A, a phosphatase responsible for reversing the 
inhibitory phosphorylation on Cdk2, reinforcing the barrier to S phase entry (Deckbar et 
al., 2010).  
In the case of damage in S phase, the removal of 53BP1 from DSBs allows the 
block on end resection to be lifted and commitment to repair by HR to ensue. Generation 
of 3’ ssDNA overhangs activates ATR kinase and its effector Chk1, shifting DNA damage 
signalling away from ATM and Chk2 exclusively. During DNA replication p21 is marked for 
degradation by the PCNA-associated CRL4-Cdt2 (from the family of cullin ring E3 ubiquitin 
ligases) that is present at replication forks (Havens & Walter, 2011), which means that the 
intra-S checkpoint has to rely on a different Cdk inhibitor to arrest cycle progression into 
G2. Chk1 an d Chk2 activate the kinase Wee1 which in turn phosphorylates Cdk2 
inhibiting its activity, while also marking the counteracting phosphatase, Cdc25A, for 
degradation thus initiating the checkpoint (Beck et al., 2010). 
G2 checkpoint activation, on the other hand, requires both p21 and Wee1 
activities. Since DNA replication has been concluded, accumulation of p21 levels is 
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reinstated in G2 and this pathway, involving ATM and Chk2, is necessary for initiation of 
cell cycle arrest after DNA damage. However, maintenance of a stable checkpoint 
depends on ATR and Chk1 signalling, suggesting that engagement of HR is critical for G2 
checkpoint maintenance (Shibata et al., 2010). In regards to the mitotic spindle assembly 
checkpoint, it is not of particular relevance for this work since it does not respond to DNA 
damage due to almost complete inhibition of the DDR response during mitosis (Giunta, 
Belotserkovskaya, & Jackson, 2010) and thus will not be detailed here.    
DNA checkpoints are indeed useful for allowing additional time for DNA repair but 
only if they can be reversed when appropriate. Just as the DDR is able to trigger a wide 
range of protein posttranslational modifications that culminate in the activation of 
checkpoints, removal of these modifications or degradation of modified proteins by 
dedicated enzymes is necessary to release cells from damage-induced checkpoints and 
allow them to re-enter their cycle . After G2 checkpoint activation, for instance, polo-like 
kinase 1 (Plk1) acts as the key regulator of checkpoint reversal by contributing to the 
activation of the pro-mitotic cyclin B1/Cdk1 complex while also disabling Chk1 by 
targeting its activator for degradation, as well as negatively regulating Wee1, 53BP1 and 
Chk2 (Mamely et al., 2006; Van Vugt, Brás, & Medema, 2004). Plk1 thus pushes cells away 
from arrest in G2 to cycle re-entry into mitosis. The mechanics of G1 checkpoint reversal, 
on the other hand, are not yet fully understood but have been shown not to depend on 
Plk1, which is absent in G1, and to require silencing of Chk2 and p38 MAPK (mitogen-
activated protein kinase) signalling to prevent the stabilization of p53 and p21, 
respectively, thus denying enforcement of the checkpoint (Lafarga et al., 2009; Shaltiel et 
al., 2014).   
It is still a general belief that recovery from checkpoints induced by DSBs only 
occurs following completion of DNA repair. However, this notion has begun to change in 
recent decades. Although checkpoints do contribute to preventing genomic instability 
they were found to carry inherent limitations and are no longer considered flawless. For 
instance, the G1/S checkpoint was shown not to initiate until 4 to 5 hours post-damage, 
allowing a large fraction of cells to enter S phase with unrepaired DSBs (Deckbar et al., 
2010), and the G2/M checkpoint to carry limitations of a different nature, only being 
activated above a certain threshold level of DNA damage and DDR signalling (Deckbar et 
al., 2011). Furthermore, despite the presence of DNA damage cells can terminate G2 
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checkpoint and enter mitosis, a phenomenon that has been termed “checkpoint 
adaptation”. It has been observed that G2 checkpoint activation is followed by a gradual 
increase in Plk1 levels and it was hypothesized that once a certain threshold is reached it 
triggers reversal of the arrest independently of any subsisting DNA damage. Although it 
was proved that increased Plk1 levels alone could not override an established DNA 
damage checkpoint, they may be a component of the mechanism behind this event 
(Shaltiel et al., 2015). More research is still necessary to fully understand what factors 
determine whether a cell remains blocked from progressing in its cycle while harboring 
severe DNA damage, or chooses to continue though at the risk of its genomic integrity.   
 
 
1.6 .  Topoisomerase-mediated DNA lesions 
 
  
Under particular non-physiological conditions, certain nuclear enzymes may also 
generate persistent protein-mediated DSBs. One such example is Topoisomerase II 
(Topo2), an enzyme consistently present in cells since it solves topological problems of 
DNA, such as knots and entanglements, which may arise during replication, transcription 
and chromosome condensation (Wang, 2002). Topo2 acts by generating a transient DSB 
on DNA while remaining covalently linked to the 5’ end of the break, through which it 
subsequently promotes the passage of another double-strand of DNA, concluding by 
catalyzing DSB relegation (Fig.3). In mammalian cells there are two Topo2 isoforms, α and 
β, with similar structures and catalytic activities although Topo2α is mainly implicated in 
DNA replication, decatenation and segregation and Topo2β is mostly associated with 
transcription. Their expression is also differently regulated, with Topo2α levels rising from 
S to M phase while Topo2β remains constant throughout the entire cell cycle (Agostinho 
et al., 2008; Agostinho, Ferreira, & Steffensen, 2004; de Campos-Nebel et al., 2010) . 
Topo2 is the target of several anti-cancer drugs commonly used in chemotherapy, 
such as Etoposide and Doxorubicin, which poison the enzyme by stabilizing the Topo2-
DNA complex, called cleavage complex, preventing religation of the broken DNA ends. 
While the stabilized cleavage complexes are reversible by drug removal, they can give rise 
to persistent breaks if they remain for enough time to ultimately collide with either the 
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transcription or replication machinery as these processes progress through the DNA. The 
collapse of the cleavage complex that results from this collision leaves behind a 
permanent DSB that are able to trigger the DDR and checkpoint pathways (Hisang, Lihou, 
& Liu, 1989; Wu & Liu, 1997). Repair of Topo2-mediated DSBs has been shown to utilize 
NHEJ and HR in G1 and S/G2, respectively (de Campos-Nebel et al., 2010). Topo2 poisons 
thus indirectly induce persistent DSBs by converting this enzyme into a potent genotoxin 
that is particularly harmful to rapidly dividing cells due to its essential role in transcription 
and replication.   
 
 
 
Although Topo2 poisons are currently widely used to induce tumor cell death, they 
have been associated with development of secondary malignancies in treated patients, 
most frequently myeloid leukemia (Felix, Kolaris, & Osheroff, 2006). This has generated a 
significant interest in how cells handle the repair of Topo2-mediated DNA lesions in order 
to better predict and prevent undesired mutagenic effects of anti-cancer chemotherapy. 
As an example, the discovery that inhibition of HDAC activity results in increased 
sensitivity to Topo2-mediated DNA damage has already been translated into practice in 
Figure 3. Schematic diagram for the 
proposed two-gate mechanism of 
Topoisomerase type IIA enzyme. The 
catalytic cycle starts from the 
association of G-segment (red) with 
its binding pocket (dark blue), 
followed by the capture and passage 
of T-segment (pink) through the N-
gate, DNA-gate, and C-gate. Regions 
expected to interact transiently with 
T-segment during its passage are 
colored in light blue. From C. C. 
Chang, Wang, Chen, Wu, & Chan, 
2013. 
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clinical oncology with the development of new chemotherapy schemes combining drugs 
that target Topo2 and small molecule inhibitors of HDACs (Namdar, Perez, Ngo, & Marks, 
2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thesis Aims 
21 
 
Thesis aims 
 
 
Many current cancer therapy strategies rely on the use of drugs capable of 
inducing levels of DNA damage too extreme for cells to repair, reliably causing cellular 
death or permanent proliferation arrest. Although these agents have preferential targets 
in cells with rapid cycle turnover or inadequate DNA repair, two characteristics frequent 
in many tumors, they often also affect non-cancer cells resulting in severe side effects for 
the patients, thus limiting their therapeutical potential (Hühn, Bolck, & Sartori, 2013).  
As previously mentioned in the introduction, the regulation of cell cycle 
checkpoints, of DNA repair pathways and of chromatin structure have all emerged as key 
elements that determine how both normal and cancer cells will respond to DSBs 
introduced by chemotherapy treatments. These three critical components of cellular 
activity interact and coordinate with each other through vast networks of regulatory 
proteins that enact post-translational modifications at the protein and chromatin levels, 
many of which already described as participating in more than one of these processes 
(Fig.4). The precise articulation between these three different mechanisms remains the 
focus of intense research, directed in particular to the uncovering of exploitable 
vulnerabilities in tumor cells that may enhance the specificity and efficacy of future 
cancer therapies.  
Correspondingly, the present work is aimed at investigating the interplay between 
the three systems in response to Topo2-mediated DSBs.  The Topo2 poison Etoposide was 
the preferred agent to induce DNA damage in cultured cancer cell lines. Etoposide-bound 
Topo2 is able to reliably introduce DSBs at all stages of the cell cycle and, during S phase, 
it is mainly recruited to assist in DNA replication, which means Etoposide specifically 
targets replicating DNA when used during that stage of the cell cycle. Since replication of 
euchromatin and heterochromatin occur separated in time, with EC replicating early in S 
phase while HC replication takes place in the later S stages (O’Keefe, Henderson, & 
Spector, 1992), it is possible to selectively introduce DSBs in either replicating EC or HC 
with proper cell cycle synchronization in early or late S phase, respectively (Fig.5). This 
characteristic of Topo2 conveniently allows for the development of experimental 
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methodologies to study the interplay between all the three mechanisms: cell cycle, DSB 
repair and chromatin structure regulation.   
  
 
 
Therefore, the two main goals of this thesis are as follow: 
 
A) To establish the dependence of distinct cell cycle stages (G1, early S, late S and G2) 
on each of the two main DSB repair pathways (non-homologous end joining and 
homologous recombination) for repair of Topo2-mediated DSBs. 
 
B) To determine how different chromatin structural conformations (euchromatin vs. 
heterochromatin) influence repair of Topo2-mediated DSBs and long term cellular 
outcome.     
 
 
Figure 4. Cell cycle progression, the damage response to DSBs and the regulation of 
chromatin structure exhibit extensive coordination and overlap of factors. Cell cycle 
position influences repair system choice and chromatin condensation state (e.g. during 
replication and chromosome formation), while the DDR can trigger cell cycle checkpoints 
and chromatin remodeling to facilitate repair. Finally, chromatin structure can also impact 
efficiency and usage of repair factors. 
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Figure 5. Topoisomerase II specifically targets heterochromatin in late S phase. Cells 
were exposed to Etoposide (50 µM, 15 mins) prior to immunostaining for BrdU 
(replicated DNA) and γH2AX (DSBs). Notice signal overlap (yellow) in late S. Red: BRDU; 
Green: ƴH2AX; Blue: DAPI. 
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2. Methods 
 
Cell culture, chemicals and antibodies  
Human colorectal carcinoma HCT-116 (ATCC CCL-247) and HCT-116 deficient for 
DNA-PK were obtained from the laboratory of Dr. Bert Vogelstein (Johns Hopkins School 
of Medicine, Baltimore, MD, USA). HCC1937 (ATCC CRL-2336) breast carcinoma with a 
homozygous loss of function mutation in the BRCA1 gene (BRCA1(-)), along with HCC1937 
cells with retroviral-induced expression of wild type BRCA1 (BRCA1(+)) (Scully et al., 1999) 
were provided by Dr. Ralph Scully (Harvard Medical School, Boston, MA, USA). These cells 
also carry a homozygous loss of function mutation in p53. THP1 leukaemia cell line was 
obtained from ATCC (TIB-202).  
HCT-116 cells were cultured in McCoy’s 5A Modified medium supplemented with 
10% heat inactivated foetal bovine serum (FBS), 2 mM L-glutamine, 10mM MEM non-
essential amino acids,  and 100 U/ml penicillin/streptomycin (all from Gibco, Thermo-
Fisher Scientific, Waltham, MA, USA). HCC1937 cells were cultured in RPMI-1640 medium 
(Gibco) supplemented as above. THP1 cells were cultured in  RPMI-1640 medium (Gibco) 
supplemented with 10% heat inactivated foetal bovine serum (FBS), 2 mM L-glutamine, 
10 mM MEM non-essential amino acids, 100 U/ml penicillin/streptomycin, and 0,05 mM 
2-mercaptoethanol. Cells were maintained at 37ᵒC in a humidified incubator at 5% CO2. 
Cells were passaged on alternate days at a constant plating density of ≈3 x 104 cells/cm2 
or ≈2 x 105 cells/ml.  
Etoposide, RO-3306, thymidine, propidium iodide (PI), 4',6-diamidino-2-
phenylindole (DAPI), 3-deazaneplanocin A (DZNep) and RNase A were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Suberoylanilide hydroxamic acid (SAHA) was 
purchased from Cayman Chemical (Ann Harbor, MI, USA). 
The following antibodies were used in this research: rabbit polyclonal to histone H2A.X 
(ab11175, Abcam, UK (Dawson et al., 2009)), mouse monoclonal IgG1 to phospho-histone 
H2A.X (Ser139; clone JBW 301; Merck-Millipore, Darmstadt, Germany (Smith-Roe et al., 
2015)), mouse monoclonal IgG1 to RPA32/RPA2 (clone 9H8; ab2175 Abcam, UK (Ciccia et 
al., 2009)), affinity-purified rabbit polyclonal to phospho-RPA32/RPA2 (Ser4/Ser8; Cat. 
A300-245A; Bethyl Laboratories, Montgomery, TX, USA (King et al., 2015)), rabbit 
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polyclonal to phospho-KAP1 (S824; Cat.A300-767A; Bethyl Laboratories), mouse 
monoclonal to RAD51 (ab213; Abcam), rabbit polyclonal to p21 (C-19;  sc-397, Santa Cruz 
Biotechnology, Dallas, TX, USA), mouse monoclonal to phospho-ATM (S1981; Rockland 
Immunochemicals, Limerick, PA, USA), rabbit polyclonal to phospho-DNAPKcs (T2609; 
Rockland Immunochemicals), rabbit polyclonal to phospho-p53 (S15; ab1431; Abcam), 
mouse monoclonal to cyclin E (HE12; sc247; Santa Cruz Biotechnologies), rabbit 
polyclonal to cyclin A (H-432; sc751, Santa Cruz Biotechnologies), mouse monoclonal to α 
tubulin (B-7; sc5286; Santa Cruz Biotechnologies), rabbit polyclonal to EZH2 (cat.07-689, 
Merck-Millipore), mouse monoclonal to H3K27me3 (ab6002, Abcam),  affinity-purified 
Alexa 488-conjugated and Cy3-conjugated anti-mouse secondary antibodies (Jackson 
ImmunoResearch Laboratories, Sacramento, CA, USA), and peroxidase-conjugated 
affinity-purified goat anti-mouse IgG and goat anti-rabbit IgG (BioRad Laboratories, 
Hercules, CA, USA).  
 
Flow cytometry instrumentation and data analysis  
Samples stained for PI, DAPI and γH2AX were analyzed using a three laser (blue-
488nm; red-640nm; violet-605nm) BD LSR Fortessa flow cytometer (BD Biosciences, San 
Jose, CA). γH2AX and PI signals were measured upon excitation by the blue laser using 
530/30 and 695/40 bandpass filters, respectively. DAPI signals were measured upon 
excitation by the violet laser with the 525/50 bandpass filter. A minimum of 30000 events 
were acquired per experiment in slow rate mode to avoid doublets. Sample 
measurements were performed with FACSDiva Software (Version 6.2, BD Biosciences, San 
Jose, CA, USA). Data analysis for cell cycle parameters and mean fluorescence intensities 
was performed with FlowJo Software (Ashland, OR, USA). Cell debris and aggregates were 
excluded from the analysis using pulse processing FSC-A vs FSC-H, FSC-H vs FSC-W, SSC-H 
vs SSC-W, and FL2-A vs Fl2-W when appropriate.  
 
Immunofluorescence staining  
For immunofluorescence analysis, HCT-116 cells growing on coverslips were 
routinely fixed in freshly prepared 3.7% paraformaldehyde in HPEM buffer (30 mM 
HEPES, 65 mM Pipes, 10 mM EGTA, 2 mM MgCl2 (pH 6.9)) plus 0.5% Triton X-100 for 10 
mins at room temperature before incubation with antibodies. All washes were performed 
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with PBS containing 0.05% Triton X-100. Antibodies used for immunofluorescence were 
diluted in PBS containing fish skin gelatin (0.1%) and Triton X-100 (0.05%) as follows: anti-
phospho-RPA2 at 1/200, anti-RAD51 at 1/200, anti-phospho-histone H2AX (Ser139) at 
1/300 and Cy3-conjugated anti-mouse secondary antibodies at 1/100. After 
immunolabeling, total DNA was stained with DAPI (0.5 µg/mL) and coverslips were 
mounted in Vectashield (Vector Laboratories Inc., Burlingame, CA, USA) before analysis by 
fluorescence microscopy. 
 
Confocal microscopy  
Samples were examined using a Zeiss 510 confocal microscope (Carl Zeiss, Jena, 
Germany) equipped with lasers giving excitation lines at 405, 488 and 543 nm. Data from 
the channels were collected separately using narrow-band-pass filter settings. In multiple 
staining experiments, the laser intensities were adjusted to avoid bleedthrough between 
channels. Data were collected with two- to fourfold averaging at resolution of 1024 X 
1024 pixels using pinhole settings between 1.05 and 1.10 airy units. Data sets were 
processed using Zeiss 510 version 2.8 software package and were subsequently exported 
for preparation for printing using Adobe Photoshop, version CS5.1. Quantification of cell 
number, foci number, nuclei area and signal amount per image was performed using the 
UBCr Foci software developed in MATLAB (MathWorks, Natick, MA, USA) by the 
Bioimmaging unit from Instituto de Medicina Molecular da Faculdade de Medicina de 
Lisboa (Dr. José Rino). 
 
Cell cycle synchronization and Etoposide exposure  
In order to synchronize exponentially growing HCT116 cells at G1/S phase 
transition, we used the double-thymidine block approach. Briefly, cells were incubated in 
culture medium containing thymidine at a final concentration of 2 mM for 12 h (1st 
thymidine block), allowing time for cells to arrest in S phase. Thymidine was removed 
through repeated washes with fresh medium and cells were incubated with fresh 
thymidine-free medium for 7.5 h, to allow full exit from S phase. Cells were subsequently 
incubated with 2 mM thymidine for another 12 h (2nd thymidine block) to obtain a 
population precisely arrested at the G1/S phase transition that will progress into S phase 
upon release from thymidine. To induce DSBs in cells synchronized at different cycle 
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phases, 50 µM Etoposide was added to separate groups of cells at specific times after 
thymidine release. Cells were exposed to drug 15 mins, after which drug was removed 
through washing and cells incubated with fresh medium until collection at different time 
points after Etoposide pulse. Times for cycle phase specific Etoposide pulse: early S at 30 
mins post thymidine release; late S at 3.5h, G2 at 5.5h and G1 at 10.5h.  
   
Western blotting 
For immunoblotting, cell lysates were prepared in boiling 1X Laemmli´s sample 
buffer were supplemented with PMSF (1 mM) and a commercially available mixture of 
protease inhibitors (Complete Mini EDTA-free; Roche Diagnostics, Mannheim, Germany; 1 
tablet/mL). DNA was first fragmented mechanically by passing the sample into a syringe 
(≈10 times) through a 25-gauge needle and, subsequently, after supplementation with 
MgCl2 (5 mM), by digestion with benzonase (0.4 Units/ml; Sigma-Aldrich) for 30 mins at 
room temperature. Lysates were then separated on 12 or 14% SDS-PAGE under reducing 
conditions and transferred to nitrocellulose membranes (Schleicher & Schuel, Keene, NH). 
Membranes were blocked for 1h with 5% non-fat dry milk powder in PBS and incubated 
for a minimum of 2h with the specific primary and secondary antibodies. Antibodies used 
for immunoblotting were diluted in PBS supplemented with nonfat dry milk (2.5%) and 
Triton X-100 (0.05%) and used at the following dilutions: anti-phospho-RPA2 (Ser4/Ser8; 
1/2000), anti-phospho-histone H2AX (Ser139; 1/1000), anti-histone H2AX (total H2AX; 
1/1000), anti-phospho-KAP1 (S824; 1/1000), anti-p21 (1/1000), anti-phospho-ATM 
(S1981; 1/1000), anti-phospho-DNAPKcs (T2609; 1/2000), anti-cyclin E (1/500), anti-
phospho-p53 (S15; 1/500), anti-tubulin α (1/5000) and peroxidase-conjugated affinity-
purified goat anti-mouse and goat anti-rabbit were diluted at 1/3000. Total H2AX, 
tubulin-α and Ponceau staining provided loading controls. The detection reaction was 
developed by enhanced chemoluminescent (ECL) staining according to the specifications 
of the manufacturer (ECL Amersham, Western Blotting Detection Reagents, UK). 
 
shEZH2 lentiviral transfection 
Plasmids clones for expression of shEZH2 were selected from a library of shRNA 
enriched for human kinases and phosphatases from Prof. Luís Moita (Rato et al., 2010). 
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Functional clones were selected by their ability to confer resistance to puromycin 
(resistance gene is co-expressed with shEZH2) to HCT116 cell cultures. 
For transfections, HCT116 cells were seeded at the appropriate density according 
to the type of plate one day prior to infection. Medium was removed and virus added to 
cells. Fresh medium with polybrene (Sigma-Aldrich) at a final concentration of 8 µg/ml 
was added and cells centrifuged for 90 mins at 37ºC. Medium was replaced and cells were 
incubated for 24h at 37ºC, 5% CO2. Medium containing puromycin (Sigma-Aldrich) was 
added and cells were incubated for 3 days, replacing growth medium with puromycin 
each day. Surviving cells were incubated in the presence of puromycin until reaching 
proper density for experiments. 
   
Drug combinations assays 
For sequential incubations of DZNep and Etoposide, THP1 cells were diluted to 1 x 
105 cells/ml and seeded in 6-well plates, at 1 ml per well. 1 ml of medium containing 
different concentrations of DZNep was added to wells followed by 24h incubation. Cells 
were washed and 2ml drug-free fresh medium was added, followed by 48h incubation. 
100 µl from each well were resuspended and transferred several times to fill the wells of 
a 96-well plate. 50 µl of respective Etoposide dilution was added to each well and plates 
were incubated for 72h.  Cells were washed and fresh medium and drugs added every 
24h. 50 µl (final concentration 1/200) of alamarBlue reagent (Invitrogen, Carlsbad, CA, 
USA) was added to each well and incubated for 2h. Plates were read for luminescence 
resulting from metabolic activity in the presence of alamarBlue using a Tecan Infinite 200 
microplate reader (Tecan Group, Mannedorf, Switzerland). 
For simultaneous combinations of SAHA and Etoposide, THP1 cells were diluted to 
1 x 105 cells/ml and seeded in 96 well plates, 100 µl per well. 50 µl of different SAHA-Etop 
combinations was added to each well. Cells were incubated for 72h. Drug medium was 
refreshed every 24h.  50 µl (final concentration 1/200) of alamarBlue reagent was added 
to each well and incubated for 2h. Plates were read for luminescence as previously. 
 
Clonogenic assay 
For clonogenic survival assays, cells lines were first subjected to Etoposide pulses 
of varying concentrations for 15 mins then washed, trypsinized and seeded at ≈2000 
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cells/plate.  After 8 days of unperturbed incubation, cells were washed and fixed for 5 
mins in methanol, followed by staining of nuclei with nuclear fast red dye solution (Sigma-
Aldrich) for 5 mins, followed by several washes with ethanol. Proliferating and senescent-
like colonies were counted using a 20x magnifying lens.    
 
Statistical analysis  
Data are reported as the mean ± SD or mean ± SE, as specified.  Results were 
compared by 2-tailed Student’s t test for two groups and one-way ANOVA followed by 
Dunnett’s multiple comparison test for multiple groups. GraphPad Prism version 5.03 for 
Windows (GraphPad Software, La Jolla, CA, USA) was used for statistical analysis. 
Differences were considered statistically significant at P < 0.05 
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3. Results  
 
 
3.1. Damage checkpoint activation in separate cell cycle phases  
 
 
Herein we aim to address the first proposed objective which consists of determining 
whether Topo2-induced DNA lesions are differently handled when introduced in separate 
cell cycle phases, and to what extent they rely on HR and NHEJ for repair. To this end, we 
first established a protocol to reliably synchronize populations of cells at each of the 
intended cell cycle phases. Briefly, by means of a double thymidine block followed by 
carefully planned periods of unblocked cell cycle progression (see Methods), entire 
populations of HCT116 cells were synchronized in either G1, early S, late S or G2 phases 
prior to induction of DNA damage. Afterwards, DSBs were induced by a short pulse of 
Topo2 poison Etoposide (50 µM, 15 mins). Cell cycle progression was monitored at 
predetermined time points after DNA damage by DNA content (PI staining) analysis using 
flow cytometry. Since the normal duration of each cell cycle phase in proliferating HCT116 
cells is well established (≈ 5.5h for G1, 6.5h for S and 4h for G2; see article in this thesis: 
Pereira et al., 2017), we thus have a base of comparison for cell cycle profiles of 
synchronized cells after Etoposide exposure. This allows us to detect potential deviations 
from expected cycling times, which serve as indications of checkpoint activation.   
As shown by the cell cycle profiles in Figure 6, the starting populations collected prior 
to Etoposide treatment were all properly synchronized at the different cell cycle stages. 
Subsequently, Etoposide-Topo2 mediated DSBs triggered the respective cycle checkpoints 
in G1- and G2-damaged cells. This is indicated by the considerable loss of population 
synchronization these cells have suffered 8 hours after DNA damage. 24 hours after DNA 
damage, the G1-damaged population was clearly divided into two main fractions 
determined by DNA content, a 2n fraction corresponding to cells still in G1 phase, and 4n 
fraction corresponding to cells that had reached G2. The G2-damaged population at 24h 
was also composed of two prominent subpopulations, one still halted in G2 and another 
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already in G1. Cells damaged in either early or late S phase remained well synchronized 
and reached the S/G2 transition by the 8h time point, indicating they were not 
substantially delayed by the intra-S checkpoint (based on S-phase lasting ≈ 6.5h). 
However, these cells did not advance into G1 even after an additional 16 hours (24h time 
 
Figure 6. At 8h post Etoposide the G1- and G2-damaged populations have lost synchronization, an 
indication of that only a portion of these populations was delayed by checkpoint arrest. Shown are 
differences in cell cycle progression and γH2AX foci in synchronized HCT116 cells after Etoposide pulse 
at separate cell cycle stages. Separate populations of cells were synchronized in G1, early S, late S or 
G2 using the double-thymidine block methodology, subjected to an Etoposide pulse (50 µM, 15 mins), 
and collected at the specified time points post Etoposide. DNA was stained using Propidium Iodide and 
cell cycle profiles were obtained by flow cytometry. Also, notice that a substancial number of γH2AX 
foci still remain 24h after Etoposide. Population percentages in each phase were estimated using the 
Dean/Jett/Fox algorythm within FlowJo software. Shown are results representative of 3 independent 
experiments. Red: γH2AX; Blue: DAPI.  
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point), which taking into account that S + G2 phase duration is expectedly 10.5h, 
highlights the occurrence of a robust G2 checkpoint arrest. These results show that while 
Topo2-mediated DSBs do trigger checkpoint activation in the same cycle phase in which 
they are introduced, a substantial fraction of the cell population is able to escape 
prolonged cell cycle arrest. 
Next, we wanted to investigate whether cells were exiting from their checkpoints due 
to genuine repair of DSBs to basal levels. Thus, to evaluate DSB repair dynamics 
immunofluorescent staining of cells against histone H2AX phosphorylated in serine 139 
(γH2AX), an histone mark known to signal DSBs (Rogakou, Pilch, Orr, Ivanova, & Bonner, 
1998), was performed in cells collected in parallel with the ones for flow cytometry. Cells 
were then documented by confocal microscopy. For quantification of γH2AX foci numbers 
to be performed in large numbers of cells in a time-efficient manner, analysis software 
was developed by the Bioimaging Unit of Lisbon’s Instituto de Medicina Molecular (IMM). 
Using this software we were capable of extracting these data from cell images in an 
automated fashion (see Methods). This showed that γH2AX foci numbers were at their 
highest 30 minutes after exposure to Etoposide in all cell cycle phases (mean number of 
foci per cell 42 ± 0.8 for G1; 52 ± 0.9 for early S; 50 ± 0.8 for late S and 39 ± 0.7 for G2;) 
and significantly decrease in subsequent time points as cells repair their DNA (Fig.6 and 
7A). Interestingly, this analysis revealed that the great majority of cells in all phases 
tested still contained substantial amounts of γH2Ax foci 8h after Etoposide exposure 
compared to non-damaged controls. Cells damaged in early S (37 ± 1 foci per cell) 
presented the highest average number of foci at 8h followed by late-S-damaged cells (24 
± 0.8 foci per cell). Cells damaged in G1 or G2 displayed lower γH2Ax foci numbers (17 ± 
0.7 and 14 ± 0.5 foci per cell, respectively) than replicating cells, but nonetheless much 
superior to non-damaged controls (2 ± 3 foci per cell).  
By comparing these results with the cell cycle data previously obtained using flow 
cytometry, we conclude that, at 8h, approximately half of G1- and G2-damaged cells 
escapes checkpoint arrest and advances into the subsequent cell cycle stage, while still 
harbouring non-basal levels (though much less than at 30 minutes) of potentially harmful 
DSBs. This becomes even more evident at 24h. Also, almost all cells damaged in early or 
late S phase were able to reach G2 by 24h with high levels of DSBs (31 ± 1.2 and 19 ± 0.8 
foci per cell, respectively). An estimate of DSB levels was also obtained by 
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immunostaining cells with fluorescent anti-γH2AX antibodies and measuring total cell 
intensity by flow cytometry. This type analysis revealed a similar trend to 
immunofluorescence results except for the presence of elevated γH2AX levels in controls 
(Fig.7B). This was not totally unexpected since signal quantification by flow cytometry 
detects all background signals from dispersed histone γH2AX, while in microscopy images 
signals are concentrated in foci, which are easy to separate from the background, 
resulting in the very low damage levels seen in controls.  
 
To confirm if checkpoint activation was in fact being triggered after DNA damage 
induction in all the targeted cycle phases, we decided to detect the presence of key 
Figure 7. Two different methodologies confirm that DSBs still remain 24h after Etoposide 
exposure. Quantification of γH2AX at different time points in synchronized HCT116 cells 
damaged with Etoposide at separate cell cycle phases. (A) Mean γH2AX foci number per cell. 
Cells grown on glass slides were immunostained against γH2AX and visualized using confocal 
microscopy. Foci numbers were quantified by software analysis. Results are shown as mean + 
SEM of three independent experiments. (B) Mean γH2AX fluorescence signal. Cells in 
suspension were immunostained against γH2AX and mean fluorescence intensity for each 
population was measured by flow cytometry. Results are shown as mean + SD of three 
independent experiments.  
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checkpoint and cell cycle regulation factors by protein immunobloting (western blot), 
using extracts collected from cells at the same time points as the previous experiments. 
The targeted proteins included the major regulators and effectors of checkpoint arrest 
phosphorylated ATM, phosphorylated p53, p21, phosphorylated KAP1, and also cyclins A 
and E to certify positioning of cells along the cell cycle. We also detected γH2AX for 
comparison with previously used methods. The response patterns obtained were indeed 
reflective of checkpoint activation in all cell cycle stages after Etoposide treatment (Fig.8). 
Levels of γH2AX followed a pattern that seen with previous techniques, with detection of 
signal peaking at 30 minutes and gradually decreasing for ensuing time points. 
Phosphorylated ATM kinase displayed a rapid increase at 30 mins in response to 
Etoposide exposure, though this increase was not as prominent in early-S-damaged cells 
given the role of ATR as the predominant DDR master kinase in that phase (Awasthi et al., 
2016). Phospho-ATM remained detectable up to 24h in cells damaged at all cell cycle 
stages, except for those damaged in early S phase. Two direct phosphorylation targets of 
ATM that lead to checkpoint activation, p53 and KAP1, also exhibited a clear increase in 
their active (phosphorylated) forms following DNA damage and ATM activation. In the 
case of KAP1, this increase was most noticeable at 30 mins post Etoposide in all 
synchronized populations, particularly in G1, and remained detectable up to 24h, though 
at decreased levels compared to the 30 mins time point. p53, on the other hand, 
presented a slow but sustained increment peaking at 24h in all synchronized populations, 
with G1-damaged cells showing the highest detected signal. This is consistent with the 
known higher dependence of G1 checkpoint on p53 activation compared to other 
checkpoints (Shaltiel et al., 2015). p21, a major repressor of cyclin/Cdk complexes whose 
expression is activated by p53, began to be noticed at 8h in G1 and early-S-damaged 
populations, becoming very prominent by 24h. In late-S- and G2-damaged cells, p21 was 
not noticeable up until 8h but revealed a strong presence by 24h. Taken together, the 
temporal patterns of these proteins serve as evidence of initiation of checkpoint 
activation in all targeted cell cycle stages. However, the late manifestation of phospho-
p53 and p21 indicates that a robust arrest of progression through the cell cycle only 
occurs 8 to 24 hours after DNA damage.     
Detection of cyclins A and E throughout the course of these experiments served as 
an additional control to monitor at which phase of the cell cycle cells were positioned at 
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each time point. The pattern of oscillation of these cyclins fully complied with cell cycle 
 
 
data obtained through flow cytometry analyses (Fig.6). For example, cells damaged in G1 
had low starting levels of cyclin A but a gradual increase up to 24h indicative of 
advancement into G2, whereas cells synchronized in G2 showed a reversed pattern.  
In sum, these results point to the occurrence of “checkpoint leakage”, i.e. 
substantial transition of cells from one cycle phase to the next while full repair of DSBs 
has not yet taken place, in the hours following Topo2-mediated DNA damage, 
independently of the phase at which  DNA lesions have been introduced.  
 
Figure 8. G1-damaged cells display high levels of phospho-RPA2, contrary to G2-damaged 
cells. Western blot assays performed with cellular extracts from HCT116 cells synchronized at 
different phases and damaged using Etoposide (50 µM, 15 mins). Presence of phospho-ATM 
and phospho-KAP1 is indicative of checkpoint activation, p21 and phospho-p53 are indicative 
of persistence of cell cycle arrest. Notice also that Topo2-induced lesions in late S trigger 
phosphorylation of RPA2, but not in early S. Shown are results representative of several 
experiments. 
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3.2. Topo2-mediated DNA damage in separate cycle phases and repair 
system usage 
 
 
If cells were indeed slipping through their checkpoints while still carrying 
considerable levels of DSBs, it is conceivable that these lesions would still be able to 
activate a response from the DNA repair pathways operating in subsequent cycle phases.  
To test this hypothesis, western blotting was also performed for major components of the 
HR and NHEJ pathways. Tested proteins included the end-resection protein RPA2 in its 
active (phosphorylated) form, and the activated catalytic subunit of the DNAPK complex, 
phospho-DNAPKcs (Fig.8). DSBs introduced in G1 elicited the strongest reaction from 
RPA2 compared to other groups, which started increasing at 3h and strongly intensified 
up until the 24h time point. Curiously, the later time points for G1-synchronized (8h and 
24h) cells were previously shown to already contain a substantial fraction of cells in 
phases subsequent to G1 (Fig.6). At those later time points, phospho-DNAPKcs detection 
was also high in these cells. Cells damaged in G2, on the other hand, exhibited the lowest 
phospho-RPA2 signal detection of all groups with little variation across all time points. 
Phospho-DNAPKcs, by contrast, displayed a steady increase in these cells 6h after DNA 
damage that was even more prominent at 24h. The 24h time point coincides with the 
occurrence of a large fraction of cells that have exited G2 and entered G1, as shown by 
flow cytometry results (Fig.6). Finally, lesions introduced in either early or late S phase 
seemed to elicit a different use of repair systems. DSBs in late S clearly induced a higher 
phospho-RPA2 signal than those in early S, although its detection followed a similar 
pattern for both, starting to increase at 3h but only peaking at 8 and 24h. However, while 
phospho-DNAPKcs levels displayed an increase at 6 and 24h after DNA damage in the 
early-S-damaged group, this increase was barely noticeable in late S cells.  
To complement western blot results, fluorescent immunostaining for RAD51, an 
HR partner of RPA2 that acts later in end-resection, and for phospho-DNAPKcs was also 
performed in cells subjected to identical synchronization procedures and Etoposide-
Topo2 damage induction. Quantification of the fluorescent signal emitted by the nuclei of 
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these cells after DNA damage was performed using the same software as before for 
images obtained by confocal microscopy. Unfortunately, the anti-phospho-DNAPKcs 
antibody proved unreliable for immunofluorescence staining. There were, however, clear 
similarities between the patterns of phospho-RPA2 levels obtained by western blot (Fig.8) 
and by microscopic quantification of RAD51 signal per nuclear area (Fig.9). For instance, 
G1-damaged cells showed the highest RAD51 signal of all synchronized populations, 
particularly at 6h after Etoposide. A rapid increase in RAD51 signal intensity was already 
noticeable at 30 minutes in late-S-damaged cells, and this level was sustained in 
subsequent time points, which also coincides with the high level of HR observed in these 
cells in western blots. Cells damaged earlier in S phase also aligned very well with blot 
results, showing reduced signal emission at all time points compared to other stages, 
though presenting a small, gradual increase over time. Only cells damaged in G2 displayed 
a pattern different to that of western blots with an increase in signal at 6h, but less 
pronounced than in G1 cells. Overall, these results support to the observations obtained 
using protein blotting which suggest, on one hand, existence of variations in repair factor 
activity dependent on the initial cell cycle phase at which DSBs are introduced. And on the 
other hand, that these changes in repair factor activity coincide with times at which 
significant transitions of cells harbouring DSBs occur between different cycle phases, even 
though checkpoint activation was initiated.  
 
 
Figure 9. RAD51 fluorescence signal supports RPA2 results obtained by 
western blot. HCT116 cells synchronized at different cycle phases and 
damaged with Etoposide (50 µM, 15 mins). Cells immunostained against 
RAD51 were documented by confocal microscopy and amount of signal per 
nuclei area was measured by software analysis. Results are shown as mean 
+ SEM of three independent experiements.  
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3.3. Effects of targeted repair system impairment on repair dynamics and 
checkpoint arrest 
 
  
Based on the previous results, we thus decided to test if we could induce changes 
in repair system usage and if these changes could contribute to the reversal or 
maintenance of damage-induced checkpoint arrest. To this end, different cell lines were 
employed to investigate whether, by decreasing the efficacy of one of the two repair 
pathways, cells can shift their reliance towards the alternative pathway and whether this 
affects checkpoint behaviour. These included two HCT116 cell lines, one with a targeted 
loss-of-function mutation in one of the DNAPKcs alleles (designated as HCT DNAPK(+/-)) 
and another with loss of both alleles (HCT DNAPK(-/-)). Additionally, a breast carcinoma 
cell line with a germline inactivating mutation in the BRCA1 gene (HCC1937 BRCA1(-)) was 
also used, along with a congenic line in which expression of wild type BRCA1 was restored 
by means of retroviral insertion (HCC1937 BRCA1(+)) (Scully et al., 1999). Non-
synchronized populations of these different cell lines were exposed to a short term 
Etoposide pulse (50 µM, 15 mins) and collected at subsequent time points. We next 
stained cells for DNA content flow cytometry analysis and performed protein 
immnunobloting against key participants in HR and NHEJ repair systems. 
Analysis of HCC1937 BRCA1(+) and BRCA1(-) cell cycle profiles after drug exposure 
revealed that both populations tended to accumulate in G2 phase at the 12h time point 
after damage induction (≈55% of both populations in G2). However, a substantial fraction 
of BRCA1(-) cells was able to progress into G1 by 24h (≈ 48% in G1, 42% in G2) as opposed 
to BRCA1(+) cells that retained a robust G2 arrest (≈ 16% in G1, 70% in G2) (Fig.10A). 
Western blot assays showed that HCC BRCA(-) cells appear to suffer from impairment in 
DSB repair since these cells had higher γH2AX levels at 6 and 24 h after being exposed to 
Etoposide when compared to BRCA1(+) cells. Additionally, loss of BRCA1 clearly promoted 
a switch towards DNAPK activation for DNA repair, while drastically reducing the levels of 
active RPA2 across the entire time course, in agreement with impaired repair of DSBs by 
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Figure 10. Deficiency in BRCA1 causes an increase in phospho-DNAPKcs levels along with G2/M 
checkpoint slippage, whereas deficiency in DNAPKcs leads to increased levels of phospho-RPA2 and a 
more robust G2/M arrest. Asynchronous HCC1937 and HCT116 populations with different BRCA1 and 
DNAPKcs genetic backgrounds after Etoposide pulse (50 µM, 15 mins). (A) Cell cycle profiles of HCC1937 
BRCA1(+) and (-) cells. Cells were stained with Propidium Iodide and analysed by flow cytometry. (B) 
Cell cycle profiles of HCT116 DNAPKcs (+/+), (+/-) and (-/-) cells. Cells were stained with Propidium 
Iodide and analysed by flow cytometry. Cell cycle percentages were estimated using Dean/Jett/Fox 
algorythm. (C) Western blot for detection of repair factor activation in HCC1937 BRCA1(+) and (-) cells. 
(D) Western blot for repair factors in HCT116 DNAPKcs (+/+), (+/-) and (-/-) cells. Shown are results 
representative of three independent experiments. 
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HR. Phospho-ATM levels were also markedly increased in BRCA1(-) cells at all time points 
after DNA damage when compared to BRCA1(+) cells (Fig.10C). 
By comparison, cell cycle profiles in wild type HCT116 DNAPK(+/+) and DNAPK 
knockout lines revealed that, while almost the entire population of DNAPK(-/-) cells was 
arrested in G2 phase 24 hours after Etoposide insult, a large fraction of DNAPK(+/+) and, 
to a lesser extent, DNAPK(+/-) cells had escaped into G1 (Fig.10B). Additionally, depletion 
of DNAPK also seemed to affect the progression of cells through S phase, as can be 
noticed at the 12h time point. This is likely due to an intensification of the intra-S 
checkpoint. Regarding the behaviour of repair factors in DNAPK-deficient lines, DNAPK(-/-
) cells displayed, as was expected, a marked decline in detectable phospho-DNAPKcs 
compared to the other cell lines. This was consistent with higher γH2AX signalling in these 
cells at 24h, suggesting impaired repair of DSBs (Fig.10D). RPA2 activation, however, 
showed a pronounced increase at the 24h time point compared to DNAPK(+/+) cells. 
DNAPK(+/-) exhibited intermediate levels of γH2AX and phospho-RPA2 compared to 
DNAPK(+/+) and DNAPK(-/-), but maintained levels of activated DNAPK similar to the 
DNAPK(+/+) group. These observations therefore support the hypothesis that cells are 
able to compensate loss of function in one system with increased activation of the 
remaining functional one, if available. Also, this change in system usage influences 
checkpoint arrest duration.   
We wanted to further explore how loss of function in one repair system affects 
checkpoint arrest and DNA repair, but this time at the level of different cell cycle phases. 
As such, the cell lines HCT116 DNAPK(+/+) and DNAPK(+/-) were synchronized at G1, early 
S, late S and G2 phases and exposed to a short term Etoposide pulse to induce DSBs; 
synchronization of DNAPK(-/-) cells was not possible due to high levels of cell death.  Cell 
cycle analysis by flow cytometry was performed for all groups as previously. We observed 
a clear divergence between DNAPK(+/+) and (+/-) cell cycle profiles at the later time point 
(22h after Etoposide pulse) (Fig.11A). DNAPK(+/-) cells damaged in G2, late S and early S 
phases displayed a higher tendency to accumulate in G2 at 22h, at the expense of a 
noticeable decrease in G1 transition when compared with DNAPK(+/+) populations. 
Interestingly, there were no observable differences in cell cycle progression between G1-
damaged DNAPK(+/+) and (+/-) groups, suggesting that loss of DNAPK function affects the 
G2/M transition but not necessarily G1/S. 
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We also performed immunoblotting to detect differences in repair factor 
dynamics between G1- and G2-damaged populations with impairment in NHEJ (Fig.11B). 
DNAPK(+/-) cells damaged in G1 showed an overall similar but stronger pattern of RPA2 
activation to DNAPK(+/+). A stronger RPA2 phosphorylation was also observed for DNAPK 
(+/-) cells relative to their DNAPK(+/+) counterparts when Etoposide-Topo2 mediated 
DNA damage was introduced in G2. Also, in DNAPK-deficient cells, the levels of γH2AX 
remained higher until 12h after exposure to Etoposide. This once more supports our 
hypothesis that loss of NHEJ factor DNAPK elicits a stronger end resection response, 
 
Figure 11. DNAPKcs deficiency induces an increase of end-ressection by phospho-RPA2 and a robust 
G2/M arrest at 22h after Etoposide. HCT116 DNAPK(+/+) and (+/-) cells synchronized at separate cell 
cycle phases and exposed to Etoposide pulse (50µM, 15 mins). (A) Cell cycle profiles obtained by flow 
cytometry. Cellular DNA was stained with Propidium Iodide. Cell cycle phase frequencies were 
estimated using Dean/Jett/Fox algorythm. (B) Western blot for detection of repair factor usage. Shown 
are representative results from several independent experiments. 
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particularly noticeable in G2-damaged cells. Once again, the switch in repair system 
leading to activation of HR is accompanied by a prolonged G2 arrest. 
 
 
3.4. DNA repair under forced cell cycle arrest at the G2/M transition 
 
 
In order to understand if the switch from NHEJ to HR that occurs in G2, when 
DNAPK function is decreased, affects the level of lesion repair, we used a competitive 
inhibitor of Cdk1, RO-3306, at a final concentration of 10 µM in HCT116 cells synchronized 
in G2 and subjected to a short Etoposide pulse.  Cdk1 is necessary for initiation of mitosis 
as it acts as an essential mediator of chromosome segregation (Enserink & Kolodner, 
2010). Its inhibition thus prevents cells from advancing past the G2/M transition point, 
effectively inducing a forced cell cycle arrest. Staining of DNA content and flow cytometry 
analysis confirmed that cells treated with Cdk1 inhibitor were unable to exit from G2/M 
even after 18 hours, in clear contrast to non-Cdk1i treated cells, which were already 
mostly in G1 after 10h (Fig.12A). Immunoblotting for γH2AX, along with quantification of 
immunofluorescent foci by confocal microscopy imaging and software analysis, revealed 
that Cdk1 inhibition resulted in cells accumulating higher γH2AX levels than non-treated 
controls (Fig.12B and 12C). Interestingly, Cdk1-inhibited cells also displayed an evident 
intensification of phospho-RPA2 levels after DNA damage, whereas phospho-DNAPKcs 
and phospho-53BP1 levels appeared to be reduced compared to the control group 
(Fig.12B). A prolonged G2/M arrest seems therefore to allow for an intensification of end-
resection-based repair, though it curiously appears to not promote conclusion of DSB 
repair.   
 
 
3.5. Loss of function in DSB repair factors and resulting cellular outcomes 
after Topo2-mediated DNA damage  
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Since predominance of one DSB repair system over the other seems to influence 
the maintenance or reversal of checkpoint arrest, particularly in the case of the G2/M 
checkpoint, we decided to investigate the long term consequences of loss of function in 
either NHEJ or HR repair pathways in terms of cell survival and cellular fate. As previously 
shown, DNAPK knockout (-/-) and BRCA1(-) cell lines have very different G2/M checkpoint 
behaviours after Topo2-mediated DNA damage. DNAPK(-/-) exhibited a robust checkpoint 
arrest, with almost the entire population in G2 24 hours after exposure to Etoposide, 
 
Figure 12. Forced arrest at G2/M transition by use of Cdk1 inhibitor RO-3306 leads to increased RPA2 
phosphorylation but decrease of lesion repair efficiency. HCT116 cells were synchronized in G2, pulsed 
with Etoposide (50 µM, 15 mins) and incubated in the presence of RO-3306 (10 µM) until collection. (A) 
Cell cycle profiles with and without Ro-3306. Propidium Iodide was used to stain celular DNA. Notice 
that after prolonged arrest with RO-3306 a supra-4n population begins to appear as a result of mitotic 
aberrations. (B) Western blot for the detection of repair factor usage. (C) Mean γH2AX foci number per 
nuclei area. Cells were immunostained against γH2AX and documented by confocal microscopy. Foci 
number and nuclear areas were measured by software analysis. Notice the number of γH2AXfoci 
remaining at 18h in Cdk1-inhibitided cells compared to no Cdk1 inhibitor. Results are shown as mean + 
SD.   
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while half of the population of BRCA1(-) cells was already in G1 at the same time point  
after passing through mitosis. Since NHEJ repair is known to be error prone and 
undergoing mitosis in the presence of unrepaired DSBs further adds to the risk of 
genomic instability, these divergent responses to DSBs could also have divergent long 
term effects on cellular fate.  So in order to determine if these cell lines would differ in 
terms of cellular outcomes, we seeded HCT116 DNAPK(+/+), (+/-) and (-/-), and HCC1937 
BRCA1(+) and (-) at clonogenic dilutions (≈2000 cells/plate) and subjected them to short 
pulses of varying concentrations of Etoposide. Clonogenic survival assays were preferred 
because they allow us to monitor cell fate at an almost individual level.  Also, under mass-
growth conditions non-proliferating cells are quickly overcome by proliferating ones, 
causing underestimation of cell fates such as senescence. After 8 days in culture, cell 
plates were fixed and stained and percentages of proliferating and senescent colonies 
were quantified after examining colony size and morphology (see Methods).  
Results show, interestingly, that loss of function in either BRCA1 or DNAPK indeed 
yielded contrasting cell fates. HCC1937 BRCA1(-) populations displayed a very high 
percentage of colonies with the senescent phenotype, becoming very large, flat and filled 
with lysosomes. However, this effect was not dependent on Etoposide since, even with 
no drug exposure, ≈54% of these colonies already showed signs of spontaneous 
senescence compared to ≈26% in BRCA1 (+) cells (Fig.13A). Although Etoposide did 
increase senescent outcome in concentrations up to 5 µM, this increase was similar in 
both BRCA1(-) (≈65%, increased 11%) and  (+) groups (≈45%, increased 19%). Also, higher 
drug doses did not increase senescence numbers further. Such a high initial propensity for 
the senescent outcome was unexpected since the HCC1937 cell line carries an inactivating 
mutation in the p53 gene, a key promoter of senescence. The high percentage of non-
proliferating colonies (including senescent-like colonies and colonies with very few cells, 
an indication of cell death or proliferation arrest) exhibited by these cell lines after 
Etoposide insult (≈78% in BRCA1(-) and ≈65% in BRCA1(+), 30 µM Etop) is thus mostly a 
result of cellular senescence. Since BRCA(-) cells have a high percentage of checkpoint 
leakage into G1 while carrying unrepaired DSBs, they incur the risk of chromosome 
segregation defects, which might be associated with the high propensity for senescence 
seen in these cells.   
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In HCT cells, the senescent phenotype was not as prevalent as in HCC cells, though 
there was a small dose-dependent increase in senescent colonies after Etoposide pulse 
that was consistent for all DNAPK backgrounds (Fig.13B). DNAPK (-/-) cells displayed ≈28% 
of senescent colonies after a 50 μM dose of Etoposide, followed by DNAPK (+/-) (≈16%) 
and (+/+) cells (≈11%), from initial basal levels of ≈14%, ≈5% and ≈2%, respectively. The 
viability of DNAPK knockout lines was nonetheless still seriously compromised by 
exposure to Etoposide in a clear dose-dependent manner. DNAPK (-/-) cells suffered an 
almost complete loss of proliferating capability with a 10 μM Etoposide dose (only ≈6% of 
proliferating colonies compared to ≈63% initially) and, at high concentrations of 50 μM, 
DNAPK (+/-) cells also evidenced a similar response (down to ≈15% compared to 91% 
initially). Curiously, this loss of viability did not present the morphological hallmarks of 
 
Figure 13. HCC1937 cells deficient in BRCA1 have increased spontaneous senescence, whereas 
HCT116 cells deficient in DNAPKcs display na Etoposide-dose-dependent loss of viability by causes 
other than senescence. Clonogenic assays for assessing long term (after 8 days) effects of loss of repair 
factor combined with Etoposide pulses (15 mins) of increasing concentrations. (A) Percentage of 
proliferating colonies and senescent colonies in HCC1937 BRCA1(+) and (-) cells. (B) Percentage of 
proliferating colonies and senescent colonies in HCT116 DNAPKcs(+/+), (+/-) and (-/-). Results are 
shown as mean + SD of three independent experiments per cell line.  
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senescence. Cells maintained normal size and appearance, but did not divide, appearing 
to be in an arrested, quiescent state.  
These observations support our proposition that limiting the availability of either 
NHEJ or HR repair factors can result in different cellular outcomes, with loss of function in 
BRCA1 eliciting a predominance of cellular senescence that is not dependent on Topo2-
mediated DNA damage, while decreased DNAPK activity seems to favor quiescence or cell 
death, but in a Etoposide-dose dependent manner.            
 
 
3.6. Disruption of heterochromatin structure and resulting cellular 
outcomes after Topo2-mediated DNA damage 
 
 
We next decided to address our second main objective, to determine if different 
chromatin states, relaxed (EC) or condensed (HC), can influence the response to Topo2-
mediated DNA lesions and long term cell fate. To that end, we first performed the 
knockdown of the catalytic subunit of the polycomb repressor complex (PRC2), EZH2, in 
HCT116 cells. PRC2 is a major effector of gene silencing responsible for catalyzing the 
trimethylation of histone 3 on lysine 27 (H3K27me3), a repressive mark associated with 
heterochromatin formation (Kadoch, Copeland, & Keilhack, 2016). EZH2 knockdown was 
performed by lentiviral transfection of a plasmid vector encoding a shRNA (small hairpin 
RNA) that specifically interferes with EZH2 mRNA (shEZH2) (see Methods). A separate 
group of cells was transfected with plasmids expressing a scrambled shRNA with no 
cellular target to serve as control for any effects caused by the transfection process itself. 
Knockdown effectiveness was then tested by protein immunoblotting directed against 
EZH2 and against the product of EZH2 activity, the H3K27me3 mark on chromatin. Results 
confirmed that the knockdown had the desired effect, as EZH2 was not detectable in cells 
transfected with shEZH2 compared to scrambled controls, and the presence of the 
H3K27me3 mark was greatly reduced in the shEZH2 group as well (Fig.14A). 
Following knockdown confirmation, we performed clonogenic survival assays for 
HCT116 cells transfected with shEZH2 and Scrambled shRNA to investigate whether this 
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change in an epigenetic heterochromatin mark could affect cellular outcomes after 
Topo2-mediated DNA damage. Results revealed a clear dose-dependent response to 
Etoposide in terms of loss of proliferating capability in these cells (Fig.14B). shEZH2-
transfected cells displayed a basal percentage of non-proliferating colonies of ≈50% in the 
absence of the Topo2 poison, which gradually increased to ≈76% when Etoposide 
concentrations reached 40 µM, while Scrambled cells had a basal frequency of non-
proliferating colonies of ≈25%, but it also rose  to ≈75% at 40 µM of Etoposide. In terms of 
how much of this loss of viability is attributable to the senescence fate, EZH2-knockdown 
cells showed a basal senescence rate of ≈15% compared to ≈5% in Scrambled cells, 
gradually rising to ≈38% and ≈20% with Etoposide doses up to 40 µM, respectively. These 
results indicate that knockdown of EZH2 by itself is enough to substantially promote 
cellular senescence at the basal level (a three-fold increase compared to controls). While 
the number of senescent colonies increased with Etoposide dose, even at high drug 
concentrations the increase in senescence fate with loss of EZH2 was only two-fold that of 
controls. There appears to be only an added effect of the two factors, Etoposide and 
 
Figure 14. Cells with EZH2 knockdown showed a dose-dependent response to Etoposide similar to 
controls. HCT116 cells were knockdown for EZH2 by lentiviral infection with shRNA targeting EZH2 
mRNA. (A) Western blot assays testing EZH2 knockdown efficiency and its effect on the 
heterochromatin mark catalyzed by EZH2 H3K27me3. (B) Clonogenic assays to assess long-term effects 
of shEZH2 knockdown, combined with Etoposide pulses (15 mins) of increasing of concentrations, on 
percentage of proliferating colonies and senescent colonies after 8 days of incubation. Results are 
shown as mean + SD of three independent experiments. 
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depletion of EZH2, instead of an increase in cell sensitivity to Etoposide by means of EZH2 
knockdown. 
We therefore hypothesized that a reduction in a specific heterochromatin mark 
might not be sufficient to compromise heterochromatin structure in a manner that 
noticeably sensitizes cells to the action of a poisoned Topo2 enzyme, or affects cellular 
fates. In order to induce depletion in the levels of other repressive histone marks, such as 
H4K20me3 and H3K9me2, a potent global histone methylation inhibitor, 3-
deazaneplanocin A (DZNep), capable of inhibiting EZH2 as well as most histone 
methyltransferases (Miranda et al., 2009), was used in combination with Etoposide. 
Western blotting against EZH2 in HCT116 cells exposed to 5 or 10 µM DZNep for one or 
two days confirmed that this drug is indeed effective at depleting EZH2, drastically 
reducing the levels of this protein after a 2 days incubation period with DZNep (Fig.15A). 
We next decided to test what combination scheme would be more effective at inducing 
sensitivity to Topo2-mediated lesions in terms of the sequence in which the two drugs 
were used. We tested incubation of HCT116 cells with 10 µM DZNep alone for 24h; 
DZNep incubation prior to Etoposide pulse (15 mins, 50 µM) followed by a 24h period of 
incubation free of both drugs; Etoposide pulse prior to 24h incubation with DZNep; both 
periods of incubation with DZNep between Etop pulse; and Etoposide alone followed by 
24h without any drug. Immunofluorescent detection of γH2AX was performed and 
average of number foci per cell was quantified by software analysis (Fig.15C). Post-
incubation with DZNep following Etoposide pulse did not display any potentiating effect 
of the methyltransferase inhibitor over Topo2-mediated lesions (7 ± 1 foci per cell) 
compared to the combined sum of DZNep (2.6 ± 0.3 foci per cell) or Etoposide (5.1 ± 0.7 
foci per cell) alone. However, interestingly, pre-incubation with DZNep followed by 
Etoposide pulse presented an unexpected increase in the average number of damage foci 
observed in cells (12.1 ± 1.2 foci per cell). DZNep pre-incubation combined with post-
incubation did not substantially increased foci number (13.6 ± 1.4) compared to pre-
incubation alone, indeed pointing to the 24h pre-incubation period as being the crucial 
step in sensitizing cells to Etoposide. This possibly occurs by exposing heterochromatic 
regions to Topo2-mediated DNA damage. 
We subsequently performed flow cytometry analysis to measure DNA content in 
cells subjected to the previous combination schemes to verify if there existed any 
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significant alterations to cell cycle progression between them. Results revealed that when 
incubation for 24h with DZNep was performed prior to Etoposide pulse, there was an 
increase in the frequency of cells in G2/M phases (50%) compared to either drug alone 
(DZNep: 32%; Etoposide: 37%) or no drug (27%) (Fig.15B). The increased level of Topo2-
mediated DSBs remaining 24h after the “DZNep then Etop” drug combination scheme is 
thus likely inducing a prolonged G2/M checkpoint arrest, contrasting with a faster return 
to normal cycle progression by 24h when either drug is used alone. These results show 
that the potentiating effect of DZNep on the DNA-damaging capability of Etoposide-
bound Topo2 is only seen when DZNep is allowed to act before Topo2 cleaves the DNA, 
indicating the existence of a potential synergistic interaction between global histone 
demethylation and the introduction of Topo2-mediated DSBs.  
 
      
 
Figure 15. DZNep pre-treatment sensitizes cells to Etoposide-induced DSBs. DZNep (10 µM) effects 
were tested in HCT116 cells in combination with Etoposide (50 µM, 15 mins). (A) Western blot against 
EZH2 to confirm the inhibitory effects of DZNep on histone methyltransferases. Ponceau staining served 
as loading control. (B) Effects of DZNep (10 µM for 24h) and Etoposide (50 µM, 15 mins) alone and in 
combination (DZNep prior to Etop) on cell cycle frequencies after 24h. Cellular DNA was stained with PI 
and analysed by flow cytometry. (C) Mean γH2AX foci numbers per cell. Different sequences of DZNep 
(10 µM, 24h) and Etoposide (50 µM, 15 mins) were tested: DZNep alone; Etop alone followed by a 24h 
incubation period; Etop followed by DZNep; DZNep followed by Etop and a 24h incubation period; 
DZNep prior to Etop, followed by DZNep again. Cells were immunostained for γH2AX and documented 
by confocal microscopy. Foci numbers were measured by software analysis. Results are shown as mean 
+ SD of three independent experiments. ***: p<0.001; ns: non-significant. 
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3.7. Detection of synergism between Etoposide and DZNep 
 
 
Drug synergism requires that the combined potency of two or more drugs be more 
than the sum of the individual potencies of each drug used alone. This is a deviation from 
additivity, when each drug constituent contributes to the end effect with only its own 
potency. These deviations, which may also occur in the direction of a loss of combined 
potency known as antagonism, can be useful for illuminating the mechanisms behind the 
action of each drug and their interaction (Tallarida, 2001).  
With possible clinical applications in mind, we decided to investigate if the 
detected synergistic effect of DZNep pre-treatment could also be found at low 
concentrations, which we anticipated would be more similar to a chemotherapy setting. 
To this end, we used an acute monocytic leukemia cell line, THP1, incubated for two days 
with different concentrations of DZNep in 6-well plates, after which cells were divided 
into 96-well plates and incubated with the respective DZNep-Etoposide combinations for 
three days. The different combinations resulted from the following concentrations of 
DZNep (0.1, 0.5, 1, 2.5, 5 and 10 µM) and Etoposide (0.05, 0.1, 0.2 and 0.4 µM), with each 
dose in one group combining with all doses from the other group. We then used the 
alamarBlue survivability assay to measure cell viability after exposure to drug 
combinations. Results were read using a luminescence microplate reader (see Methods) 
(Fig.16A). Using the results obtained for cell viability we then calculated the interaction 
index for each drug combination based on the Loewe additivity model (Lee, Kong, Ayers, 
& Lotan, 2007).  An interaction index =1 means additivity, <1 synergy and >1 antagonism. 
Analysis of this data showed that we were indeed able to detect synergism with 
simultaneous low doses of DZNep and Etoposide. Two combinations, 0,5 µM DZNep with 
0,05 µM Etoposide, and 1 µM DZNep with 0,05 µM Etoposide, showed a particularly low 
interaction index (≈0,2), suggesting a very strong synergistic potential for inducing death 
in leukemia cells at low, clinically relevant, drug concentrations (Fig.16B). 
 
 
3.8. Detection of synergism between Etoposide and SAHA 
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Finally, as a proof of concept that our previous approach for the DZNep- Etoposide 
combination study was technically valid, we decided to also characterize the interaction 
between Etoposide and the HDAC inhibitor Vorinostat, also known as suberoylanilide 
hydroxamic acid (SAHA). SAHA was the first HDAC inhibitor approved for clinical use in 
cancer therapy and has been shown to induce growth arrest, differentiation and cell 
death in tumor cells. It can also have synergistic effects when used in combination with 
 
Figure 16. Pre-treatment with low concentations of DZNep synergizes with low concentrations of 
Etoposide to induce increased cell death in a leukemia cell line.THP1 cells were incubated for two 
days with different concentrations of DZNep, followed by a pulse of different Etoposide concentrations 
and incubation for three days. (A) Percentages of cell viability were obtained using alamarBlue assay to 
measure metabolic activity of cells. (B) Interaction índex values were calculated using the Loewe 
additivity model (see Methods). Interaction index =1 means additivity; >1 means antagonism and <1 
means synergism. Results are shown as mean + SD of several independent experiments. 
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other anti-tumor strategies, including Topo2 poisons such as Etoposide (Marchion et al., 
2004). We determined dose-response curves for THP1 cells incubated for three days with 
increasing concentrations of Etoposide and SAHA individually by alamarBlue assay 
(Fig.17A). A program package for R software, SynStat (University of Maryland, USA), was 
then utilized to, based on the on the individual dose-response curves, generate a matrix 
of drug combinations to be tested (see Methods). THP1 cells were incubated in 96-well 
plates for three days with simultaneous addition of Etoposide-SAHA dose combinations 
and cell viability was quantified by alamarBlue assay, as previously. The resulting matrix 
of toxicity effects of drug combinations was inputted into the SynStat software, which 
then generated a contour plot of interaction index values for a range of Etoposide-SAHA 
concentrations (Fig.17B). We then used this plot to select combinations representative of 
synergy (0,1 µM SAHA + 0,6 µM Etop; 1 µM SAHA + 1 µM Etop) , additivity (0,5 µM  SAHA 
+ 1 µM  Etop) and antagonism (1 µM SAHA + 0,2 µM Etop; 1,5 µM SAHA + 0,2 µM Etop), 
that had not been used before when building the plot, in order to test the validity of the 
projection. THP1 cells were incubated for three days with the selected drug combinations, 
after which cell viability was measured and used to calculate interaction index values. 
Comparing the experimentally obtained index values with the predicted values given by 
the contour plot for those combinations, we observe that most predicted interactions 
were confirmed correct, except for 1 µM SAHA + 1 µM Etop where only additivity was 
detected instead of synergy (Fig.17C). This suggests a consistent model fit, although it 
would be desirable to test more combinations. In sum, our technical approach appears to 
be a valid methodology to study drug combination interactions, which could prove useful 
in developing new combination strategies to increase tumor cell death with lower drug 
concentrations.   
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Figure 17. Predicted synergism between SAHA and Etoposide was confirmed. THP1 cells were 
incubated with different combinations of the HDAC inhibitor SAHA and Etoposide simultaneously for 
three days. (A) Dose-response curves for SAHA and Etoposide alone. Cell viability was measured by 
alamarBlue assay. (B) Contour plot of SAHA and Etoposide combinations (isobologram). The boundaries 
of regions with different colors indicate the levels of the interaction index (τ) at the exact value of 0, 
0.3, 0.6, 0.8, 1.3, 1.53, 1.76 and 2.1, respectively. The solid curve indicates the additive combinations 
(τ=1) and the dotted black lines indicate the 95% confidence interval contour for additivity. Green: 
Synergism (Interaction index <1); Yellow: Additivity (Interaction index =1); Red: Antagonism (Interaction 
index >1). (C) Confirmation of predicted effects on THP1 cell viability of SAHA and Etoposide 
combinations. Colors represent the interaction index obtained after experimental testing. All 
combinations yielded the predicted interaction index values except 1 µM SAHa + 1µM Etop that was 
predicted to be synergistic but only displayed additivity. Results are shown as mean + SD of several 
independent experiments.  
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In this chapter we describe the implementation of a new methodology to reliably 
quantify duration of cell cycle phases. This effort was undertaken alongside the work 
described in the previous chapter as a result of mainly two factors: 1) constantly requiring 
more accurate measurements of cell cycle percentages than those provided by standard 
DNA content mono-parametric analysis. This was especially true for cell lines with atypical 
cell cycles namely with very long G1 phase, or very short G1 and G2 phases; 2) the shift 
from using BrdU (5-bromo-2′-deoxyuridine) to using EDU (5-ethynyl-2’-deoxyuridine) in 
flow cytometry procedures and realizing the potential of its stoichiometric properties.  
Although this new methodology was not applied directly in the key experimental 
procedures of the previous chapter of this thesis since it was not yet fully validated, the 
characterization of the cells lines used, namely HCT116 wild type and DNAPK knockouts, 
proved very useful as a proof of concept, providing a comparison standard for all 
previously shown results obtained using these lines.  
 
This work was published in April 2017 in the online journal Oncotarget.     
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ABSTRACT 
 
We propose a novel single-deoxynucleoside-based assay that is easy to perform and 
provides accurate values for the absolute length (in units of time) of each of the cell cycle 
stages (G1, S and G2/M).  This flow-cytometric assay takes advantage of the excellent 
stoichiometric properties of azide-fluorochrome detection of DNA substituted with 5-
ethynyl-2’-deoxyuridine (EdU). We show that by pulsing cells with EdU for incremental 
periods of time maximal EdU-coupled fluorescence is reached when pulsing times match 
the length of S phase. These pulsing times, allowing labelling for a full S phase of a 
fraction of cells in asynchronous populations, provide accurate values for the absolute 
length of S phase. We characterized additional, lower intensity signals that allowed 
quantification of the absolute durations of G1 and G2 phases.  
Importantly, using this novel assay data on the lengths of G1, S and G2/M phases are 
obtained in parallel. Therefore, these parameters can be estimated within a time frame 
that is shorter than a full cell cycle. This method, which we designate as EdU-Coupled 
Fluorescence Intensity (E-CFI) analysis, was successfully applied to cell types with 
distinctive cell cycle features and shows excellent agreement with established 
methodologies for analysis of cell cycle kinetics. 
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INTRODUCTION  
  
The rate at which mammalian cells entry and progress through the different stages 
of their cell cycle is subject to strict regulatory mechanisms to avoid abnormal cell growth 
and division that may pose a threat to structure and function at the tissue level [1]. 
Intensive efforts have been done to accurately monitor cell cycle progression in order to 
better understand and predict tumor development [2]. By identifying changes in 
proliferation rates in response to treatment important contributes can be made to the 
development of anti-cancer therapeutic agents targeting specific steps of the cell cycle 
and the tailoring of treatment strategies for oncologic patients. In addition, determining 
cell cycle kinetics for distinct cell cycle stages is an important step for characterization of 
cancer cell lines [3].  
Kinetics of S phase, in particular, can provide important information on control 
mechanisms and shifts in DNA replication. For instance, during early embryogenesis 
changes in S phase duration are frequent and reflect a progressive slowing down of firing 
rates of replication origins [4], while neuronal progenitor cells seem to shorten their S 
phase as they switch transcription factors on the path to neuron differentiation [5]. 
Currently, various techniques are available to estimate the duration of specific 
cycle phases, each with particular advantages and short-comings. Possibly the quickest, 
easiest and most widely used approach is to stain cellular DNA with a fluorescent dye to 
measure the DNA content of a cell population using flow cytometry analysis. With the aid 
of statistical algorithms implemented within the analysis software this results in the 
distribution of cells along the G1/G0 (2n), G2/M (4n) and S (2n to 4n) phases of the cycle 
[6,7]. This method, however, only provides cell cycle distributions – i.e. relative lengths - 
at a fixed time point and suffers from variability associated with technical artifacts 
introduced by sample preparation, and density and condition of cells that can interfere 
with a uniform staining of cellular DNA [8]. Furthermore, the use of different statistical 
algorithms potentially introduces additional variability in the interpretation of DNA 
measurements between laboratories [9,10].  
Higher sensitivity strategies providing data on absolute durations of each stage of 
the cell cycle usually involve incorporation of detectable nucleoside analogues, the most 
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widely used being the thymidine analogue BrdU (5-bromo-2′-deoxyuridine). BrdU is 
incorporated into cellular DNA during replication to tag cells in S phase, allowing their 
identification by immunofluorescence microscopy or flow cytometry [11]. BrdU has 
become standard use in proliferation studies for the past two decades as it significantly 
reduced the cost and time associated with previously used radioactive analogues (e.g. 
tritium-labelled thymidine). A drawback, however, is that antibody-based detection of 
BrdU has poor stoichiometry and requires a DNA denaturation step. This step, essential to 
expose incorporated BrdU to antibodies, can induce degradation of DNA structure and 
cause variability in the detected fluorescent signals [12].  
In one immunofluorescence microscopy-based approach cell populations are briefly 
pulsed with BrdU to mark cells traversing S phase, and subsequently checked in mitosis 
over incremental chasing periods. Parameters on cell cycle phases can then be estimated 
from the time required for BrdU-labelled cells to reach M phase, yielding absolute G2 
duration, and from the time BrdU-positive cells persist showing up in mitosis, 
corresponding to absolute S phase duration [13,14]. This method boasts high resolution 
and reproducibility, although the technical steps involved in sample preparation and 
microscopic analysis can be very time consuming. Instead of screening for tagged mitotic 
fractions to identify cells that have left S phase other options involve pulsing replicating 
cells with two distinct nucleoside analogues at different times; or else, synchronizing the 
entire cell population to ensure an homogeneous entry in S phase and removal of the 
noise associated with double-pulsing methods [15]. Dual labelling requires the 
simultaneous use and detection of two antibodies specific for different analogues, hence 
special care needs to be taken to avoid cross hybridization signals [16]. Cell 
synchronization, on the other hand, carries the risk of disturbing normal cycle progression 
and inducing cell death, even when performed avoiding the use of drugs that target the 
cell cycle [17].  
In recent years another thymidine analogue, EdU (5-ethynyl-2’-deoxyuridine), has 
become established as a viable alternative to BrdU for labeling replicating DNA. EdU 
harbours a terminal alkyne group that can be detected by its highly specific covalent 
reaction with a fluorochrome-conjugated azide. This property confers several advantages 
over BrdU, namely extremely high sensitivity and ease of use, along with the small size 
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and high intracellular penetration capability of EdU reagents (1/500th the size of an 
antibody molecule). This eliminates the need for the harsh cell permeabilization and DNA 
denaturation steps typical of antibody-based detection techniques [12,18]. The 
characteristics of the EdU-azide reaction further suggest the potential for optimum 
stoichiometry detection of EdU incorporated into DNA by a quantitative methodology 
such as flow cytometry.  
We therefore reasoned that, instead of just scoring fractions of EdU-positive cells, 
it would be possible to extract accurate information on the kinetics of S phase by 
measuring the fluorescent intensities stemming from EdU-substituted DNA (EdU-DNA). 
The basic assumption was that, by pulsing asynchronous cell populations with EdU for 
incremental periods of time, when pulsing times match the length of S phase at least a 
cohort of cells would be labelled for a full S phase. These cells should thus show 
maximum labelling intensity, and the corresponding pulsing time should equal the 
absolute length of S phase. Further increments in pulsing times should only increase the 
percentage of cells featuring such intensities.  
Herein, we provide compelling evidence that this principle can be applied to 
measure the length of S phase with high temporal resolution even under conditions 
where cell cycle progression is perturbed. Furthermore, analysis of the fluorescence 
intensity plots obtained by flow cytometry also yields additional useful information on the 
lengths of G1 and G2 phases of the cell cycle. This novel method, designated here as EdU-
Coupled Fluorescence Intensity (E-CFI) analysis, can be used to characterize cell types 
featuring highly distinct cell cycle characteristics.  
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RESULTS  
 
Effects of EdU on DNA damage response, genomic instability and cell cycle progression  
 
Replacement of natural thymidine by halogenated or alkylated analogues, 
including EdU, has been shown to introduce conformational changes in the DNA helix and 
nucleotide pool imbalance; also, alterations in DNA synthesis and cell cycle progression, 
DNA damage and genomic instability, and increased cell death [19]. We have, therefore, 
tested the potentially noxious effects of EdU on HCT-116 cells to establish temporal and 
dosage constraints to the use of EdU in estimating cell cycle parameters.  
To this end, HCT-116 cells were synchronized at the G1/S transition by a double 
thymidine block and exposed to a range of EdU concentrations (5, 10, 20 and 30 µM) for a 
full S phase (see materials and methods). Cells were then analyzed 5 days later for the 
presence of EdU-labeled individual chromosome territories (CTs), only present in cells 
that underwent several rounds of mitotic division [20,21], and of micronuclei and giant 
nuclei, hallmarks of genomic instability [22]. Of note, nuclei displaying EdU-labeled CTs, 
giant nuclei and micronuclei may concur within the same cell. At low EdU concentrations 
(5 and 10 µM), a significant fraction (>80%) of labeled nuclei shows individual CTs 
consistent with continued cell division (Figure 1A). However, the presence of cells 
harboring micronuclei (19.4 ± 1.6% and 36.5 ± 5.9% for 5 and 10 µM EdU, respectively) 
and giant nuclei (8.8 ± 2.7% and 16.2 ± 3.5% for 5 and 10 µM EdU, respectively) were 
noticeably higher than in EdU-negative controls (5.9 ± 1.9% for micronuclei and 1.6 ± 
0.7% for giant nuclei) (Figure 1A). At 30 µM, EdU induced a drastic reduction of CTs (only 
11.3 ± 4.3% of positive cells) and a sharp increase in cells with signs of genomic instability 
(micronuclei: 31.9 ± 4.3%; giant nuclei: 64.3 ± 9.7%). These data indicate that in the long-
term EdU induces overt signs of genomic instability. 
Since the novel approach proposed here does not require long exposures to EdU, 
we next tested whether pulsing HCT-116 cells with EdU (2.5, 5, 10 and 20 µM) for a short 
period (11 h) induced DNA damage in the form of DNA breaks and replication stress; 
negative controls were provided by cells exposed to solvent alone. Testing the presence 
of DNA breaks (single- and double-stranded) by alkaline single-cell gel electrophoresis 
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(comet assay) revealed that EdU induced statistically significant, though modest (tail 
moments less than twice background), levels of DNA breaks (Figure 1B, also cf. Figure S1 
in Supplementary Data for percentage of DNA in comet tails). By contrast, camptothecin 
(CPT; 5 µM), a known inducer of DNA breaks, and CPT plus EdU (20 µM) induced more 
significant amounts of DNA breakage, as expected. To specifically check for the presence 
of EdU-induced DNA double-stranded breaks (DSBs), HCT-116 cells were immunostained 
for histone γH2AX (variant histone H2AX phosphorylated on serine 139), known to 
accumulate as nuclear foci at genomic sites harboring DSBs [23]. Enumeration of γH2AX 
foci showed that EdU at 20 µM induced a significant increase in damage foci (average of 
12 foci per cell; Figure 1C). Although γH2AX DNA damage foci still increased significantly 
after a 11 h exposure to 5 and 10 µM EdU (3 foci per cell on average), this increase was 
only twice background levels, becoming non-significantly different from control levels at 
2.5 µM (Figure 1C). Moreover, nuclear foci concentrating phospho-RPA (Replication 
protein A), indicative of replicative stress, were not increased in HCT-116 cells exposed to 
EdU 2.5, 5, 10 or 20 µM for 11 h (Figure 1D). In accordance, western blotting analysis for 
the presence of increased levels of phospho-RPA and γH2AX after short term exposures 
to EdU (11 h; 10 and 20 µM) did not show any noticeable difference relative to EdU-less 
controls; however, as anticipated, cells treated with CPT (plus/minus 20 µM EdU) 
displayed high levels of both phospho-RPA and γH2AX (Figure 1E). Importantly, exposure 
of different cell types namely HCT-116, mouse embryonic fibroblasts (MEFs), and mouse 
embryonic stem cells (mESCs) to EdU (10, 5 and 2.5 µM, respectively; 11 h) did not 
change cell cycle profiles obtained by flow cytometry (propidium iodide/PI and 4',6-
diamidino-2-phenylindole/ DAPI staining; Figure 1F). These data are consistent with DNA 
damage and replication stress sensitive checkpoints not being activated within this 
timeframe. 
Altogether, these results show that in the long-term (5 days) even low doses of 
EdU induce prominent signs of genomic instability and alterations in cell division, in line 
with previously reported genotoxic effects of EdU [19,24]. However, short term exposures 
(11 to 12 h) to low concentrations of EdU (2.5 to 10 µM) can conciliate with unperturbed 
cell cycle progression and thus be used in subsequent analyses.  
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Stoichiometry of detection of EdU-labeled DNA  
 
Herein, we aimed at developing a novel methodology for extracting absolute 
values (i.e. in units of time) on the duration of S phase through the analysis of 
fluorescence intensities of EdU incorporated into replicating DNA (EdU-DNA). To do so, 
we first assessed whether detection of EdU-DNA followed strict stoichiometry. 
Incorporation of different concentrations of EdU (0, 5, 10, 15, 20 and 30 µM) into cultured 
HCT-116 cells for a defined period of time (9 h) showed that, as expected, emitted 
fluorescence intensities were not proportional to EdU concentrations (Figure 2A). 
However, for a defined concentration of EdU (10 µM), incorporation for incremental 
periods of time (1 h increments) from 0 h to 11 h revealed robust stoichiometry. Indeed, 
increasing periods of incorporation correlated linearly with increased amounts of total 
fluorescence, expressed as an integral, within the cell populations (Figure 2B).  
Finally, HCT-116 cells synchronized at G1/S transition by a double-thymidine block 
were released into S phase and allowed to incorporate EdU (10 µM) continuously for 7 h 
to achieve full-S labeling before harvesting. Cells were then collected first in G2/M phase 
(8 h after release from thymidine) and later when emerging in G1 phase of the next cell 
cycle (11 h after release). As quality controls for synchronization, analysis by flow 
cytometry (PI staining) revealed that after release from G1/S most cells progressed with 
remarkable synchrony (Figure 2C). Also, more than 80% of the metaphase spreads 
obtained from cells incorporating EdU for 7 h after release from the G1/S block displayed 
fluorescent labeling of EdU-DNA across the entire length of chromosome arms; this is 
consistent with full S labeling. In contrast, a partial (banded) EdU staining pattern was 
seen when cells were only briefly pulsed with EdU (10 min, 15 µM) at 2.5 h or 4 h post 
release from thymidine (Figure S2 in Supplemental data). We then compared the 
intensities of EdU-coupled fluorescence between cells labeled for a full S phase and 
collected at G2/M stages (DNA = 4n) with those allowed to progress into G1 stage (DNA = 
2n). This revealed that appearance of G1 cells harboring half the amount of EdU-DNA 
coincided with the emergence of a half-intensity peak (mean fluorescence intensity (MFI) 
of the G2/M peak and the G1 peak are, respectively, 443 and 212; Figure 2C). 
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In all, these data showed a strict correspondence between amounts of EdU-
substituted DNA and intensities of EdU-coupled fluorescence and predicated our 
subsequent use of EdU in experiments aimed at estimating accurate cell cycle 
parameters. 
 
Analysis of EdU-coupled fluorescence intensities 
 
In the approach proposed here it is assumed that exposing asynchronously 
growing cell populations to EdU for incremental periods of time the maximum labeling 
intensity of EdU-DNA should be reached when the pulsing times approach, or equal, the 
duration of S phase. For such pulsing times, the cohort of cells in which the beginning of 
the pulse coincides with initiation of S phase shall become labeled for a full S phase and 
shall thus feature maximal labeling intensity. Absolute length of S phase shall then be 
equivalent to the minimum pulsing period with EdU that is required to achieve maximal 
EdU-coupled fluorescence intensity. Thereafter, increments in pulsing periods are 
expected to just increase the fraction of cells showing maximal labeling (Figure 3). 
To test this idea, parallel cultures of colon cancer cells (HCT-116) were pulsed with 
EdU for incremental periods from 1 h to 11 h (1 h increments). Fluorescent detection of 
EdU-DNA was performed utilizing an azide-coupled fluorophore (Alexa 488) as part of 
Click-iT chemistry (cf. Materials and Methods) and bulk DNA was stained with either PI or 
DAPI. These experiments showed that fluorescence intensities associated with EdU-DNA 
increase steadily with increasing pulsing times (Figure 4; x axis represents fluorescence 
intensities). Maximal fluorescence intensities were first reached between 6 h and 7 h of 
continuous incorporation of EdU (Figure 4, 7 h time point, peak 3; MFI: 2677). According 
to our hypothesis this should be consistent with S phase duration of 6-7 h, indeed in good 
agreement with data obtained for HCT-116 cells using established methods of cell cycle 
analysis (cf. Table 1). To estimate the duration of S phase by E-CFI with higher temporal 
resolution (n=10) HCT-116 cells were exposed for 6 to 8 h to EdU (10 µM) using pulsing 
increments of 30 min (i.e., 6, 6.5, 7, 7.5 and 8 h). This provided a more refined appraisal 
for S phase length (6.80 ± 0.35 h; Table 1). As expected, longer pulses with 10 µM EdU (8 
h to 11 h) resulted in no discernible increment in maximal fluorescence intensities (Figure 
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4). However, these longer pulsing times led to an increase in the height, i.e. number of 
events/EdU-labeled cells (y axis), of the peak corresponding to the maximally labeled cell 
population (peak 3 in Figure 4). This is also anticipated given the higher chance for 
maximal (full S) labeling by increasing pulsing periods with EdU (Figure 3).  
We then assessed whether the minimum pulsing time with EdU required for 
achieving maximal fluorescence intensity of EdU-DNA, assumed here to correspond to S 
phase length, indeed corresponds to incorporation of EdU for a single, full S phase. To do 
so, exposure to EdU was restricted to a single S phase by blocking cell cycle progression in 
G2 stage with the Cdk1 inhibitor RO-3306. Asynchronous HCT-116 cultures were thus 
exposed simultaneously to EdU (10 µM) and to RO-3306 (10 µM) for 5, 7, 9 and 16 h. 
Controls were provided by parallel cultures exposed to EdU alone for identical periods of 
time and by cells not exposed to EdU (solvent alone). This experimental design ensures 
that a substantial fraction of cells (≈24%), i.e. those that were traversing G1 stage upon 
addition of EdU, will incorporate EdU for a full (and single) S phase and will not progress 
into the next cell cycle.  
As seen in the cell cycle histograms for bulk DNA staining (PI), after addition of the 
Cdk1 inhibitor the cell population initially in G1 stage progressively disappears before cells 
finally arrest in G2 stage, as expected (Figure 5). Analysis of EdU-coupled fluorescence 
further showed that maximal fluorescence intensities of EdU-DNA overlapped 
irrespectively of the presence of RO-3306 (Figure 5).  
These data strongly support the notion that the intensity maxima seen in our 
initial founder experiments indeed correspond to labeling for a full, single S phase (Figure 
4). Importantly, the length of S phase estimated here by flow cytometric analyses of 
intensity maxima of EdU-coupled fluorescence is in excellent agreement with data 
obtained for HCT-116 cells utilizing other, previously validated methodologies (cf. Table 1 
and text further below in this section).  
 
Exploiting other EdU-coupled fluorescence intensity peaks  
 
We initially focused on a  sub-maximum intensity peak that in HCT-116 cells is 
evident after 9 h of EdU incorporation and becomes increasingly prominent thereafter 
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(Figure 4, peak 4).  Use of the Cdk1 inhibitor RO-3306 allowed elucidation of the nature of 
this intensity peak. When cells are blocked in their progression into the subsequent G1 
phase by RO-3306 this peak is absent (Figure 5, 9 h and 16 h, peak 4). Importantly, the 
mean fluorescence intensity of this accessory peak is half the intensity of the maximally 
(full S) labeled cell population (MFI of peak 4 and peak 3 are, correspondingly, 345 and 
671). Moreover, in control cells (RO-3306-minus) that progressed unperturbed for 16 h to 
G1 stage of the next cell cycle, this peak became the most prominent (Figure 5, peak 4). 
Together, these data implicate this half-maximum intensity peak as originating from G1 
cells that resulted from the mitotic division of full-S-labeled cells. Since these G1 cells 
harbor half the amount of EdU-DNA as their progenitors and, correspondingly, emitted 
half the mean fluorescence intensity, this further confirms the good stoichiometric 
properties of the EdU detection system.  
Careful analysis of the EdU incorporation histograms depicted in Figure 4 reveals 
the consistent presence of additional, lower intensity peaks of fluorescence that change 
over time; of note, these peaks are already present in cells not exposed to EdU (No-EdU 
control; cf. Figure 4). Interestingly, the lower intensity background peaks seen in this EdU-
negative population, likely due to the non-specific binding of the azide-Alexa 488 to bulk 
DNA, decomposed in two peaks after exposure to EdU even for short periods (Figure 4, 
peaks 1 and 2). Indeed, dual parameter analyses (EdU-coupled fluorescence vs total 
DNA/PI) showed that these two remaining peaks corresponded, respectively, to cells with 
G1 DNA content (2n; lower intensity peak) and G2 DNA content (4n; higher intensity 
peak) (Figure 6A). Cells with intermediate DNA contents (2n to 4n; S population), 
contributing to intermediate background intensities, have shifted to higher intensity 
regions upon incorporation of EdU leaving behind the double-peak (G1+G2) configuration 
of the background staining (Figure 6A, peaks 1 and 2). We note that background peaks do 
not always present the double-peak configuration. However, these peaks were 
consistently present in the many experiments performed here, acting as robust markers 
for the EdU-negative G1 and G2 populations. As expected, under continuous exposure to 
EdU these G1/G2 background peaks progressively disappear as cells initially at G1 and G2 
stages move steadily into S phase and acquire strongly fluorescent EdU-coupled signals 
(Figure 4). We reasoned that the dynamics of these G1/G2 background peaks during time-
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course experiments may reflect the absolute lengths of G1 and G2 stages. The duration of 
G2 stage shall therefore correspond to the period of time during which cells with G2 DNA 
content (4n) persist featuring background staining. Since this cohort of G2 cells feeds into 
the next G1 phase, the duration of G1 shall be estimated after subtracting the length of 
G2 phase from the total duration of the G1 (2n) background peak.  
We then utilized dual parameter analysis (EdU-coupled fluorescence vs total 
DNA/PI) to monitor over time the dynamics of G1 and G2 cell populations that are EdU-
unlabeled, i.e. just featuring non-specific background staining. As shown in Figure 6B 
(n=5) the percentage of G2 cells in the whole population steeply declined over time, 
reaching baseline levels after ≈4 h of exposure to EdU (G2 length: 3.8 ± 0.45 h; Table 1). 
After an initial plateau, the percentage of G1 cells decreased until 8-9 h of EdU 
incorporation followed by a smoother decline afterwards (Figure 6B). The initial plateau 
highlights the exit of G1 cells into S phase being compensated by entry into G1 stage of 
cells from the preceding G2 phase; the slower decline after the 8 h time point 
underscores the further existence of a minor population in the G1 compartment (< 5%) 
comprised of slow-(or non-)cycling cells . The length for G1 phase (5.40 ± 0.95 h) was 
estimated as the duration of G2 subtracted from the time for decline of the whole G1 
population to baseline levels; this provided a good match to data gathered using 
validated methods (Table 1). 
To further test the sensitivity of this approach we introduced in our analyses HCT-
116 cells that are deficient (knock-out/KO) for the DNA repair enzyme DNA-dependent 
Protein Kinase (DNA-PK; HCT-116 DNA-PK KO). Using the EdU-pulsing method described 
herein (E-CFI) HCT-116 DNA-PK KO cells reached maximum EdU-coupled fluorescence 
intensity after ≈7 h of EdU incorporation (Figure S3 in Supplementary data). As previously 
performed for HCT-116 (DNA-PK wt) cells, short (30 min) increments in EdU pulsing 
between 6 and 8 h allowed a more accurate estimate for S phase length in  HCT-116 DNA-
PK KO cells (6.75 ± 0.42 h; n=6; Table 1). This value is similar to that obtained for the DNA-
PK proficient (wt) HCT-116 cells used throughout this research, and was confirmed by 
previously validated methodologies (Table 1).  
We subsequently tested in HCT-116 DNA-PK KO cells, as described above for HCT-
116 cells, whether quantitative analysis of G1/G2 background peaks again provided 
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accurate values for the lengths of G1 and G2 phases.  Analysis of five independent 
experiments showed that the percentage of G2 cells sharply decreased over 4 h of EdU 
incorporation before reaching baseline levels (Figure 6C). This is consistent with a G2 
phase length (3.60 ± 0.55 h; n=5) in HCT-116 DNA-PK KO cells that is similar to HCT-116 
cells that are proficient for DNA-PK (Table 1). However, the decline in G1 cells lasted 
longer in DNA-PK KO cells than in their DNA-PK-wt counterparts. Near-baseline levels 
were reached at 9 h, with a slower decline thereafter (Figure 6C). After subtracting the 
duration of G2 this yields a length for G1 phase that is slightly higher (6.0 ± 1.45 h; n=5) 
for DNA-PK KO than for DNA-PK wt HCT-116 cells (Table 1).  Note that the fraction of 
slow/non-cycling cells (between 5 and 10%) is clearly more prominent than in HCT-116 
cells harboring wt DNA-PK (< 5%) (Figures 6B and 6C). Indeed, the fraction of slow/non-
cycling cells which do not incorporate modified deoxy-nucleosides even after prolonged 
exposure times was also shown to be higher in HCT-116 DNA-PK KO cells using other 
methods of cell cycle analysis (Figures 8C and 8D). 
In sum, these data highlight the relevance of analyzing other peaks present in EdU-
coupled fluorescence intensity histograms. Specifically, it was shown that quantitation of 
background intensity peaks provides accurate measurements for the lengths of G1 and 
G2 phases. These low intensity peaks also allow quantitative estimates of slow/non-
cycling cells within a population. 
 
EdU-coupled fluorescence intensity analysis in non-transformed mouse cells 
 
We next tested whether the analysis of fluorescence intensities associated with 
EdU-DNA could be applied to accurately judge cell cycle parameters in other cell types, 
namely in non-transformed cells. To this end, we utilized pre-quiescent (passage 26-28) 
mouse embryonic fibroblasts (MEFs) and mouse embryonic stem cells (mESCs). These cell 
types were chosen for their remarkably different duplication times. Pre-quiescent MEFs 
duplicate over a period of days, with a large proportion of cells in G1 and G2 stages 
(Figure 1F). By contrast, when under logarithmic growth mESCs feature a short cell cycle 
length with fast gap and S phases [25]. Given the exquisite sensitivity of ESCs to EdU [26], 
in this set of experiments we have consistently used lower doses of EdU (2.5 and 5 µM).  
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MEFs and mESCs were therefore exposed for increasing periods of time (0 to 11 h; 
1 h increments) to EdU (MEFs/5 µM; mESCs/2.5 µM) before analysis of EdU-DNA 
fluorescence intensities by flow cytometry, as previously described. This showed that 
MEFs reached maximal intensity after 8 h of continuous incorporation of EdU (Figure 7A). 
As expected for pre-quiescent cell populations with a long G1 phase, the G1/G2 
background peaks remained remarkably stable over the incremental pulsing periods used 
here (Figure 7A plus data not shown). By contrast, mESCs displayed maximal intensity of 
EdU-coupled fluorescence after just ≈5 h of exposure to EdU (Figure 7B; MFI: 60636). 
Also, in mESCs the G1/G2 background peak decreased to residual levels after 
incorporation of EdU for 4 to 5 h (Figure 7B plus data not shown). Quantitative analysis of 
background peaks as performed above for HCT-116 cells showed that G1 and G2 phases 
lasted ≈2 h each (data not shown). These data are consistent with a total length of ≈9 h 
for the full cell cycle in mESCs, in excellent agreement with previously published data [25].  
These experiments further extend the applicability of the novel E-CFI method to other cell 
types, even under the constraint of utilizing very low concentrations of EdU. 
 
Comparison with other methods of cell cycle analysis 
 
We subsequently tested how the method developed here compared to previously 
implemented assays aimed at estimating cell cycle parameters.  
In a robust pulse-chase method – termed “Fraction of Labeled Mitoses” - that 
allows absolute estimates of the duration of S and G2 phases, cells are first briefly pulsed 
with a radioactive or a modified deoxy-nucleoside (e.g. BrdU), chased in mitosis for 
incremental periods of time and scored for the presence of labeled chromosomes 
[13,14,27]. In this assay, the time between pulsing and the emergence of the first labeled 
mitotic cells (≈50% of labeled cells) equals the absolute duration of G2. The time period 
during which the cohort of cells previously labeled in S phase with BrdU continues 
showing up in mitosis with BrdU-labeled chromosomes corresponds to the absolute 
duration of S phase [14]. 
Parallel cultures of HCT-116 cells (DNA-PK wt and DNA-PK KO) were therefore 
pulsed with BrdU (20 µM; 15 min), collected at hourly intervals up until 12 h after pulsing, 
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immuno-stained for BrdU, and the percentage of BrdU positive mitotic cells 
(prometaphase plus metaphase stages) was assessed for each time point. These 
experiments showed values for S and G2 phases very close to those obtained using E-CFI, 
for both DNA-PK deficient and proficient HCT-116 cells (Figure 8A and Table 1). 
We also used the “Leaving Fraction” method in which cells are first pulsed with a 
modified deoxy-nucleoside, chased for a defined time period in medium free of modified 
nucleosides, and subjected to a second pulse with a differently modified nucleoside 
before collection (cf. Materials and Methods). The fraction of cells labeled by the first 
modified nucleoside but not by the second corresponds to the so-called leaving fraction, 
i.e. the fraction of cells that although initially in S phase have reached G2 during the chase 
period. Through extrapolation, the time required for all cells to leave S phase, which 
equals S phase duration, can be estimated as an absolute value (see also Materials and 
Methods) [28–30]. Notably, this microscopy-based method also yielded an S phase 
duration (6.3 ± 0.4 h) similar to that we have obtained throughout this research for HCT-
116 cells using E-CFI (Table 1). 
In a third approach we used a “Cumulative Labeling” method, also known as 
“Saturation Labeling” [31], to assess the absolute duration of G1 plus G2 stages. The 
underlying principle is that upon a brief exposure to a modified deoxy-nucleoside this is 
exclusively incorporated into the replicating DNA of cells traversing S phase. However, if 
pulsing times are progressively extended to encompass the duration of G1 plus G2 all cells 
initially at these stages will ultimately be allowed to reach S phase and thus to 
incorporate the analogue. Therefore, the minimal pulsing times with the analogue that 
allow labeling of the whole cell population will match the combined duration of G1 plus 
G2 stages for that population [32,33]. HCT-116 cells (DNA-PK wt and DNA-PK KO) were 
thus pulsed with BrdU (10 µM) for incremental periods of time up until 10.5 h before 
scoring by fluorescence microscopy. Again, the estimates for the combined duration of G1 
plus G2 (HCT-116 DNA-PK wt: 7.5 to 9 h ; HCT-116 DNA-PK KO: ≈9 h) closely agree for 
both cell lines with those obtained using E-CFI (Figure 8C, 8D and Table 1). Interestingly, 
for both cell lines a sub-population of slow-/non-cycling cells was identified that was 
slightly more prominent in DNA-PK KO cells, as previously seen in experiments using E-CFI 
(Figure 8C and 8D). 
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Additionally, we used a pulse-chase methodology for estimation of the lengths of S 
and G2 phases [19]. To this end, HCT-116 (DNA-PK wt and DNA-PK KO) and mESCs were 
pulsed with EdU (10 µM and 5 µM, respectively) for 30 min and collected either 
immediately (no chase), or else chased in EdU-free medium before collection at hourly 
intervals. The length of G2 phase was estimated as the period of time between the end of 
the EdU pulse and the time point at which the population harboring G2 DNA content (4n) 
showed the highest percentage of EdU-positive cells. This expectedly occurs when the 
cohort of EdU-labeled cells (i.e. in S phase during EdU pulsing) reaches the G2/M 
transition after traversal of G2 phase. The interval between this latter time point and the 
time point where the population with 4n DNA content reaches its lowest percentage of 
EdU-positive cells was considered as the duration of S phase. This corresponds to the 
period during which the cohort of EdU-labeled cells fully passes through the G2/M 
transition into the next G1 phase. 
Analysis by dual-parameter flow cytometry (EdU vs total DNA/PI) showed that the 
cohorts of EdU-labeled vs unlabeled cells progress evenly over time between cellular 
compartments harboring 2n and 4n DNA amounts (HCT-116 cells; Figure S4 in 
Supplementary data, plus data not shown). However, as depicted in Figures S4 and S5 
(Supplementary data; HCT-116 cells), for each of four independent experiments it proved 
difficult to judge for cells with 4n DNA the time points at which the percentage of EdU-
positive cells reached a maximum. Indeed, in these bowl-shaped curves these maximal 
values - typically reached at 4 to 6 h after the EdU pulse - are almost identical between 
neighbor time points (cf. Figure S5). When these data were combined (n=4) in a single line 
chart this showed that the maximal percentages of EdU-positive cells (4n DNA) seen at 
the 4, 5 and 6 h time points were not significantly different (81.2 ± 12.3%, 86.6 ± 9.7%, 
86.4 ± 3.5%; 4, 5 and 6 h , respectively; Figure S6A in Supplementary data). Within the 
constraints of this method, we estimated the length of S and G2 phases for HCT-116 cells 
(DNA-PK wt, n=5; DNA-PK KO, n=4; Table 1).  These values, despite their lower temporal 
resolution in particular for S phase, are in broad agreement with those obtained by E-CFI 
(Table 1). Assessment of mESCs by EdU pulse-chasing yielded better homogeneity 
between different experiments as shown in the graph depicting pooled data (n=4; Figure 
S6B in Supplemental data). The durations of S (5.75 ± 0.5 h) and G2 (4.25 ± 0.5 h) phases 
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were estimated taking the 4 h time point as that corresponding to the highest percentage 
of EdU-positive cells within the 4n DNA population (cf. Figure S6B in Supplementary data). 
Finally, we combined the commonly used analysis of the cell cycle by flow cytometry after 
PI staining of DNA with estimates of the absolute duration of the cell cycle in HCT-116 
cells. This latter parameter is essential to convert the percentage of cells at a given cell 
cycle phase, which directly correlates with the relative length of that same phase in 
reference to the full cell cycle, into absolute lengths (i.e., in units of time).  
Taking the duration of the cell cycle as the absolute parameter (14-15 h for HCT-116 
cells), the percentage of cells seen at each cell cycle stage in flow cytometry histograms of 
PI-stained DNA was then converted into absolute lengths (hours). We note that the two 
available mathematical models within FlowJo, Watson Pragmatic (WP) and Dean/Jett/Fox 
(D/J/F), yielded discrepant percentages for each of the cell cycle stages in HCT-116 cells. 
The values obtained through the WP algorithm provided a better fit to the data gathered 
throughout this research using different methodologies, including E-CFI (cf. Table 1, and 
Table 2 in Supplemental data). However, using either of these algorithms (WP or D/J/F) 
we could not generate any reliable estimates for the much less canonical cell cycle 
histograms from exponentially growing mESCs (depicted in Figure 1F).  
In sum, the E-CFI method described herein shows excellent concordance with data 
obtained through various well established methods of cell cycle analysis. 
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DISCUSSION 
 
We have herein described an assay which we termed E-CFI that allows easy and 
accurate measurements of the absolute length of all stages of the cell cycle (G1, S and 
G2/M) by flow cytometry.  
The approach of reference to analyze the duration of the different stages of the 
cell cycle is based on flow cytometric analysis of cellular DNA stained with a fluorescent 
dye that binds stoichiometrically, and thus allows measurement of DNA content [34]. This 
provides values on the proportion of cells found at each phase (G1, S and G2/M) which 
directly correspond to relative durations in reference to the length of a full cell cycle. 
Despite the use of algorithms that attempt at fitting Gaussian curves to each phase, a 
clear distinction between cells traversing very early or late S phase from cells in G1 and 
G2 phase, respectively, remains difficult by single parameter DNA analysis [10,34]. This 
difficulty becomes more obvious for cell types with atypical cell cycles namely with very 
long G1 phases, as is the case of pre-quiescent MEFs, or very short G1 and G2 phases, 
such as mESCs (Figure 1F; also Table 1). In such cases, under or overestimation of the 
length of S phase is the typical result [35]. Indeed, applying two different mathematical 
models, Dean/Jett/Fox and Watson Pragmatic, discrepant data was obtained for HCT-116 
cells with D/J/F yielding unusually short durations for S phase (≈5 h; Table 1, and Table 2 
in Supplemental data). Unfortunately, clear criteria for choice between different 
algorithms do not exist. In mESCs, in which S phase typically lasts more than 50% of the 
total cell cycle, both the D/J/F and the WP algorithms proved unreliable. Moreover, the 
conversion of these data on relative durations into absolute lengths for each phase 
requires an additional, accurate estimate of the absolute length of the cell cycle under the 
conditions being tested [7].  
Pulse-chase methods utilizing EdU (or BrdU) also provide data on absolute 
durations of cell cycle phases and stand as possible contenders to the E-CFI assay 
described herein [19]. These methods, however, rely critically on selecting the fraction of 
EdU-positive cells within sub-populations of defined DNA content. They therefore share 
the known constraints of quantitative analyses of single parameter DNA histograms 
[7,36].  As a result, estimates for the duration of S and G2 stages have lower temporal 
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resolution (higher dispersion) than those obtained with either E-CFI or other classical, 
validated methods (Table 1). 
Herein, we have utilized pulse-chasing with EdU on HCT-116 cells (DNA-PK wt and 
DNA-PK KO) and mESCs, and found that the critical time points to judge the duration of 
G2 and S phase proved difficult to determine unambiguously. Setting up these time points 
allows tracking of the cohort of EdU-positive cells over time. These correspond, 
specifically, to the time point(s) at which the G2 (4n DNA) population features the highest 
percentage of EdU-positive cells and, later, the lowest percentage of EdU-positive cells.  
The time interval between the end of the EdU pulse and the point(s) of maximal labeling 
corresponds to the length of G2; the interval between maximal and minimal labeling time 
point(s) corresponds to the length of S phase.  
The exemplary case is provided by mESCs (Figure S6B in Supplemental data). In 
these cells, the time points corresponding to maxima of EdU-positive cells (≈92% to ≈96%) 
distribute broadly between 2 and 5 h after pulsing with EdU, with the minimal fraction of 
EdU-positive cells seen at 10 h after pulsing (cf. Figure S6B in Supplemental data). Taking 
the 2 h time point as the most significant maximum would be consistent with a ≈2 h 
duration of G2 phase in mESCs, in agreement with previously published data and the 
results obtained herein using E-CFI [25]. However, the interval between this and the 10 h 
time point (minimal percentage of EdU-positive cells) would lead to an excessively long 
estimate for S phase (≈8 h). This dilemma stems, at least in part, from the duration of G2 
being much shorter than that of S phase, and also from the poor discrimination between 
cells at later stages of S phase (close-to-4n DNA) and genuine G2 cells. This latter issue 
can be appreciated at the end of the EdU pulse when most cells (>60%) harboring 4n DNA 
content have indeed incorporated EdU (cf. Figure S6B in Supplemental data; 0 h after EdU 
pulse).  
The assay we describe here, E-CFI, is easy to perform and allows accurate 
estimates of absolute lengths (in units of time) of all the different stages of the cell cycle 
(G1, S, and G2/M). The duration of S phase is assessed without selection of cell 
populations based on DNA content. Although this is required for analysis of G1 and G2 
phases, these two phases can be accurately separated given the absence of cells in the 
intervening S phase in background peaks. The classical problem of discriminating cells at 
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the G1/S and S/G2 borders is thus avoided [7,36]. Furthermore, E-CFI allowed the 
identification and quantification of sub-populations with decreased proliferative potential 
(slow-/non-cycling cells) within the G1 compartment in HCT-116 cells. We note that, in 
contrast to E-CFI, the duration of G1 is difficult to quantify in dual-parameter histograms 
from EdU pulse-chase experiments (Figure S4 in Supplemental data).  
Herein, we have used the Cdk1 inhibitor (RO-3306) to demonstrate that the 
intensity maxima reached after continuous incorporation of EdU correspond indeed to 
labeling for a single, full S phase (Figure 5). These experiments further showed that E-CFI 
allows accurate estimation of S phase length even when cell cycle progression is blocked. 
Of note, this blockage would preclude the use of other methods of cell cycle analysis 
namely pulse-chase, cumulative labeling and methods in which labeled mitosis are 
scored. 
E-CFI showed excellent correlation with the highly reproducible and precise 
methods of “Cumulative Labeling” and “Fraction-of-labeled mitosis/FLM”[15,31–33] 
(Table 1). These microscopy-based classical methods are, however, highly time consuming 
and thus not amenable to routine use. By contrast, E-CFI yields fast results by acting in a 
time-compressing fashion whereby G1, S and G2/M phases are assessed in parallel. This 
allows absolute estimates on the lengths of each cell cycle stage to be collected over a 
time period that is shorter than the duration of a full cell cycle. For example, for HCT-116 
cells whose full cell cycle lasts for 15-16 h, the length of all cell cycle phases can be 
determined in 8-9 h. 
We anticipate that E-CFI may provide a very valuable tool in the analysis of drugs 
targeting the cell cycle in the context of cancer chemotherapy, especially if coupled to 
powerful multiparametric analyses using flow cytometry or high-content imaging 
[7,37,36,38]. Also, the basic principle that predicated the development of E-CFI may be 
applied in the future to quantitative fluorescence microscopy-based approaches aimed at 
estimating absolute, accurate cell cycle parameters. 
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MATERIALS AND METHODS 
 
Cell culture, chemicals and antibodies  
Human colorectal carcinoma HCT-116 (ATCC CCL-247) and HCT-116 knock-out for 
DNA-PK were obtained from the laboratory of Dr. Bert Vogelstein, Johns Hopkins School 
of Medicine, Baltimore, MD. HCT-116 cells were cultured in McCoy’s 5A Modified medium 
supplemented with 10% heat inactivated foetal bovine serum (FBS), 2 mM L-glutamine, 
10mM MEM non-essential amino acids,  and 100 U/ml penicillin/streptomycin (all from 
Gibco, Thermo-Fisher Scientific, Waltham, MA, USA) and maintained at 37ᵒC in a 
humidified incubator at 5% CO2. Mouse embryonic fibroblasts (MEFs) were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% ES Cell-qualified 
FBS (Invitrogen, Thermo-Fisher Scientific, Waltham, MA, USA), 10 mM MEM non-essential 
amino acids, and 0.1 mM 2-mercaptoethanol (Gibco).  Mouse embryonic stem cells 
(mESCs) were grown at 37ᵒC in 5% CO2, in Glasgow Modified Eagle´s Medium (GMEM, 
Invitrogen) supplemented with 10% FBS (ES-Cell qualified), 10 mM MEM non-essential 
amino acids, 1% GlutaMAX, 1 mM 2-mercaptoethanol and 2 ng/mL Recombinant Human 
Leukemia Inhibitory Factor (LIF; serum/LIF conditions), on gelatin-coated (0.1% v/v) dishes 
(Nunc, Roskilde, Denmark). Cells were passaged on alternate days at a constant plating 
density of ≈3 x 104 cells/cm2. 
Camptothecin, RO-3306, 5-bromo-2´-deoxyuridine (BrdU), thymidine, propidium iodide 
(PI), 4',6-diamidino-2-phenylindole (DAPI) and RNase A were purchased from Sigma-
Aldrich (St. Louis, MO, USA).  
The following antibodies were used in this research: rabbit polyclonal to histone 
H2A.X (ab11175, Abcam, UK [39]), mouse monoclonal IgG1 to phospho-histone H2A.X 
(Ser139; clone JBW 301; Merck-Millipore, Darmstadt, Germany [40]), mouse monoclonal 
IgG1 to RPA32/RPA2 (clone 9H8; ab2175 Abcam, UK [41]), affinity-purified rabbit 
polyclonal to phospho-RPA32/RPA2 (Ser4/Ser8; Cat. A300-245A; Bethyl Laboratories, 
Montgomery, TX, USA [42]), mouse monoclonal antibodies to BrdU (clones BU-33 and 
BMC 9318; Sigma-Aldrich), affinity-purified Alexa 488-conjugated and Cy3-conjugated 
anti-mouse secondary antibodies (Jackson ImmunoResearch Laboratories, Sacramento, 
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CA, USA), and peroxidase-conjugated affinity-purified goat anti-mouse IgG and goat anti-
rabbit IgG (BioRad Laboratories, Hercules, CA, USA).  
 
EdU incorporation and detection for flow cytometry 
EdU (5-ethynyl-2’-deoxyuridine), supplied with Click-iT EdU Alexa Fluor 488 
Imaging Kit (#C10337, Thermo-Fisher Scientific, Waltham, MA, USA), was diluted in DMSO 
to a final concentration of 10 mM and kept at -20oC. Typically, EdU was added to parallel 
cultures growing exponentially in 30 cm2 petri dishes to final concentrations ranging from 
2.5 to 30 µM for varying lengths of time until collection. Cells exposed to DMSO (solvent) 
alone served as controls. Cell pellets (approx. 5 x 105 cells) were vigorously resuspended 
in 200 µL of ice cold 2% formaldehyde in PBS and fixed for 2 min, permeabilized by 
subsequent addition of 1 mL of 70% ice-cold ethanol (without removal of formaldehyde), 
and kept on ice for a minimum of 10 min. Cells were then washed three times in 1 mL PBS 
containing 0.05% Triton X-100 (PBS-Tx) before detection of EdU-substituted DNA (EdU-
DNA). Detection of EdU-DNA was performed according to the Click-iT EdU Alexa Fluor 488 
Imaging Kit as per manufacturer’s instructions. Cell pellets were incubated in 100 µl of 
reaction buffer for 35 min at 37ᵒC protected from light. Cells were subsequently washed 4 
X 10 min in 1 mL PBS-Tx 0.05% under constant shaking before staining of bulk DNA with PI 
or DAPI. 
For PI staining, cell pellets were resuspended in 300 µL of a solution comprised of 
10 µg/mL PI, 192 µg/mL RNase A and 0.1% Triton X-100 in PBS and incubated for 30 min 
on ice, followed by a further incubation for 30 min at 37ᵒC, protected from light.  For DAPI 
staining, cell pellets were resuspended in a solution of 1 µg/mL of DAPI in PBS containing 
0.1% TritonX-100 and incubated protected from light for 1h at 37ᵒC. Cells were washed 
three times in PBS-Tx before measuring their fluorescence by flow cytometry.  
 
Flow cytometry instrumentation and data analysis  
Samples stained for EdU, PI and DAPI were analyzed using a three laser (blue-488nm; red-
640nm; violet-605nm) BD LSR Fortessa flow cytometer (BD Biosciences, San Jose, CA). 
EdU–Alexa 488 and PI signals were measured upon excitation by the blue laser using 
530/30 and 695/40 bandpass filters, respectively. DAPI signals were measured upon 
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excitation by the violet laser with the 525/50 bandpass filter. A minimum of 30000 events 
were acquired per experiment in slow rate mode to avoid doublets.  Sample 
measurements were performed with FACSDiva Software (Version 6.2, BD Biosciences, San 
Jose, CA, USA). Data analysis, such as mean fluorescence intensity (MFI) measurements, 
was performed with FlowJo Software (Ashland, OR, USA). Cell debris and aggregates were 
excluded from the analysis using pulse processing FSC-A vs FSC-H, FSC-H vs FSC-W, SSC-H 
vs SSC-W, and FL2-A vs Fl2-W when appropriate.  
 
Immunofluorescence staining  
For immunofluorescence analysis, HCT-116 cells growing on coverslips were 
routinely fixed in freshly prepared 3.7% paraformaldehyde in HPEM buffer (30 mM 
HEPES, 65 mM Pipes, 10 mM EGTA, 2 mM MgCl2 (pH 6.9)) plus 0.5% Triton X-100 for 10 
min at room temperature before incubation with antibodies. All washes were performed 
with PBS containing 0.05% Triton X-100. For detection of BrdU incorporated into 
replicating DNA, fixed cells were further incubated with 4N HCl for 10 min to depurinate 
DNA and washed four times for 10 min in Tris 50 mM (pH 8) preceding incubation with 
anti-BrdU antibodies. For the double labeling of BrdU and EdU immunostaining of BrdU 
preceded detection of EdU by the Click-iT method. Antibodies used for 
immunofluorescence were diluted in PBS containing fish skin gelatin (0.1%) and Triton X-
100 (0.05%) as follows: anti-RPA32/RPA2 at 1/200, anti-phospho-histone H2A.X (Ser139) 
at 1/300, anti-BrdU at 1/100 and Cy3-conjugated anti-mouse secondary antibodies at 
1/100. After immunolabeling, total DNA was stained with DAPI (0.5 µg/mL) and coverslips 
were mounted in Vectashield (Vector Laboratories Inc., Burlingame, CA, USA) before 
analysis by fluorescence microscopy. 
 
Confocal microscopy  
Samples were examined using a Zeiss 510 confocal microscope (Carl Zeiss, Jena, 
Germany) equipped with lasers giving excitation lines at 405, 488 and 543 nm. Data from 
the channels were collected separately using narrow-band-pass filter settings. In multiple 
staining experiments, the laser intensities were adjusted to avoid bleedthrough between 
channels. Data were collected with two- to fourfold averaging at resolution of 1024 X 
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1024 pixels using pinhole settings between 1.05 and 1.10 airy units. Data sets were 
processed using Zeiss 510 version 2.8 software package and were subsequently exported 
for preparation for printing using Adobe Photoshop, version CS5.1. 
 
Other methods for estimation of cell cycle parameters 
In the methods described below BrdU was administered either as a single pulse or 
in association with a second, distinct pulse with EdU (double-pulsing). Asynchronous 
cultures of HCT-116 cells were grown on glass coverslips before fixation and microscopic 
analysis. 
To estimate the absolute durations of G2 and S phases HCT-116 cells were briefly 
pulsed with BrdU (10 µM, 15 min) and chased in BrdU-free medium for incremental 
periods of time from 3 to 11 h (1 h increments) before collection.  Cells were then fixed in 
paraformaldehyde and immunostained for BrdU as described herein. After staining of 
DNA with DAPI (0.5 µg/mL) cell populations were scored for the presence of BrdU-
positive mitotic cells under the fluorescence microscope (Olympus BX50). G2 length was 
estimated as the shorter chasing time that resulted in ≈50% of BrdU-labeled mitotic cells, 
and the duration of S phase as the interval of time during which ≥50% of mitotic cells 
displayed staining for BrdU [13,27]. 
Duration of the G1 plus G2 phases of the cell cycle was assessed using a 
cumulative (or saturation) labeling method [32]. Briefly, exponentially growing HCT-116 
cells were continuously pulsed with BrdU (10 µM) for incremental periods from 1.5 h to 9 
h (1.5 h increments) before collection. Cells were fixed in paraformaldehyde and 
immunostained for BrdU, and the percentage of BrdU-positive cells was scored for each 
time point. The duration of G1 + G2 stages was estimated as the minimum pulsing time 
required for ≈100% of the cells to become positive for BrdU [33]. 
To judge the absolute length of S phase we also used the so-called “leaving fraction” 
method [28,29]. To this end, HCT-116 cells were first pulsed with BrdU (10 µM, 15 min) 
and chased in BrdU-free medium for 75 min before exposure to a second pulse with EdU 
(15 µM, 15 min). Cells were then processed for the simultaneous detection of BrdU and 
EdU, as described here. The leaving fraction, corresponding to the fraction of cells that 
although initially in S phase – and thus BrdU-positive - have left S phase during the 
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chasing period (thus EdU-negative) was used for extrapolation of the length of S phase 
according to the formula: BrdUpositive/BrdUpositive+ EdUnegative X chase time (h) = Length of S 
(h).  
 
 
Cell cycle synchronization 
In order to synchronize exponentially growing HCT116 cells at G1/S phase 
transition, we used the double-thymidine block approach. Briefly, cells were incubated in 
culture medium containing thymidine at a final concentration of 2 mM for 12 h (1st 
thymidine block), allowing time for cells to arrest in S phase. Thymidine was removed 
through repeated washes with fresh medium and cells were incubated with fresh 
thymidine-free medium for 7.5 h, to allow full exit from S phase. Cells were subsequently 
incubated with 2 mM thymidine for another 12 h (2nd thymidine block) to obtain a 
population precisely arrested at the G1/S phase transition that will progress into S phase 
upon release from thymidine.  
 
Metaphase spreads 
Metaphase spreads were prepared as described [43]. EdU-substituted DNA was 
detected using the Click-iT assay exactly as described herein for flow cytometry except 
that the 100 µL of reaction buffer were applied per coverslip (4 cm2). Total DNA was 
stained with DAPI (0.5 µg/mL) immediately before mounting in Vectashield and imaging 
by confocal microscopy. 
 
Western blotting 
For immunoblotting, cell lysates prepared in boiling 1X Laemmli´s sample buffer 
were supplemented with PMSF (1 mM) and a commercially available mixture of protease 
inhibitors (Complete Mini EDTA-free; Roche Diagnostics, Mannheim, Germany; 1 
tablet/mL). DNA was first fragmented mechanically by passing the sample into a syringe 
(≈10 times) through a 25-gauge needle and, subsequently, after supplementation with 
MgCl2 (5 mM), by digestion with benzonase (0.4 Units/ml; Sigma-Aldrich) for 30 min at 
room temperature. Lysates were then separated on 12 or 14% SDS-PAGE under reducing 
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conditions and transferred to nitrocellulose membranes (Schleicher & Schuel, Keene, NH). 
Membranes were blocked for 1 h with 5% nonfat dry milk powder in PBS and incubated 
for a minimum of 2 h with the specific primary and secondary antibodies. Antibodies used 
for immunoblotting were diluted in PBS supplemented with nonfat dry milk (2.5%) and 
Triton X-100 (0.05%) and used at the following dilutions: anti-phospho-RPA32/RPA2 
(Ser4/Ser8; 1/2000), anti-RPA32/RPA2 (total RPA32; 1/1000), anti-phospho-histone H2A.X 
(Ser139; 1/1000), anti-histone H2A.X (total H2A.X; 1/1000), and peroxidase-conjugated 
affinity-purified goat anti-mouse and goat anti-rabbit were diluted at 1/3000. Total H2A.X 
provided loading controls. The detection reaction was developed by enhanced 
chemoluminescent (ECL) staining according to the specifications of the manufacturer (ECL 
Amersham, Western Blotting Detection Reagents, UK). 
 
Alkaline comet assay  
DNA strand breaks were measured using Trevigen Comet Assay kit (Trevigen Inc., 
Gaithersburg, MD, USA). Cells were resuspended in ice cold PBS (Ca2+ and Mg2+ free) to a 
concentration of 1 × 105 cells/ml. A 5 μl aliquot of cells was added to 50 μl of molten 1% 
low-melting agarose warmed to 37 °C. 50 μl were immediately pipetted and evenly 
spread onto the comet slides. Slides were incubated at 4°C in the dark for 10 min to 
accelerate gelling of the agarose disc and then transferred to prechilled lysis solution 
(2.5 M NaCl, 100 mM EDTA, 10 mM Tris-base, 1% sodium lauryl sarcosinate, 1% Triton X-
100, pH 10) for 30 min at 4 °C. A denaturation step was performed in alkali solution 
(300 mM NaOH, 1 mM EDTA, pH > 13) at room temperature for 30 min in the dark. Slides 
were then transferred to prechilled alkaline electrophoresis solution pH > 13 (300 mM 
NaOH, 1 mM EDTA) and subjected to electrophoresis at 1 V/cm, 300 mA for 30 min in the 
dark at 4°C. Subsequently, the slides were washed with deionized water and immersed in 
70% ethanol at room temperature for 5 min and air dried. DNA was stained with 100 μl of 
SYBR Green I dye (supplied with the kit) for 10 min at 4ºC in the dark and immediately 
analyzed using a CCD camera (Roper Scientific Coolsnap HQ CCD, Roper Technologies Inc., 
Sarasota, FA, USA) attached to a Zeiss Axiovert 200M wide field fluorescence microscope. 
For each slide, 100 randomly chosen comets were analyzed with an excitation filter of 
450–490 nm and an emission filter of 515 nm. Images were scored for tail length and 
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percentage of DNA in tail using the Tritek CometScore Freeware v1.5 image analysis 
software (TriTek Corp., Sumerduck, VA, USA).  
 
Statistical analysis  
Data are reported as the mean ± SD.  Results were compared by 2-tailed Student’s 
t test for two groups and one-way ANOVA followed by Dunnett’s multiple comparison 
test for multiple groups. GraphPad Prism version 5.03 for Windows (GraphPad Software, 
La Jolla, CA, USA) was used for statistical analysis. Differences were considered 
statistically significant at P < 0.05 
  When using incremental pulsing times with EdU in the context of EdU -Coupled-
Fluorescence-Intensity analysis (E-CFI), the duration of S phase was estimated as the first 
time point after which maximal EdU-coupled fluorescence intensities clustered within 2 
SDs from each other. Also in the context of E-CFI, total length of cell cycle was estimated 
from the lengths of G1, G2 and S phases by standard error propagation. 
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FIGURES  
 
 
FIGURE 1 Effects of EdU on genomic instability, DNA damage and cell cycle 
progression. (A) Synchronized HCT-116 cells exposed for a single full S phase (7 h) to 
different concentrations of EdU (5, 10, 20 and 30 µM; controls exposed to solvent/DMSO alone) 
and analyzed 5 days later for the presence of chromosome territories, micronuclei and giant 
nuclei. Note that chromosome territories cannot be formally assessed in controls not exposed to 
EdU. (B) HCT-116 cells exposed for 11 h to EdU (2.5, 5, 10 and 20 µM; negative controls 
exposed to DMSO) or CPT (positive control; +/- EdU 20 µM) and analyzed by alkaline single-
cell gel electrophoresis (comet assay; parameter: tail moment). (C) HCT-116 exposed to EdU 
(11 h) as above and analyzed for the presence of γH2AX nuclear foci by immunofluorescence. 
(D) HCT-116 exposed to EdU (11 h) or CPT (+/- EdU 20 µM) as above and analyzed by 
immunofluorescence for the presence of nuclear foci concentrating RPA. (E) Western blots of 
cells exposed to EdU (11 h; +/- CPT; negative controls exposed to DMSO) and probed for 
phospho-RPA, RPA, γH2AX and H2AX. H2AX provides loading controls. (F) Flow cytometry 
histograms of HCT-116 cells and mESCs (PI staining), and MEFs (DAPI staining) either 
exposed to EdU for 11 h (HCT-116: 10 µM; mESCs: 2.5 µM; MEFs: 5 µM; blue) or not (controls; 
red). Results for all figures are presented as mean + SD; ***: p<0.001; **: p<0.01; ns: p>0.05.  
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FIGURE 2 Stoichiometry of detection of EdU-labeled DNA. (A) HCT-116 cells were exposed to 
different concentrations of EdU (5, 10, 15, 20 and 30 µM) or DMSO (controls) for 9 h followed by 
detection of EdU-DNA by Click-iT chemistry (Alexa Fluor 488). (B) HCT-116 cells exposed to a 
fixed concentration of EdU (10 µM) for incremental periods of time (1 to 11 h; 1 h increments) 
before detection of EdU-DNA by Click-iT chemistry. Results are expressed as an integral (sum of 
fluorescence intensities above background levels) for each time point. (C) Synchronized HCT-116 
cells were allowed to incorporate EdU for a single full S phase and collected while traversing G2 
stage, and later after passage into G1 stage of the next cell cycle. Histograms from cells stained for 
EdU-DNA (Click-iT; Alexa 488; green) and bulk DNA (PI staining; red) are depicted. Note that the 
EdU-coupled fluorescence peak of G1-synchronized cells (MFI: 212) has ≈48% of the intensity of 
the peak resulting from G2-synchronized cells (MFI: 443). 
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FIGURE 3 EdU-coupled Fluorescence Intensity analysis – the principle. Arrows 
represent pulsing times of different lengths with EdU. Fluorescence intensities are denoted 
by thickness of arrows. Note that cells in asynchronous populations are placed at any of 
many possible positions of the cell cycle upon exposure to the EdU pulse. Duration of S 
phase is probed by pulsing cells with EdU for defined, incremental periods of time. When 
pulsing times match the duration of S phase the cohort of cells that, by chance, at the 
beginning of the pulse are initiating S phase will incorporate EdU for a full S phase. This cell 
population shall thus feature maximal EdU-coupled fluorescence intensity. Increasing 
pulsing times beyond the duration of S phase shall not increase maximal fluorescence 
intensities but just the percentage of cells displaying intensity maxima. Duration of S phase 
is thus estimated from the minimal pulsing time with EdU that elicits emergence of a 
population featuring maximal fluorescence intensity. Clearly, pulsing times shorter than S 
phase length shall not allow reaching maximal intensities. In this assay the time variable is 
introduced by pulsing times of defined duration and the key parameter is fluorescence 
intensity, not the fraction of labeled cells.  
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FIGURE 4 Estimation of S phase duration. HCT-116 cells were exposed to EdU (10 µM) for 1 
to 11 h (1 h increments) followed by detection of EdU-DNA by Click-iT chemistry (Alexa 488) and 
analysis by flow cytometry. EdU-coupled fluorescence intensities are displayed along the x axis 
in logarithmic scale. Arrowheads denote the mean fluorescence intensity (MFI) reached by 
maximally labeled cell populations that incorporated EdU for a full S phase (peak 3; MFI: 2677). 
Background peaks 1 and 2 correspond to, respectively, G1 and G2 cells that have not yet 
incorporated EdU. Note that peak 4 stemming from maximally labeled cells that reached G1 
stage of the subsequent cell cycle features ≈1/2 the mean intensity of peak 3 (MFI: 1430, ≈53% 
of peak 3). Histograms are representative of one out of twelve independent experiments. 
Minimum number of analyzed events was 30000 per time point.  
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FIGURE 5 Intensity maxima of EdU-coupled fluorescence correspond to labeling for a 
single full S phase. Asynchronous HCT-116 cells pulsed with EdU (10 µM) +/- Cdk inhibitor 
(RO-3306; 10 µM) and collected at defined time points (5, 7, 9 and 16 h) were analyzed by 
flow cytometry. Detection of EdU-DNA was done with Click-iT chemistry (Alexa 488; green) 
and total DNA was stained with PI (red). Fluorescence peak 1 corresponds to G1 background; 
peak 2 to G2 background; peak 3 to maximal intensity coupled to cells maximally labeled for 
EdU-DNA (MFI: 671); and peak 4 to half-maximal intensity associated to cells that reached G1 
stage of the next cell cycle (RO-3306-minus group, MFI: 345). Note that maximal fluorescence 
intensities are similar irrespectively of the presence of RO-3306, and that peak 4 is absent 
from cells arrested in G2 by RO-3306. 
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FIGURE 6 Identity of background intensity peaks. (A) HCT-116 cells exposed for 1 h to EdU 
(10 µM) were stained for EdU-DNA (Click-iT; Alexa 488; green) and total DNA (PI) and 
subjected to dual-parameter processing (EdU vs total DNA). Gating for G1 and G2 populations 
and superimposing their fluorescence profiles with those of the entire cell population reveals the 
identity of the two background peaks. Note that the G1 peak (red frame) overlaps with 
background peak 1 and that the G2 peak (blue frame) overlaps with background peak 2.  (B) 
HCT-116 cells were exposed to EdU (10 µM) for incremental pulsing times (1-10 h) according to 
the E-CFI protocol. The corresponding background peaks were decomposed in their constituent 
G1 (red line) and G2 (blue line) populations which were quantified over time. Data shown are 
from 5 independent experiments. (C) HCT-116 cells (DNA-PK KO) and the corresponding 
background peaks were processed as above for DNA-PK wt HCT-116 cells. Data shown are 
from 4 independent experiments. Results in B and C are presented as mean + SD. 
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FIGURE 7 EdU-coupled fluorescence intensity analysis in non-transformed mouse 
cells. Arrowheads denote the mean fluorescence intensity (MFI) reached by maximally 
labeled cell populations that incorporated EdU for a full S phase. EdU-coupled fluorescence 
intensities are displayed along the x axis in logarithmic scale. (A) MEFs were pulsed with EdU 
(5 µM) for 1 to 11 h (1 h increments) followed by detection of EdU-DNA by Click-iT chemistry 
(Alexa 488) and analysis by flow cytometry. Only select pulsing times are shown. Note that 
maximal fluorescence intensity is reached at 7-8 h. (B) Mouse ESCs were pulsed with EdU 
(2.5 µM) and processed as above. Maximal fluorescence intensity is reached at 5 h. 
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FIGURE 8 Comparison with other methods of cell cycle analysis. (A) Fraction of labelled 
mitoses, HCT-116 cells. Cells were briefly pulsed with BrdU (20 µM; 15 min) and collected 
hourly up until 12 h after pulsing. The fraction of BrdU-positive mitotic cells was assessed per 
time point. Three independent experiments were performed per time point, each scored in 
technical triplicates; a minimum of 300 mitotic cells were counted per technical triplicate. (B) 
Fraction of labelled mitoses, HCT-116 DNA-PK KO cells. Cells were processed and scored as 
above for HCT-116 DNA-PK wt cells. Shown are results from three independent experiments. 
(C) Cumulative labeling, HCT-116 cells. Asynchronous HCT-116 cells were pulsed with BrdU 
(10 µM) for incremental periods (1.5 to 9 h; 1.5 h increments). Three independent experiments 
were performed per time point, each scored in technical triplicates; a minimum of 600 cells were 
counted per technical triplicate. (D) Cumulative labeling, HCT-116 DNA-PK KO cells. Cells were 
processed and scored exactly as in C, except that continuous pulsing with BrdU was extended 
to 10.5 h. Shown are results from three independent. All results are presented as mean + SD. 
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TABLE 
 
Table 1. Comparison of estimates for cell cycle phase length obtained for HCT-
116 DNA-PK WT and HCT-116 DNA-PK KO through different methodologies. 
 
 
 
 
* Estimated cell phase durations are derived from the percentage of cells in each cell cycle stage calculated using cell cycle 
analysis algorithms within FlowJo software, assuming a total cell cycle length of 15 h. Tc: Total length of cell cycle. 
 
 
 
 
 
 
HCT-116 DNA-PK WT 
Method G1 G2 G1+G2 S Tc 
EdU-coupled Fluorescence Intensity (E-CFI) 3-4 h 4-5 h ≈8 h ≈7 h 14-15 h 
Fraction of Labeled Mitotic cells (FLM)  ≈4.5 h  ≈6.5 h  
Cumulative Labeling   
≈7.5 h  
(EdU+ cells: 
97.6 ± 1.8%) 
  
Leaving Fraction    6.3 ± 0.4 h  
EdU pulse-chase  4-6 h  6-8 h  
DNA Content (Dean Jett Fox cell cycle algorithm)* 4.8 ± 0.7 h 3.9 ± 0.6 h  5 ± 1.2 h  
DNA Content (Watson Pragmatic cell cycle algorithm)* 4.3 ± 0.6 h 4.1 ± 2.5 h  6.7 ± 2 h  
HCT-116 DNA-PK KO 
Method G1 G2 G1+G2 S Tc 
EdU-coupled Fluorescence Intensity (E-CFI) 4-5 h 4-5 h ≈9 h ≈7 h 15-16 h 
Fraction of Labeled Mitotic cells (FLM)  4-5 h  ≈6.5 h  
Cumulative Labeling   
≈9 h  
(EdU+ cells: 
94.6 ± 2.8%) 
  
EdU pulse-chase  4-6 h  6-8 h  
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SUPPLEMENTAL DATA 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE S1 DNA damage induced by EdU – 
comet assay. HCT-116 cells exposed for 11 h to 
EdU (2.5, 5, 10 and 20 µM; negative controls 
exposed to DMSO) or CPT (positive control; +/- EdU 
20 µM) and analyzed by alkaline single-cell gel 
electrophoresis (comet assay; parameter: 
percentage of DNA in tail). Results are presented as 
mean + SD; ***: p<0.001; **: p<0.01; *: p<0.05; ns: 
p>0.05. 
 
FIGURE S2 Metaphase spreads after full and partial S phase labeling. (a, b and c) 
Synchronized HCT-116 cells (double-thymidine block) were pulsed with EdU (10 µM; 7 h) for a full 
S phase before harvesting in M phase. Metaphase spreads were stained for (a) EdU (Click-iT; 
Alexa 488; green) and (b) DNA (DAPI; blue); (c) merge of EdU and DAPI staining. Note labeling 
for EdU across the entire length of chromosome arms. (d, e and f) HCT-116 cells synchronized as 
above were allowed to progress 4 h into S phase and briefly pulsed with EdU (15min, 10 µM) 
before harvesting in M phase. Metaphase spreads were stained for (d) EdU and (e) DNA, as 
above; (f) merge of both channels. Note discontinuous (banded) labeling for EdU. Bar: 10 µm. 
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FIGURE S3 Estimation of S phase length in HCT-116 DNA-PK KO cells using E-CFI. 
Asynchronous HCT-116 DNA-PK KO cells cells were exposed to EdU (10 µM) for 1 to 11 h (1 h 
increments) followed by detection of EdU-DNA using Click-iT chemistry (Alexa 488) and analysis by 
flow cytometry. Fluorescence intensities after 1 h (blue), 7 h (dark green) and 9 h (light green) of EdU 
incorporation are depicted along the x axis in logarithmic scale (other pulsing times not shown).  Note 
that the 7 h and 9 h time points share identical maxima of EdU-coupled fluorescence intensity. 
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FIGURE S4 Dual parameter histograms (EdU vs total DNA) after EdU pulse-chase. 
Asynchronous HCT-116 cells pulsed with EdU (10 µM; 30 min) were either collected 
immediately after pulsing (0 h) or else chased for the indicated times (1-12 h) before 
collection. EdU-DNA was detected using Click-iT chemistry (azide-Alexa 488); total DNA was 
stained with DAPI before dual-parameter processing (EdU vs total DNA). Controls comprise 
EdU-minus cells that were exposed to azide-Alexa 488 (EdU detection system) before 
staining with DAPI (No EdU control). Selected events (within boxes) in chase times 4 and 5 h, 
and 11 and 12 h denote populations with 4n DNA that are either EdU-negative (left) or EdU-
positive (right). The corresponding percentages within the whole cell population are denoted. 
Also denoted are the percentages of 4n DNA cells that are EdU-positive within the whole 4n 
DNA population. Data from a single experiment are shown. 
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FIGURE S5 Fraction of EdU-labeled cells harboring 4n DNA over time – single 
experiments. Asynchronous HCT-116 cells pulsed with EdU (10 µM; 30 min) were collected 
immediately after pulsing (0 h) and for the indicated times (1-12 h) thereafter. Shown at defined 
times after EdU pulsing are the percentages of cells with 4n DNA content that are labeled for 
EdU; numbers above the curves denote the highest percentages of EdU-positive cells. Data 
were extracted from dual-parameter histograms after detection of EdU-DNA using Click-iT 
chemistry (azide-Alexa 488) and staining total DNA with PI. Data shown are from four 
independent experiments. 
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FIGURE S6 Fraction of EdU-labeled cells harboring 4n DNA over time – pooled data. (A) 
Asynchronous HCT-116 cells were pulsed with EdU (10 µM; 30 min) and collected at the 
indicated times (0-12 h). Dual-parameter histograms (EdU/DNA vs total DNA/PI) were used to 
distinguish cells with 4n DNA content that incorporated EdU. Represented over time are the 
percentages of cells with 4n DNA content that are EdU-positive.  (B) mESCs were pulsed with 
EdU (5 µM; 30 min) and processed as above. Results are presented as mean + SD from four 
independent experiments per cell line. Values for maximal percentages are presented above 
time points. 2-tailed Student’s t test was used to compare neighboring time points; *: p<0.05; ns: 
p>0.05.  
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Supplemental Table 2. Comparison of estimates for cell cycle phase length 
calculated for HCT-116 DNA-PK WT (DAPI stained, 3 independent experiments, 
mean + SD) using two different cell cycle analysis algorithms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Estimated cell phase durations are derived from the percentage of cells in each cell cycle stage calculated using cell cycle 
algorithms within FlowJo software, assuming a total cell cycle length of 15 h.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell Cycle Algorithm G1 G2 S 
Dean Jett Fox 
   
Population  percentage 32.3 ± 5 % 25.9 ± 4.2 % 33.5 ± 8.3 % 
Estimated length* 4.8 ± 0.7 h 3.9 ± 0.6 h 5 ± 1.2 h 
Watson Pragmatic 
   
Population  percentage 28.9 ± 4.3 % 27.5 ± 16.5 % 44.9 ± 7.9 % 
Estimated length* 4.3 ± 0.6 h 4.1 ± 2.5 h 6.7 ± 1. 2 h 
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5. General discussion 
 
 
Topoisomerase II (Topo2) poisons are already extensively used in cancer therapy 
strategies, although most studies on cellular response to DNA damage, along with long-
term consequences, have relied on ionizing radiation (IR) to generate DNA damage  
(Deckbar, Jeggo, & Löbrich, 2011; Ikura et al., 2007; Kakarougkas et al., 2013; Suzuki, 
Suzuki, Kodama, & Watanabe, 2006). IR can induce several types of DNA lesions in an 
indiscriminate manner across the whole genome including cross-links, modified bases and 
abasic sites, as well as single- and double-strand breaks. DSBs generated by IR often 
display “messy” DNA ends with deletions and loss of sequence homology (Nikitaki et al., 
2016; Sankaranarayanan & Wassom, 2005). Topo2 poisons, on the other hand, generate 
protein-DNA complexes that require the enzyme securing the break to first be removed, 
leaving behind “clean” DSBs with high DNA end homology (McClendon & Osheroff, 2007). 
Another important difference between IR- and Topo2-induced lesions is that Topo2 
function requires unobstructed access to DNA, suggesting that chromatin condensation 
could potentially influence the sensitivity of certain chromatin regions to this type of DNA 
damage. As such, the cellular response to the particular type of DSBs introduced by Topo2 
is necessarily different from IR-induced lesions but more studies are needed to detail how 
this may translate into different outcomes post cancer therapy.   
One of the aims of the present work was to clarify how each of the two main DSB 
repair pathways, non-homologous end joining (NHEJ) and homologous recombination 
(HR), contributes to repair of Topo2-mediated DSBs introduced in separate cell cycle 
phases. The results obtained in synchronized HCT116 cells damaged using the Topo2 
poison Etoposide in G1, early S, late S or G2 cycle stages revealed that, while the 
respective damage checkpoints of each phase are activated in response to the drug insult, 
there is substantial passage of cells with above-basal levels of DSBs to subsequent cell 
cycle phases. While this goes against the generalized idea that full repair of DNA lesions 
needs to occur after cell cycle arrest  for the cell cycle to resume, this phenomenon is well 
characterized in yeast and is known as checkpoint adaptation (Paulovich, Toczyski, & 
Hartwell, 1997). It has been proposed that checkpoints have in wired mechanisms for 
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their overcoming after a certain time independently of DNA repair. The G2/M checkpoint 
is the best understood in this regard, as it has been shown that Cdk2 levels during arrest 
are finely regulated to be low enough to suppress Cdk-driven transcriptional activation of 
genes promoting mitotic entry, but retain sufficient expression to be able to drive an 
eventual recovery from arrest (Shaltiel, Krenning, Bruinsma, & Medema, 2015). Indeed, 
checkpoint adaptation might be an evolutionarily conserved process necessary for cells to 
maintain the ability to exit from permanent arrest caused by high levels of DNA damage 
to potentially undergo genetic changes that may give them a selective advantage. The 
fact that this phenomenon has also been observed in non-transformed cell lines - since 
there is a clear advantage for cancer cells to lose checkpoint regulation (Alvarez-
Fernández & Medema, 2010) - supports this proposition.       
 By comparing cell cycle and protein immunoblotting results, a diverging pattern of 
DSB repair system usage was found between lesions introduced in different cell cycle 
stages. The G1/S checkpoint has been described as taking 4 to 6 hours to initiate in 
response to irradiation damage (Deckbar et al., 2011) and this also appears to be true for 
Topo2-mediated DSBs. Cells damaged in G1 showed a strong activation of RPA2 starting 
at 3 hours after introduction of DSBs. Phosphorylation of RPA2 correlates with DNA end-
resection, a step that occurs early during HR, which requires cells to be in S or G2 phase 
(Scully & Xie, 2013). Afterwards, at 8h, an arrest in G1 was observable by the separation 
of cells into G1 and S subpopulations. This suggests that the large fraction of G1-damaged 
cells that progress into S phase are predominantly repaired by HR, since the G1/S 
checkpoint did not activate in time to allow NHEJ to work. On the other hand, in G2-
damaged cells that could potentially take more advantage of HR than G1 cells, a 
substantial increase in levels of phosphorylated RPA2, which highlights ongoing HR, was 
not observed. In fact, these cells relied instead on NHEJ for DSB repair, as indicated by 
phosphorylation of DNAPKcs, a central factor in NHEJ. This is in accordance with previous 
studies using ionizing radiation that point to NHEJ as the major DSB repair system in G2 
(Beucher et al., 2009).  
We also show that cells damaged in the beginning of S phase do not elicit a 
significant RPA2 activation compared to late-S-damaged cells. This provides evidence that 
DSBs in euchromatin (EC) are preferentially repaired by NHEJ, but DSBs within 
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heterochromatin (HC) require HR. Replication of EC takes place in early S phase while HC 
regions only replicate towards the end of the phase (Folle, 2008). This means that 
Etoposide-poisoned Topo2, which is particularly active during replication since Topo2 is 
required to unwind the DNA to allow for replication fork progression, will predominantly 
cleave replicating EC in early S and replicating HC in late S. The behaviour of RPA2 in 
respect to lesions introduced in late S instead of G2 was also surprisingly different. Late-S-
damaged cells triggered RPA2 activation at 24h during their subsequent arrest in G2, 
whereas for G2-damaged cells, as mentioned before, the requirement for HR was less 
obvious. This indicates that HR in G2 is devoted specifically towards the repair of DNA 
damage in HC. 
The interplay between the two key regulators of DSB repair system choice, BRCA1 
and 53BP1, has been well detailed in recent years (Daley & Sung, 2014; Kakarougkas et 
al., 2013). Loss of BRCA1 is described as leading to 53BP1 recruitment to DSBs in G2, 
increasing repair by NHEJ by blocking of HR  (Daley & Sung, 2014). This was verified by us 
in HCC1937 cells, which carry a homozygous loss of function mutation in the BRCA1 gene. 
Accordingly, BRCA1(-) cells displayed an almost complete absence of phospho-RPA2 after 
exposure to Etoposide, showing instead an increase in activated DNAPKcs, a key 
component of the DNAPK complex recruited by 53BP1 during NHEJ. We showed that 
these cells lose the ability to activate a robust G2/M checkpoint, and, conversely, that 
HCT116 cells harbouring a knockout of the gene codifying DNAPKcs feature increased 
levels of phospho-RPA2 at 8h and 24h after Etoposide insult, along with a very robust and 
sustained G2/M arrest in their cycle. We thus propose that the decrease in NHEJ repair 
efficiency caused by DNAPKcs loss results in a heavy lesion burden that causes cells to 
activate and maintain a very strong checkpoint arrest when they reach G2. Checkpoint 
signalling, in parallel with accumulation of unrepaired DSBs, is then able to presumably 
bypass the 53BP1 block on end-resection. Also, deficiency in NHEJ was shown not to 
increase γH2AX levels for cells damaged in G1, supporting the low requirement of damage 
introduced in G1 for NHEJ repair.  
A consequence of the defect in G2/M checkpoint arrest seen in the absence of 
BRCA1 could be manifested in the increased frequency of spontaneous senescent cells 
(≈54% compared to ≈26% in BRCA1(+) cells) observed in this cell line after 8 days of 
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incubation under clonogenic conditions. Not being able to properly delay mitotic entry to 
allow sufficient time for repair means that cells undergo mitosis in the presence of severe 
DNA damage, which can result in cell death through mitotic catastrophe (Bunz et al., 
1998). Moreover, surviving cells have a high risk of carrying abnormal chromosome 
ploidy, such as aneuploidy and tetraploidy. Tetraploid cells are known to trigger cell death 
and cell cycle arrest pathways, such as senescence, as a defence against the tumorigenic 
effects of these aberrations (Hayashi & Karlseder, 2013). Curiously, high levels of 
senescence in a cell line carrying a homozygous loss of function mutation in the p53 gene 
were unexpected since p53 activation is considered a requirement for initiation of the 
senescence pathway (Itahana, Dimri, & Campisi, 2001). However, low levels of p53 have 
been found to be sufficient to permit, and to potentially even promote, cellular 
senescence over either quiescence or cell death (Leontieva, Gudkov, & Blagosklonny, 
2010). By comparison, DNAPKcs knockout lines, which have functional p53, displayed a 
G2/M checkpoint behaviour opposite to that of BRCA1(-) cells along with a lower 
propensity for senescence (≈ 14%, 5% and 2% in non-damaged DNAPK(-/-), (+/-) and (+/+), 
respectively). Furthermore, loss of DNAPKcs elicited a pronounced increase in cellular 
sensitivity to Etoposide, in a dose-dependent manner, drastically reducing colony viability 
(by almost 100% at 50μM Etoposide). This indicates that prolongation of G2/M arrest 
might promote other cell death or arrest pathways besides senescence, such as 
quiescence or apoptosis.  
Our results also showed that a forced G2/M arrest induced by cdk1 inhibition, 
although leading to an intensification of end-resection by phospho-RPA2, does not 
benefit cells in terms of repair efficiency. It is possible that this forced cell cycle arrest, by 
means of a feedback mechanism, also forces the switch from NHEJ to HR, driving lesions 
that could otherwise be repaired by NHEJ to accumulate while waiting for HR. This point 
remains to be clarified. It should be mentioned that prolonged Cdk1 inhibition can result 
in the occurrence of mitotic defects due to impaired mitotic spindle formation, such as 
generation of cells with wrong numbers of segregated chromosomes (Enserink & 
Kolodner, 2010), a likely cause for the supra-4n population seen at 18h. 
We also provide evidence that, when G2/M checkpoint is maintained for longer 
periods, these consistently correspond to increases in the levels of phosphorylation of 
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RPA2, which reflect an increment in end resection and HR repair. Shibata et.al. 
demonstrated utilizing ionizing radiation that ATM-dependent DNA end resection, even at 
a low level, is required to initiate ATR-dependent recruitment of Chk1 in G2, contributing 
to checkpoint maintenance (Shibata et al., 2010). We thus hypothesize that when HR has 
to take on the task of major repair system left by impaired NHEJ, in the presence of a 
severe lesion burden a persistent G2/M arrest occurs as cells continuously activate Chk1 
through end-resection-dependent ATR activation. On the other hand, our clonogenic 
experiments suggest that when BRCA1 is depleted, NHEJ is able to ensure that increasing 
doses of Etoposide do not affect long term viability, which raises interesting questions: 
are DSBs in HC able to be repaired efficiently also by NHEJ when necessary? Or is this 
specific to Topo2-mediated DSBs that are by nature more “clean” and easier to repair? 
More studies will be necessary to enlighten these issues. 
Overall, these results lead us to propose a model where slippage through 
checkpoint arrest is also a major determinant of repair system usage, particularly for DSBs 
arising in G1 and G2 phase since escaping arrest and passing to the following cell cycle 
phase will change the availability of repair pathways. Because of intrinsic limitations of 
the checkpoints operating at these stages, we conclude that a significant number of DSBs 
introduced in G1 are repaired by HR in S and G2 phases, whereas DSBs induced in G2 are 
mostly repaired by NHEJ in both G2 and G1.   
In regards to chromatin structure sensitivity to Etoposide-mediated lesions, the 
differences observed between early S (when DSBs are introduced mostly in replicating EC) 
and late S (when HC becomes the preferential target) were not significant or consistent 
enough across different techniques to allow for a conclusive distinction between the two. 
Although late S lesions do rely on HR contrary to EC lesions, the overall level of repair was 
similar. We will need to test more restrictive time points to allow for differences in the 
early steps of repair to be noticed.     
 Knockdown of EZH2 and consequent decrease in H3K27 methylation showed that 
the loss of this heterochromatin mark is not sufficient to disrupt heterochromatin 
structure in a way that facilitates the DNA damaging effect of Etoposide-bound Topo2. 
This was evidenced by the fact that increasing Etoposide concentrations did not result in a 
decrease in HCT116 cell viability beyond the level induced by EZH2 knockdown alone. The 
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decreased level of proliferative ability, as well as the increase in spontaneous senescence 
outcome, caused by EZH2 knockdown is thus likely associated to expression of genes 
formerly repressed by the H3K27me3 mark. This is in accordance with previous studies 
that showed that EZH2 represses expression of genes up-regulated by the E2F 
transcription factor family, which include mainly proliferation, differentiation and 
apoptosis regulators (Wu et al., 2010). EZH2 function therefore suppresses a large 
number of tumor suppressor genes, which understandably results in its over-expression 
in several tumors (Chang & Hung, 2012).  
In an effort to disturb heterochromatin stability in a more effective manner, we 
also tested the global histone methylation inhibitor DZNep. Interestingly, we found that a 
one to two hours exposure period to DZNep prior to an Etoposide pulse greatly 
potentiated the number of Topo2-mediated DSBs observable in HCT116 cells 24h after 
insult. This effect was seen only in pre-treatment and not by adding DZNep after 
Etoposide, which points to DZNep sensitizing cells to the introduction of DSBs by Topo2. 
We believe that this effect could result from global destabilization of heterochromatin 
regions, which would allow easier access to Topo2. We even wonder if Topo2 might 
actively be recruited to these regions as a result of topological problems that may arise 
with such chromatin decompaction. Again, this remains to be confirmed in future 
experiments. As a note, the synergistic effect of DZNep prior to Etoposide treatment was 
subsequently confirmed by another study (Unland et al., 2015). We confirmed that this 
effect also induced severe viability loss in a leukaemia cell line and used a drug 
combination study approach to identify low concentrations of each drug that are most 
effective at killing tumor cells. Although these were just exploratory experiments, there is 
potential for the use of DZNep in new clinical strategies.    
In light of our interest in monitoring cycle progression of unconventional cell 
populations, we found a new use for the thymidine analogue EdU (5-ethynyl-2’-
deoxyuridine), detailed in chapter 4 of this thesis, in allowing to accurately measure cell 
cycle kinetics in absolute values (hours) in asynchronous populations and without prior 
knowledge of population doubling times. We hope that this new methodology will prove 
useful for characterization of new cell types and for the analysis of drugs targeting the cell 
cycle, as is frequent in the context of cancer chemotherapy.     
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Hydroquinone  is  a benzene  metabolite  with  a  wide  range  of  industrial  applications,  which
has potential  for widespread  human  exposure;  however,  the  toxicity  of  hydroquinone
on  human  cells  remains  unclear.  The  aims  of  this  study  are  to investigate  the  cytotox-
icity  and  genotoxicity  of  hydroquinone  in  human  primary  ﬁbroblasts  and  human  colon
cancer  cells  (HCT116).  Low  doses  of  hydroquinone  (227-454  M)  reduce  the  viability  of
ﬁbroblasts  and  HCT116  cells,  determined  by resazurin  conversion,  and  induce  genotoxic
damage  (DNA  strand  breaks),  as  assessed  by alkaline  comet  assays.  Bioremediation  may
provide  an  excellent  alternative  to promote  the degradation  of hydroquinone,  however
few microorganisms  are  known  that  efﬁciently  degrade  it. Here  we also  investigate  the
capacity  of a halotolerant  fungus,  Penicillium  chrysogenum  var.  halophenolicum, to  remove
hydroquinone  toxicity  under  hypersaline  condition.  The  fungus  is  able  to  tolerate  high
concentrations  of hydroquinone  and  can reverse  these  noxious  effects  via  degradation  of
hydroquinone  to  completion,  even  when  the initial  concentration  of this  compound  is  as
high  as  7265  M. Our  ﬁndings  reveal  that  P.  chrysogenum  var.  halophenolicum  efﬁciently
degrade  hydroquinone  under  hypersaline  conditions,  placing  this  fungus  among  the  best
candidates  for  the  detoxiﬁcation  of habitats  contaminated  with  this  aromatic  compound.
©  2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
Y-NC-Nthe  CC  B
1. Introduction
Human exposure to hydroquinone, a phenolic com-
pound also known as the major benzene metabolite,
can occur by dietary, smoke, occupational and environ-
mental sources. Due to the rapid industrialization and
urbanization, the number of hydroquinone sources has
increased and consequently its discharge into the envi-
ronment, leading to serious toxic effects on fauna and
ﬂora. Hydroquinone is commonly used as a photographic
developer, dye intermediate, stabilizer in paints, varnishes
∗ Corresponding author. Tel.: +351 21 2948543; fax: +351 21 2948543.
E-mail address: aldl@fct.unl.pt (A.L. Leitão).
http://dx.doi.org/10.1016/j.toxrep.2014.10.024
2214-7500/© 2014 The Authors. Published by Elsevier Ireland Ltd. Th
(http://creativecommons.org/licenses/by-nc-nd/3.0/).D  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
oils and motor fuels as well as in the rubber, antiox-
idant and food industry. Moreover, hydroquinone can
be the product of several phenolic biotransformations,
such as benzaldehyde, benzoic acid, 4-ethylphenol, 4-
hydroxyacetophenone, phenol and substituted phenols,
including 4-chloro, 4-ﬂuoro, 4-bromo, 4-iodo and 4-
nitrophenol [3,11,18,20,22,31]. It is known that phenolic
compounds can negatively inﬂuence the organoleptic
properties of ﬁsh and shellﬁsh when present at concentra-
tions of part-per-billion [14]. In fact, phenolic compounds
are one of the priority pollutants of the United States Envi-
ronmental Protection Agency (USEPA) list.
Although there are already some studies on the
hydroquinone potential hazard to aquatic organisms,
its genotoxic capacity and mechanism remain largely
is is an open access article under the CC BY-NC-ND license
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nknown. Most of the attention has been focused on acute
oxicity. Bahrs and coworkers [4] determined 48-h EC50
alues of 1.5 mg/l, 0.68 mg/l, 0.21 mg/l and 0.054 mg/l for
esmodesmus armatus, Synechocystis sp., Nostoc sp. and
icrocystis aeruginosa, respectively, showing that hydro-
uinone can be highly toxic to aquatic organisms at
oncentrations of parts-per-million. Green algal species
ere found to be relatively less sensitive to hydroquinone
han cyanobacterial species [4]. Meanwhile, 48-h EC50
alue of 0.15 mg/l for Daphnia magna and 24-h LC50 val-
es ranging from 0.22 to 0.28 mg/l for Brachionus plicatilis
ave been reported [14]. Hydroquinone was also toxic to
arine bacteria as well as to ﬁshes like rainbow trout
nd fathead minnows [9]. Indeed, hydroquinone can be a
housand times more toxic to Vibrio ﬁscheri NRRL B-11177
han its isomers [19]. In epidemiological studies, correla-
ions between the genotoxic concern of aquatic ecosystems
nd carcinogenic effects in human have been detected
7,12,15].
Despite the fact that hydroquinone seems to be one of
he benzene metabolites implicated as causative agent of
enzene-associated disease, there is no consensus among
esearchers regarding the relevance of the severity of
ydroquinone on human cell viability and DNA dam-
ge. Some researchers proposed that hydroquinone could
nduce DNA damage by a combination of damage to the
itotic spindle, inhibition of topoisomerase II and the
ormation of DNA strand breaks via generation of reac-
ive oxygen species [1,32,34], however others considered
ydroquinone to be inactive by analyzing the frequency of
NA breaks using comet assay [21]. For the above reason,
n the present study, we  evaluated the cytotoxic effects of
ydroquinone on the viability of human primary ﬁbroblasts
nd human colon cancer cells (HCT116) using a commercial
ell health indicator assay, and for assessment of the geno-
oxicity, alkaline comet assay was performed. In addition,
he potential of a Penicillium chrysogenum strain for reduc-
ng hydroquinone concentrations and reversing its noxious
ffects via degradation of hydroquinone was evaluated.
yto/genotoxic studies were conducted to determine the
ffect of exposure to medium conditioned by the metabolic
ctivity of this fungal strain.
. Materials and methods
.1. Design of fungal experiments
P. chrysogenum var. halophenolicum was used through-
ut this study; this strain was isolated from a salt mine
n Algarve, Portugal, and previously characterized [22,23].
he fungal strain was maintained at 4 ◦C on nutrient
gar plates with 5.9% (w/v) NaCl. Precultures of cells
ere routinely aerobically cultivated in MC  medium as
escribed by [13].
To study the utilization of hydroquinone, the strain
as cultivated in 500-ml ﬂasks containing 100 ml  of MC
edium for 68 h at 160 rpm in an orbital shaker (Certomat®S-T Incubator, Sartorius Stedim Biotech, Goettingen,
ermany). Cells were centrifuged for 10 min  at 10,000 × g
nd washed three times in 0.85% (w/v) of NaCl. Then, a 10%
liquot was inoculated in MMFe  medium (50 ml  in 250-mlrts 1 (2014) 1096–1105 1097
ﬂasks) [13] with different concentrations of hydroquinone
(Sigma–Aldrich, ReagentPlusTM, ≥99%, Batch#: 114K2623)
(see Section 3). Three replicates were used per test for
each hydroquinone concentration. Uninoculated control
ﬂasks (duplicates) were incubated and aerated in parallel
as negative controls of the experiment. Hydroquinone con-
centration was  monitored up to an incubation time of 96 h.
Biosorption by dead biomass was  determined by batch
adsorption equilibrium experiments as follows. The strain
P. chrysogenum var. halophenolicum was  grown in the
MC liquid medium at 25 ◦C in a shaker incubator at
160 rpm for 68 h. Mycelium pellets were separated from
the growth medium by centrifugation and washed twice
with NaCl solution (0.85% (w/v)). The biomass was  ster-
ilized for 15 min  at 121 ◦C and 124 kPa to kill the fungus,
preventing biodegradation and bioaccumulation of hydro-
quinone in the subsequent adsorption experiments. The
biomass was then rewashed with NaCl solution (0.85%
(w/v)), centrifuged and approximately 50 ml  of MMFe  with
300 mg/l of hydroquinone were mixed with 0.10 g biomass
(dry weight). The suspension was shaken at 25 ◦C in a
rotary shaker at 160 rpm for 56 h, before the residual
aqueous concentration of hydroquinone was measured by
HPLC.
2.2. Analytical methods
Hydroquinone concentrations were quantiﬁed by High
Performance Liquid Chromatography apparatus L-7100
(LaChrom HPLC System, Merck), equipped with a quater-
nary pump system, and L-7400 UV detector according to
a previously published method [22]. Hydroquinone could
be separated and concentrations estimated within 10 min,
using standard (Sigma–Aldrich, ReagentPlusTM, ≥99%).
The OxiTop® respirometric system (WTW,  Germany)
was used for assessing the biodegradability of hydro-
quinone over 5 days. The principle of the operation was
based on the measurement of the pressure difference in
the closed system. During hydroquinone biodegradation
the respiration increases, the produced CO2 was captured
by an alkaline solution, and microbial oxygen consumption
resulted in the subsequent pressure drop. All experiments
were performed in reactors consisting of headspace and
glass bottles (510 ml nominal volume) with a carbon diox-
ide trap (approximately 0.5 g of NaOH was added in each
trap) with 97 ml  of sample volume (MMFe  with 5% of
inoculum supplemented with 4541 and 7265 M of hydro-
quinone). Fungal blanks were analyzed in parallel to correct
for endogenous respiration. Respirometric analyses were
conducted for 120 h in a temperature controlled chamber
at 20 ± 1 ◦C and in the darkness. Decrease in headspace
pressure inside the reactor was continuously and auto-
matically recorded. Three experiments were performed,
samples were done in triplicate and controls in dupli-
cate. The quantity of oxygen consumption was  calculated
according to the manufacturer instructions.2.3. Culture of human cells and cell viability assay
Colon cancer HCT116 cells (ATCC number CCL-247)
and human primary ﬁbroblasts (Coriell Institute, Candem,
gy Repo1098 P. Pereira et al. / Toxicolo
NJ, Ref. GM05565) were cultured in McCoy’s 5a Modiﬁed
medium supplemented with 10% heat inactivated fetal
bovine serum, 2 mM l-glutamine, 1% MEM  non-essential
amino acids and 100 U/ml penicillin/streptomycin (Gibco,
Life Technologies), and maintained at 37 ◦C in a humidi-
ﬁed incubator under 6% CO2. Cells were cultured in 24-well
plates for 24 h before initiation of experiments using
McCoy’s supplemented with either (1) MMFe  medium orig-
inating from cultures of P. chrysogenum var. halophenolicum
(conditioned composite medium), (2) freshly prepared
MMFe  medium (plain composite medium), or (3) either
hydroquinone, etoposide or drug solvent (controls).
Cell viability was assessed using Alamar Blue® (Molec-
ular Probes, Life Technologies), a commercial assay which
is based on the reduction of the cell permeable redox
indicator resazurin (deep blue) into resoruﬁn (pink and ﬂu-
orescent) by viable, metabolically active cells. At the end
of speciﬁed incubation times, 50 l of Alamar Blue® solu-
tion was added per 1 ml  of culture medium and incubated
for an additional 2 h. Plates were then analysed for ﬂuo-
rescence emission in a Tecan Inﬁnite M200 plate reader,
using an excitation wavelength of 530 nm and an emission
wavelength of 590 nm.  Results were read using Tecan i-
Control v. 1.4.5.0 plate reader software. Each experiment
was performed as a triplicate.
2.4. Alkaline single cell gel electrophoresis
DNA strand breaks were evaluated using Trevigen
Comet Assay® kit (Trevigen Inc., Gaithersburg, MD, USA).
Brieﬂy, cells were resuspended in ice cold PBS (Ca2+ and
Mg2+ free) to a concentration of 1 × 105 cells/ml. An aliquot
of 5 l of cells was added to 50 l of molten LM Agarose
(1% low-melting agarose) kept at 37 ◦C. 50 l were pipet-
ted immediately and evenly spread onto the comet slides.
Slides were incubated at 4 ◦C in the dark for 10 min  to
accelerate gelling of the agarose disc and then trans-
ferred to prechilled lysis solution (2.5 M NaCl, 100 mM
EDTA, 10 mM Tris-base, 1% sodium lauryl sarcosinate, 1%
Triton X-100, pH 10) for 30 min  at 4 ◦C. A denaturation
step was performed in alkali solution (300 mM NaOH,
1 mM EDTA, pH > 13) at room temperature for 30 min,
in the dark. Slides were then transferred to prechilled
alkaline electrophoresis solution pH > 13 (300 mM NaOH,
1 mM EDTA) and subjected to electrophoresis at 1 V/cm,
300 mA  for 30 min  in the dark at 4 ◦C. The slides were
then washed with deionized water and immersed in 70%
ethanol at room temperature for 5 min  and air dried.
DNA was stained with 100 l of SYBR Green I dye (Tre-
vigen, 1:10,000 in Tris–EDTA buffer, pH 7.5) for 10 min
at 4 ◦C in the dark and immediately analyzed using a
CCD camera (Roper Scientiﬁc Coolsnap HQ CCD) attached
to a Zeiss Axiovert 200M wideﬁeld ﬂuorescence micro-
scope. Comets were visualized with an excitation ﬁlter
of 450–490 nm and an emission ﬁlter of 515 nm and ﬂu-
orescent images of single cells were captured at 200×
magniﬁcation. A minimum of 100 randomly chosen cells
per experimental group were scored for comet parame-
ters such as tail length and percentage of DNA in tail [28]
using the Tritek CometScore Freeware v1.5 image analysis
software.rts 1 (2014) 1096–1105
3. Results
3.1. Cytotoxicity effects of hydroquinone
Results from the Alamar Blue® assay showed that
hydroquinone treatment reduced the viability of human
primary ﬁbroblasts and colon cancer HCT116 cells in a
dose-dependent manner. As shown in Fig. 1, high con-
centrations of hydroquinone (227 M,  454 M, 908 M,
2270 M and 4541 M)  greatly decreased cell viabil-
ity. Compared to control, metabolic activity drastically
dropped after exposure to any concentration equal or
above 227 M of hydroquinone. This negative effect
on metabolic activity is more effective in HCT116 cells
(11.25%) than ﬁbroblasts cells (43.22%). EC50 for cytotoxic-
ity in ﬁbroblasts and HCT116 cells was  329.2 ± 4.8 M and
132.3 ± 10.7 M,  respectively. There is a good ﬁt between
the dose response curve and the data points for cyto-
toxic effects on HCT116 cells and ﬁbroblasts cells after 24 h
(r2 = 0.9175 and r2 = 0.9773, respectively).
3.2. Genotoxicity of hydroquinone in cancer cells
One of the possible ways by which hydroquinone
reduces cell survival could be through induction of
DNA damage. We then addressed whether hydroquinone
induced DNA damage in primary human skin ﬁbroblasts
and HCT116 cells, using the same range of concentrations
previously demonstrated to reduce survival of both cells.
To this end, we  exposed HCT116 cells to increasing con-
centrations of hydroquinone (9.08, 45.4, 90.8, 227.0 and
454.1 M;  Table 1) for 24 h using as controls cells exposed
to either no drug (solvent alone; negative control), or to
etoposide for 15 min  (50 M;  positive control), a well-
known potent inducer of DNA breaks [10]. Since ﬁbroblasts
cells were less sensitive to hydroquinone as shown by
the Alamar Blue® assay, we  exposed ﬁbroblasts cells to
concentrations of 454.1 and 908.2 M of hydroquinone
(Table 1). DNA breaks were detected using the highly sen-
sitive alkaline comet assay, an electrophoresis-based assay
that allows detection of both single and double-stranded
DNA breaks at the single cell level. As expected, etoposide
induced signiﬁcant DNA damage on ﬁbroblasts and HCT116
cells with ∼50% and 80%, respectively, of the DNA leav-
ing the nucleus and migrating as the comet tail (Table 1).
Importantly, treatment of HCT116 cells with 227 or 454 M
hydroquinone induced DNA damage similar to that caused
by sub-apoptotic levels of etoposide in the same cell line.
In ﬁbroblasts, however, exposure to 454.1 M of hydro-
quinone induced a much higher % of tail DNA in comets
compared to etoposide (Table 1).
3.3. Genotoxicity of hydroquinone in cancer cells can be
abolished by fungal treatment
To investigate if the presence of a fungal strain capable
of degrading phenols, P. chrysogenum var. halophenolicum,
reduces the toxicity of hydroquinone in ﬁbroblasts and
human colon cancer cells (HCT116), new experiments
were done. Fungal cultures in minimal medium containing
hydroquinone were incubated at several times to ensure
P. Pereira et al. / Toxicology Reports 1 (2014) 1096–1105 1099
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Fig. 1. Dose response curves of hydroquinone in ﬁbroblasts cells (A) and HCT 116 cells (B).
Table 1
Evaluation of primary DNA damage measured in HCT 116 and ﬁbroblasts cells following exposure to hydroquinone.
Cell treatment Conc. (M) Tail intensity (%DNA) Tail length (pixels) Tail moment
HCT116
Etop 15 min  50.0a 85.58 ± 5.30 161.23 ± 7.13 91.29 ± 9.75
NegC  24 h 18.09 ± 3.52 47.61 ± 7.09 7.30 ± 1.89
HQ  24 h 0 12.90 ± 1.88 60.97 ± 5.97 4.73 ± 1.25
9.08  22.05 ± 3.42 75.76 ± 8.63 10.79 ± 2.70
45.4  17.74 ± 3.16 87.37 ± 6.55 8.16 ± 1.97
90.8  17.13 ± 4.28 95.93 ± 11.11 12.25 ± 5.44
227.0  85.45 ± 4.60 298.40 ± 31.50 150.22 ± 16.42
454.1 89.15 ± 1.44 320.78 ± 26.82 163.35 ± 10.95
Fibroblasts
Etop  15 min  50.0* 46.12 ± 3.24 55.97 ± 2.23 19.78 ± 1.76
NegC  24 h 10.22 ± 1.05 35.09 ± 1.82 9.99 ± 2.46
HQ  24 h 454.1 82.82 ± 6.31 244.30 ± 34.40 123.50 ± 21.90
908.0  87.42 ± 2.31 215.00 ± 14.05 107.20 ± 6.60
HQ, hydroquinone; Etop, etoposide; NegC, no drug.
a mg/l.
BA
*
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Cig. 2. Effects of the remaining hydroquinone concentrations after fungal
f  exposure. Data are expressed as the mean with SD of three independ
etween controls and each treatment is given in parentheses: ***, P < 0.00
ifferent degradation yields. Fungal mycelium was  then
eparated by centrifugation and the supernatants buffered
o pH 7.4 and isotonic conditions. Those samples obtained
fter fungal treatment (AFT) were then added to the ﬁbro-
last and HCT116 cells growing in McCoy’s medium (Fig. 2).
ell survival was evaluated by a well-established methodnt (AFT) on cell viability of ﬁbroblasts (A) and HCT116 (B) cells after 24 h
eriments. The probability in the ANOVA one-way test for the difference
 0.01; *, P < 0.05.
based on the ﬂuorescent conversion of a redox indica-
tor (Alamar Blue®) after 24 h of culture on AFT samples.
Controls were provided by ﬁbroblasts and HCT116 cells cul-
tivated exactly for the same periods of time in plain MMFe
medium i.e. in which the fraction of saline medium was
freshly prepared without hydroquinone. The data show a
1100 P. Pereira et al. / Toxicology Repo
***
***
Fig. 3. Cytotoxicity effects of fungal treated samples (AFT) in HCT 116 cells
observed in the presence or absence of hydroquinone addition (227 M).
(A)  Sample from a batch with an initial concentration of hydroquinone
of  4541 M;  (B) sample from a batch with an initial concentration of
hydroquinone of 7265 M.  Data are expressed as the mean with SD of
three independent experiments. The probability in the ANOVA one-way
medium without hydroquinone for the same durationtest  for the difference between controls and each treatment is given in
parentheses: ***, P < 0.001.
strong correlation between higher remaining concentra-
tions of hydroquinone and reduced survival of HCT116
cells (Fig. 2). A different survival pattern was observed on
ﬁbroblasts; data depicted in Fig. 2 shows that concentra-
tions of 33.6 M of hydroquinone obtained after fungal
treatment can reduce approximately 70% of the survival
of ﬁbroblasts cells. These data suggests that P. chrysogenum
var. halophenolicum produces one or more metabolites dur-
ing hydroquinone degradation that increase its toxicity, in
particularly to ﬁbroblasts cells. On the other hand, the salt
medium composition (controls) did not affect cell viability.
To further address whether hydroquinone itself did play
the key role in reduced survival of human cells, we cul-
tivated HCT116 cells in medium in which hydroquinone
had been reduced to undetectable levels by P. chrysogenum
from initial concentrations of 4541 or 7265 M (Fig. 3).
The results show that, irrespectively of the initial con-
centration of hydroquinone, survival of HCT116 cells is
only minimally affected when compared to controls cul-
tured in freshly prepared salt medium (Figs. 2 and 3).
Importantly, when puriﬁed hydroquinone was added back
to a ﬁnal concentration of 227 M,  survival of HCT116
cells were reduced to levels comparable to those observed
when hydroquinone reached similar concentrations via
P. chrysogenum-dependent degradation (Figs. 2 and 3).
Together, these data demonstrate that P. chrysogenum var.
halophenolicum is able to reduce the toxicity exerted by
hydroquinone on cultured human cells.rts 1 (2014) 1096–1105
3.4. P. chrysogenum var. halophenolicum eliminate
toxicity via degradation of hydroquinone
We  subsequently tested whether the capacity P. chryso-
genum to eliminate the negative effect of hydroquinone on
ﬁbroblasts and HCT116 cells observed previously, was due
to the hydroquinone degradation to undetectable levels
in culture. To do so, batch cultures with P. chrysogenum
var. halophenolicum and hydroquinone at different ini-
tial concentrations of 4541 and 7265 M in saline liquid
media (MMFe) were performed. The results are shown in
Fig. 4. Since no abiotic loss of hydroquinone was detected
in controls and less than 3% of hydroquinone becomes
adsorbed to fungal cell surface, the decrease of hydro-
quinone concentration in the presence of fungus can be
mostly attributed to cell metabolism. Hydroquinone at ini-
tial concentration of 4541 M was  completely removed
within 56 h of treatment; while 75% of hydroquinone was
removed in fungal cultures when the initial concentra-
tion was  7265 M after the same time of treatment. These
results demonstrate that Penicillium var. halophenolicum
can remove hydroquinone to undetectable concentrations
by HPLC method.
Additional studies were done to assess the complete
biological conversion of hydroquinone to CO2 and H2O by
the P. chrysogenum strain, using the OxiTop® respiromet-
ric system. The OxiTop® respirometric system is a simple,
batch device, which is appropriate and sensitive for deter-
mination and analysis of wastewater biological oxygen
demand (BOD). Fig. 5 shows hydroquinone BOD data from
the respirometric study. Each BOD value was  corrected for
endogenous respiration (i.e., BOD obtained from the fun-
gal blank). Since the biodegradation test was carried out
within a brown dark bottle container and in the absence of
light, the possible existence of photodegradation was with-
drawn. The 5-day BOD for the initial concentrations of 4541
and 7265 M of hydroquinone was 440 mg/l and 720 mg/l,
respectively. The initial mineralization of the biodegraded
hydroquinone is slightly lower at the initial concentra-
tion of 7265 M than that at 4541 M up to the ﬁrst day.
This fact suggests that hydroquinone at high concentra-
tions induces smaller rates of respiration than low initial
concentrations and agrees with the observation that hydro-
quinone can reduce enzyme activity of microbial biomass
[8].
3.5. Effect of P. chrysogenum var. halophenolicum on
hydroquinone genotoxic activity
Finally, we tested whether P. chrysogenum could
degrade hydroquinone to levels that were non-genotoxic
to cultured human cells. HCT116 and ﬁbroblasts cells were
thus exposed for 24 h to fungal treated samples contain-
ing different concentrations of hydroquinone as the result
of progressive degradation of this compound by P. chryso-
genum and then subjected to the alkaline comet assay
protocol; controls were provided by cells exposed to plain(Table 2 and Fig. 6). As expected for a genotoxic agent,
metabolites coming from an incomplete degradation of
hydroquinone still might led to signiﬁcant DNA damage in
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Fig. 4. Hydroquinone removal by P. chrysogenum var. halophenolicum at different initial concentrations as indicated in the legend. Data shown represents
average of triplicates ± standard deviations.
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amples  from duplicate reactors.
CT116 or ﬁbroblasts cells. HCT116 cells exposed to 86.3,
08.1 and 274.3 M of remaining hydroquinone after fun-
al treatment showed in the range between 40% and 80%
f total DNA fractured enough to leave the cell nucleus and
orm the comet tail (Fig. 6 and Table 2). In the case of ﬁbro-
lasts, a remaining hydroquinone concentration of 86.3 M
id not induce a noticeable increase in DNA damage, while
ith 274.3 M more than 80% of DNA in the comet tail
as observed (Table 2). However, when hydroquinone was
ither fully degraded (0 M)  or degraded almost to comple-
ion (33.6 M ﬁnal concentration) by P. chrysogenum, the
mount of DNA damage induced in HCT116 and ﬁbroblastshe fungal blank BOD from respirometric analysis. Error bars are based on
cells was similar to that observed in the control cells (NegC)
(Table 2).
Overall, these data show that P. chrysogenum var.
halophenolicum is capable of degrading hydroquinone from
highly cytotoxic initial concentrations to levels that are
non-genotoxic and are well tolerated by ﬁbroblasts and
HCT116 cell (Fig. 7).4. Discussion
The toxicity of hydroquinone may  have been under-
estimated, given the small number of studies performed
1102 P. Pereira et al. / Toxicology Reports 1 (2014) 1096–1105
Fig. 6. Depicted are the results of alkaline comet assays performed using ﬁbroblasts (a) and HCT116 cells (b) cultured for 24 h in medium containing
either  drug solvent alone (controls), etoposide (50 M for 15 min), AFT medium containing varying ﬁnal concentrations of hydroquinone. The different
concentrations of hydroquinone were obtained by progressive treatment of hydroquinone by P. chrysogenum var. halophenolicum (initial concentration
4541  and 7265 M).  The 0 M concentration corresponds to full (maximal) degradation. Controls correspond to HCT116 cells and ﬁbroblasts grown in the
absence of hydroquinone. In the graphs, boxes correspond to the 75th percentile, whiskers to the 95th percentile and lines identify the median obtained
from  triplicates.
Fig. 7. Hydroquinone induces DNA double-strand breaks in HCT116 cancer cells. Representative photos are shown for (A) negative control (medium), (B)
positive control (etoposide), (C) standard hydroquinone (454 M)  and (D) AFT sample where the remaining concentration of hydroquinone is zero.
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Table  2
Measurement of DNA damage-related parameters obtained by alkaline comet assay in HCT 116 and ﬁbroblast cells following exposure to AFT medium.
Data  are expressed as the mean with SD of three independent experiments. The probability in the ANOVA one-way test for the difference between controls
and  each treatment is given in parentheses: ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, P > 0.05.
Cell treatment Concentration (M) % DNA in tail Tail length (pixels)
HCT116
Control 18.09 ± 3.52 47.61 ± 3.56
HQ  24 h 0 17.77 ± 4.50 (ns) 38.01 ± 3.88 (ns)
33.6  16.06 ± 4.30 (ns) 40.10 ± 3.24 (ns)
86.3  43.61 ± 7.86 (***) 93.26 ± 5.81 (***)
108.1  57.77 ± 7.43 (***) 110.00 ± 5.51 (***)
274.3  73.97 ± 7.63 (***) 153.70 ± 8.64 (***)
Fibroblasts
Control 10.22 ± 1.05 35.09 ± 0.93
HQ  24 h 0 5.58 ± 0.84 (***) 21.89 ± 0.94 (**)
33.6  6.47 ± 1.06 (***) 29.10 ± 1.30 (ns)
86.3 11.03 ± 1.90 (ns) 27.40 ± 1.11 (ns)
274.3  87.26 ± 5.50 (***) 506.00 ± 39.28 (***)
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n animal models, the difﬁculty to extrapolate to humans
ost of the data obtained in models, and the limited statis-
ical power of cohort studies already performed in human
ubjects [30]. There is growing evidence that hydroquinone
nd some of its metabolites have genotoxic activity to
ammalian cells, namely human cells, either primary or
ransformed [11].
In initial work on the cytotoxicity of hydroquinone on
ammalian cells a requirement for copper was described
25]. Indeed, Cu(II) through a copper-redox cycling mech-
nism promotes the oxidation of hydroquinone with
eneration of benzoquinone and reactive oxygen species
ROS) [26], and several reports have subsequently impli-
ated oxidative damage to DNA as a major mechanism
or the cytotoxic effects of hydroquinone (reviewed in
11]). Later, Luo and coworkers showed that hydro-
uinone induced genotoxicity and oxidative DNA damage
n human hepatoma HepG2 cells independently of the pres-
nce of transition metals, and afterwards several articles
ere published supporting these researchers [16,29,33].
n this study, P. chrysogenum var. halophenolicum ability
o degrade hydroquinone was investigated using saline
edium (MMFe) with iron in its composition. The pres-
nce of iron did not affect the toxicity of hydroquinone
ver ﬁbroblasts and HCT116 cells. These ﬁndings in
broblasts and HCT116 cells, are in agreement with pre-
iously published data obtained using other cell types
24], not excluding a role for endogenous copper in medi-
ting the cellular effects of hydroquinone. The median
ffective concentration (EC50) of hydroquinone in sev-
ral cancer lines was reported to be 8.5 M,  10.0 M,
8 M for HL-60, HL-60/MX2 and Huh7, respectively, and
100 M for Hep3B and HepG2 [16]. Our data showed
hat hydroquinone decreased cell viability of HCT116 cells
EC50 = 132.3 M)  and, to a lesser extent, primary human
broblasts (EC50 = 329.2 M).  These data are in agreement
ith the data published by other researcher who has foundhat primary human ﬁbroblasts were relatively more resis-
ant to hydroquinone compared to lymphocytes [24]. As it
as previously reported, differences between a cancer cell
ine and primary ﬁbroblasts can be attributed to differencesin cell sensitivity to the compound that was  assayed and
would be mainly related with the cell division rate [36].
Reactive species generated by hydroquinone have been
implicated in the formation of modiﬁed bases (e.g., 8-oxo-
deoxyguanine) in the DNA molecule, which appear to be
removed with fast kinetics [33], but also single and double-
stranded DNA strand breaks [17,29,33]. Moreover, both
hydroquinone and its degradation product benzoquinone
are topoisomerase II poisons which inhibit the ﬁnal ligation
step of the catalytic cycle of the enzyme, thus stabilizing
topoisomerase-mediated DNA scissions [27]. Although the
relative contributions of reactive oxygen species and topoi-
somerases in hydroquinone-mediated genotoxicity remain
to be elucidated, it is clear that that DNA breaks gener-
ated by hydroquinone pose a serious challenge to genome
integrity [5,11]. Herein, we have analyzed the capacity of
hydroquinone to generate both single and double-strand
DNA breaks using the well characterized comet assay
under alkaline conditions (cf. Table 1). We  showed that the
hydroquinone-induced increment in DNA strand breaks in
HCT116 cells was dose-related. In HCT116 cells, hydro-
quinone at concentrations of 227.0 and 454.1 M caused
a marked increase of the olive tail moment (the product of
% tail DNA and tail length) compared to lower concentra-
tions. Hydroquinone concentrations up to 90.8 M induced
a gradual but slow increment of the olive tail moments
and this was  due more to the increase in the tail length of
comets than to the amount of DNA in the tail. The relative
amount of DNA in the comet tail (the % tail DNA or tail inten-
sity) has been related to DNA break frequency over a wide
genome range, while tail length has been related to the
frequency of the smallest detectable DNA fragments and,
since it quickly reaches a maximum, its useful only for low
levels of damage [2]. Taking this into account, we can say
that hydroquinone concentrations higher than 90.8 M are
required in order to induce a high frequency of DNA breaks
throughout the whole genome of HCT116 cells, resulting in
overall cell death, as evidenced by the survivability assay
(Fig. 2). Hydroquinone alone induced greater loss of via-
bility in HTC116 cells than in ﬁbroblasts cells (cf. Fig. 1)
but surprisingly, when cells were exposed to medium
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previously incubated with P. chrysogenum var. halopheno-
licum, ﬁbroblast survivability seemed to be dependent on
more than just the remaining hydroquinone concentration
in the medium. This suggests that ﬁbroblasts are more sen-
sitive than HCT116 cells to the metabolites resulting from
hydroquinone degradation. Interestingly, the comet assay
data also indicates that, except for very high remaining
hydroquinone concentrations, DNA strand breaks are not
the major cause of the viability loss in ﬁbroblasts after fun-
gal treatment (compare Figs. 2 and 6). This data suggest
that the toxic effect of the hydroquinone metabolites orig-
inated by fungal treatment on primary ﬁbroblasts may  be
due to a mechanism which does not involve DNA damage.
This increase of DNA damage on ﬁbroblasts and HCT116
cells may  be due to fungal metabolites originated during
hydroquinone degradation. Nevertheless, this fungal strain
showed the capacity to reduce hydroquinone to concen-
trations at which DNA strand breaks become basal level in
human ﬁbroblasts and HCT116 cells (Table 2).
Given that hydroquinone is a relevant environment pol-
lutant, and that bioremediation has obvious advantages
over chemical degradation, efforts have been made to iden-
tify microorganisms capable of hydroquinone degradation
under harsh conditions [6,11,23,35]. However, studies
monitoring the efﬁciency of hydroquinone removal have
remained scarce. The present study shows that P. chryso-
genum var. halophenolicum exhibits high tolerance and
degradation capacity to hydroquinone, as it was able to
remove up to 7265 M of the aromatic compound under
1 M NaCl. Furthermore, a cumulative O2 uptake of 440 and
720 mg/l was obtained in respirometric assays for initial
hydroquinone concentrations of 4541 M and 7265 M,
respectively. Since the theoretical carbonaceous oxygen
demand (ThOD) for 4541 and 7265 M of hydroquinone
was calculated to be 872 mg/l and 1395 mg/l, respectively,
our results indicate that at least 50% of carbon from hydro-
quinone is converted to CO2, supporting the hypothesis
that hydroquinone is a substrate readily and efﬁciently
used by fungus.
In conclusion, in vitro tests showed that hydroquinone
is cytotoxic for human ﬁbroblasts and HCT116 cells. More-
over, hydroquinone induces DNA damage to ﬁbroblast and
HCT116 cells in the form of DNA single and double strand
breaks as it was demonstrated by alkaline comet assay.
Our data provides also the ﬁrst evidence that, without
prior acclimation, P. chrysogenum var. halophenolicum has
the capacity to degrade hydroquinone present at high ini-
tial concentrations in hypersaline media to levels that are
non-genotoxic to human cells. Overall, the present study
supports the potential of P. chrysogenum var. halopheno-
licum for the treatment of salty phenolic-contaminated
wastewaters.
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Summary
Severe sepsis remains a poorly understood systemic inflammatory condition with high mortality
rates and limited therapeutic options in addition to organ support measures. Here we show that the
clinically approved group of anthracyclines acts therapeutically at a low dose regimen to confer
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robust protection against severe sepsis in mice. This salutary effect is strictly dependent on the
activation of DNA damage response and autophagy pathways in the lung, as demonstrated by
deletion of the ataxia telangiectasia mutated (Atm) or the autophagy-related protein 7 (Atg7)
specifically in this organ. The protective effect of anthracyclines occurs irrespectively of pathogen
burden, conferring disease tolerance to severe sepsis. These findings demonstrate that DNA
damage responses, including the ATM and Fancony Anemia pathways, are important modulators
of immune responses and might be exploited to confer protection to inflammation-driven
conditions, including severe sepsis.
Keywords
Sepsis; ATM; Autophagy; Anthracyclines
INTRODUCTION
Sepsis is a life-threatening condition that arises as a systemic inflammatory response to an
infection (Bone et al., 1992; Levy et al., 2003). It includes a continuum of clinical severity
ranging from systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis to
septic shock (Suffredini and Munford, 2011). It is the leading cause of death in intensive
care units and the third cause of overall hospital mortality (Angus and Wax, 2001; Ulloa and
Tracey, 2005). In spite of substantial improvement in diagnosis and support measures, the
global annual mortality rate is ~28% (Hotchkiss and Karl, 2003), ranging from less than
10% in SIRS to up to 70% in septic shock (Angus and Wax, 2001; Annane et al., 2003). The
pathophysiology of sepsis remains poorly understood. As a result, the basic elements of
treatment – early antibiotics, prompt control of the source of infection and organ support -
have not changed substantially in the last fifty years, and attempts to translate basic research
results into effective new interventions have been met with limited or no success (Suffredini
and Munford, 2011). In the same period, the incidence of sepsis and its economic burden has
increased by 1% each year (Martin et al., 2003; Ulloa and Tracey, 2005), indicating the
urgent need for novel therapeutic options.
Inflammation is a response to harmful stimuli that limits tissue damage and aims at restoring
homeostasis (Medzhitov, 2008). Pathogen-associated molecular patterns (PAMPs) on
microorganisms and damage-associated molecular patterns (DAMPs) originating from dying
cells are sensed by the host through germline-encoded pattern recognition receptors (PRRs)
that recognize conserved signature structures in non-self and self (Janeway and Medzhitov,
2002). These sensors are present in both professional (including neutrophils, macrophages
and dendritic cells) and non-professional immune cells and their activation initiates
intracellular signaling cascades leading to the transcriptional expression of inflammatory
mediators, such as cytokines and chemokines. Inflammation needs to be effectively
terminated after removal of the original trigger for repair of damaged tissue to occur. In the
susceptible host, overproduction of inflammatory mediators or an exaggerated response to
their presence can lead to septic shock, tissue destruction or permanent loss of function
(Takeuchi and Akira, 2010).
There are two evolutionarily conserved defense strategies against infection that can limit
host disease severity. One relies on reducing pathogen load, i.e. resistance to infection, while
the other provides host tissue damage control, limiting disease severity irrespectively of
pathogen load, i.e. tolerance to infection (Raberg et al., 2009; Schneider and Ayres, 2008).
As demonstrated originally for plants and thereafter in Drosophila, tolerance to infection
also operates in mammals, as revealed for Plasmodium (Raberg et al., 2007; Seixas et al.,
2009) and polymicrobial infections in severe sepsis (Larsen et al., 2010).
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Here we show in an experimental mouse model that anthracyclines confer strong protection
against sepsis by increasing disease tolerance to infection, that is, acting irrespectively of
pathogen burden. We further show that ATM (ataxia telangiectasia mutated) kinase and the
induction of autophagy are strictly required for the in vivo protection against sepsis. These
molecular pathways provide strong damage control in tissues, specifically in the lung.
RESULTS
Anthracyclines confer strong protection against severe sepsis
In an in vitro chemical screen using ~2320 compounds, we identified several lead candidates
capable of inhibiting inflammatory cytokine production in response to E. coli challenge by
the THP-1 macrophage line (Figure S1a and Supplemental Table S1). This inhibitory effect
was dissociated from cytotoxicity of the compounds tested on THP-1 cells (Figure S1b).
Among these, we found 3 representatives of the anthracycline family of chemotherapeutic
agents namely epirubicin, doxorubicin and daunorubicin, and validated their inhibitory
activity on cytokine production (Figure S1c).
We then used the cecal ligation and puncture (CLP) mouse model of experimental sepsis to
investigate the in vivo effects of epirubicin (Rittirsch et al., 2009). In CLP, sepsis results
from a polymicrobial infection of abdominal origin, leading to bacteremia and a systemic
inflammatory response (Rittirsch et al., 2009). We adjusted CLP severity to a high-grade
sepsis, where at least 80% of C57BL/6 mice succumbed within 48 h after the initial
procedure. Under these conditions, epirubicin administered i.p. at the time of CLP and again
24 h later in a total of 1.2μg/g of body weight reproducibly and significantly (p<0.001)
increased the survival of C57BL/6 mice subjected to CLP by nearly 80%, without the use of
antibiotics (Figure 1a). A similar protective effect was observed in epirubicin-treated
animals with the same dose and schedule but administered i.v. (Figure S1d). This appeared
to be a general property of the anthracycline family because other representative members of
this family of drugs identified in the initial chemical screen conferred a similar degree of
protection against CLP (Figure 1b). The protective effect of anthracyclines was not
dependent on the mouse strain as outbread NMRI mice were similarly protected by
epirubicin (Figure 1c). Epirubicin was equally effective against another clinically relevant
pathogen causing sepsis, K. pneumoniae administered intranasally (Figure 1d), arguing that
epirubicin can be effective in the treatment of sepsis of different origins in addition to
peritoneal sepsis. Mice previously subjected to CLP and treated with epirubicin were not
immunocompromised as they could clear a secondary intranasal viral infection similarly to
control mice (Figure 1e). Taken together, these results indicate that low doses of the
anthracycline family of chemotherapeutic agents confer strong protection against severe
sepsis, without causing host immunosuppression.
Epirubicin acts therapeutically to promote disease tolerance to severe sepsis
We found that in epirubicin-treated mice subjected to CLP the bacterial load in blood and
target organs of sepsis, e.g., lung, liver, kidney and spleen 24 h post-CLP did not differ from
that of untreated controls (Figure 2a). While at 48 h post-CLP we noticed a trend towards a
lower bacterial load in the target organs of epirubicin-treated animals, the differences were
not statistically significant, even if most untreated control animals die between 24 and 48 h
after the CLP procedure. These results raised the possibility that the protective effect of
epirubicin in vivo is related to disease tolerance without directly affecting the pathogen
burden(Medzhitov et al., 2012). This idea was supported by the observation that the serum
concentrations of several markers of tissue damage such as LDH (lung and general cellular
damage), CK (muscle), ALT (liver) and urea (kidney) were substantially reduced to almost
basal levels in epirubicin-treated mice, 24 h after CLP, compared to untreated mice (Figure
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2b). In addition, we observed a substantial reduction in the levels of inflammatory mediators
including TNF, IL-1β, IL-6 and HMGB1 compared to non-treated CLP mice (Figure 2c).
We have also observed improvement of histological lesions in the lung, liver and kidney
after CLP by treatment with epirubicin (Figure S2). To explore this further in the absence of
bacteria, we found that the drug protected C57BL/6 mice from lethal septic shock caused by
lipopolysaccharide (LPS, endotoxin) (Figure 2d).
Large spectrum antibiotics such as meropenem are very effective at lowering bacteremia and
are standard drugs used in sepsis (Russell, 2006). We tested the efficacy of meropenem in
CLP in comparison to epirubicin and found that while meropenem delayed the death rate of
CLP-subjected mice, it did not prevent mortality (Figure 2e), in spite of a strong impact on
bacterial burden (Figure 2f). This was in sharp contrast to the action of epirubicin, that did
not interfere with bacteremia (Figure 2f) but prevented CLP-induced mortality (Figure 2e),
again arguing for a role of epirubicin in conferring disease tolerance against severe sepsis
(Larsen et al., 2010; Medzhitov et al., 2012).
Both epirubicin and meropenem decreased the amounts of IL-1β, TNF and HMGB1 in the
serum of mice subjected to CLP (Figure 2g). This indicates that whereas decreased
circulating levels of inflammatory mediators may contribute to confer protection against
severe sepsis, inhibition of IL-1β, TNF and HMGB1 is not sufficient per se to explain the
protective effect of epirubicin, which is in accordance with what is observed for other
therapeutic approaches in the clinical setting (Hotchkiss and Karl, 2003). Taken together
these data suggest that epirubicin acts through an additional alternative mechanism to
cytokine inhibition to confer tolerance to sepsis.
Epirubicin protection against sepsis is mediated by ATM
Next, in order to explore the molecular mechanism behind the protective effects of
anthracyclines, we used our in vitro assay system to perform a short hairpin RNA (shRNA)-
based screen in THP-1 cells, focusing on kinases and phosphatases and using IL-1β and
TNF secretion as assay readouts. While our in vivo results suggested the possibility that
anthracyclines ameliorate the lethal effects of sepsis by a mechanism affecting tissue
tolerance, we reasoned that our in vitro assay would be useful for the identification of
candidate pathways mediating the anthracycline effects. We found several negative
regulators of IL-1β productionin response to E. coli challenge, including the genes encoding
Ataxia Telangiectasia Mutated (ATM), Checkpoint Kinase 1 (CHEK1) and Ataxia
Telangiectasia and Rad3 Related (ATR) (Figure S3 and Supplemental Table S2). These
findings suggest that DNA damage response (DDR) components are negative regulators of
IL-1β secretion. Using a phospho-specific antibody against the activated form of ATM, we
found that although E. coli alone was a poor, but reproducible ATM activator (Figure S3),
epirubicin alone or in combination with E. coli triggered a robust ATM activation (Figure
S3). This was confirmed using immunoblotting (Figure S3).
ATM is a master regulator of the DDR (Ciccia and Elledge, 2010) and is known to be
activated by anthracyclines and other DNA damaging agents (Siu et al., 2004). Therefore we
used ATM-deficient mice to test the contribution of the DDR to the protective effect of
anthracyclines against severe sepsis. ATM-deficient (Atm−/−) mice were not protected by
epirubicin against CLP and died with similar kinetics to those of wild-type (Atm+/+) animals
that were treated with PBS alone (Figure 3a). We conclude that ATM expression is
necessary to mediate the protective effect of epirubicin in sepsis. In striking contrast to wild-
type mice (Figures 2b and c), in the absence of ATM, epirubicin no longer normalized the
serologic markers of organ lesion (Figure 3b) or decreased the levels of inflammatory
mediators (Figure 3c). However, in mice subjected to CLP and treated with etoposide (after
in vivo titration to find the best and most effective dose), an agent known to cause DNA
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double strand breaks and to activate ATM-dependent pathways (Montecucco and Biamonti,
2007), mortality induced by CLP was only partially rescued (Figure 3d), suggesting that
ATM is necessary but not sufficient for the protection conferred by anthracyclines against
sepsis.
In addition to double strand breaks (repaired in an ATM-dependent manner), anthracyclines
also cause DNA interstrand cross-links, a DNA lesion known to be repaired by the Fanconi
Anemia (FA) pathway (Ciccia and Elledge, 2010). Interestingly, FA patients were reported
to spontaneously overproduce TNF (Briot et al., 2008; Vanderwerf et al., 2009), possibly
because the FA protein FANCD2can directly inhibit TNF promoter activity (Matsushita et
al., 2011). In THP-1 cells, we observed that FANCD2 is activated in an ATM-independent
manner upon epirubicin treatment, as shown by its mono-ubiquitination (Figure 3e). These
findings support the independence of signaling events initiated by the generation of DNA
double strand breaks and DNA interstrand cross-links. We examined the contribution of this
pathway for epirubicin protection of CLP and found that Fancd2−/− mice were slightly but
significantly (p<0.05) impaired for the protective effects (Figure 3f).
These results suggest that activation of DDR is protective against sepsis. To further test this
hypothesis we have used whole body sub-lethal γ-irradiation. We found a significant
increase in the number of cells with γH2AX-positive foci (p<0.001), a surrogate marker of
ATM activation (Ciccia and Elledge, 2010), in the lungs of whole body sub-lethal γ-
irradiated mice as compared to controls (figure 3g). Mice subjected to CLP that were
irradiated showed a significant increased survival (p<0.001) as compared to non-irradiated
mice (Figure 3h). We conclude that the protective phenotype induced by epirubicin is
dependent on the activation of multiple pathways downstream of a DDR. The activation of
the ATM pathway is the main contributor, but the full protection requires the activation of
additional DDR pathways, including the FA pathway.
The protective effect of epirubicin is dependent on the autophagy pathway
Although it is possible that the dominant ATM-mediated protection against sepsis might rely
on ROS scavenging (Cosentino et al., 2010), on the induction of apoptosis of inflammatory
cells (Garrison et al., 2011), on the preservation of genomic stability (Westbrook and
Schiestl, 2010), or on the biogenesis of anti-inflammatory microRNAs such as miR-146a
(Zhang et al., 2011), we found no significant contribution for any of these processes (Figure
S4). We, therefore, explored a possible role for autophagy in this process, given that ATM is
a negative regulator of mTOR, which is itself, an inhibitor of autophagy (Alexander et al.,
2010a; Alexander et al., 2010b). Using autophagy-defective (Lc3b−/−) mice, we found that
the autophagy pathway is required for the in vivo effect of epirubicin (Figure 4a). Similarly
to Atm−/− mice (Figure 3b and c), epirubicin was not able to decrease the serologic markers
associated with organ lesion (Figure 4b) or to normalize cytokine levels in autophagy-
defective mice (Figure 4c).
We then used LC3b-GFP mice to study the contribution of the autophagy pathway in the
protection conferred by epirubicin. While FACS analysis shows that CLP alone induces
LC3b aggregation in different splenocyte populations, namely monocytes and neutrophils,
epirubicin treatment did not increase the autophagy pathway in these critical players in
sepsis (Figure 5a). We then tested the impact of epirubicin on the survival of a conditional
depletion of Atg7 specifically in neutrophils and monocytes upon CLP, using
Atg7loxP/loxPLysMCre GFP-LC3b animals. Strikingly, these animals were equally protected
by epirubicin as compared to control mice (Figure 5b), suggesting that the autophagy
pathway is not required in the myeloid compartment for the protective effects of epirubicin
against sepsis.
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Autophagy can be effectively monitored by the conversion and immobilization of LC3
(Kabeya et al., 2000). Because the autophagy pathway was not required in the myeloid
compartment for protection against sepsis by epirubicin, we then looked at target organs of
sepsis (lung, liver and kidney) using immunobloting to identify lipidation of LC3b as
indicative of activation of the autophagy pathway. We found that epirubicin specifically
induced lipidation of LC3b in the lung at 6 h, but not in the liver or kidney (Figure 5c).
Although LC3 was transiently lipidated after CLP in the liver at 6 and 24 h as previously
reported (Chien et al., 2011), levels of LC3 were not altered by epirubicin treatment (Figure
5c). We have further confirmed that autophagy was induced in the lung as shown by the
increase of LC3b positive vesicles in lung sections at 6 h and 24 h comparing epirubicin
treated and non-treated mice (Figure 5d).
We then deleted Atg7 specifically in the lung (Figure S5), using an adenovirus-expressing
CRE (Adcre) to intranasally infect Atg7loxP/loxP mice (Komatsu et al., 2005). When subjected
to CLP, these mice were no longer protected from CLP by epirubicin treatment (Figure 5e).
In contrast to control mice, in Atg7loxP/loxPAd cre mice the treatment with epirubicin does
not improve the levels of circulating markers of organ lesion (Figure 5f). Accordingly, we
observed a significant protective effect in survival after overexpression of ATG7 in the lung
using adenovirus (Figure 5g).
By assessing the levels of γH2AX in the lungs of control or epirubicin-treated CLP-
subjected mice, we found a significant increase in the number of cells with γH2AX-positive
foci in lungs of epirubicin-treated mice (Figure 5h). To test whether ATM activation was
also required in the lung, we used AtmloxP/loxP mice and Adcre to delete ATM specifically in
the lung. Upon Adcre-mediated ATM deletion in the lung, mice were no longer protected
against sepsis by treatment with epirubicin (Figure 5i). We therefore conclude that the
protective effect of epirubicin in sepsis is, at least in part, dependent on the activation of
ATM and of autophagy in target organs, namely the lung. These conclusions are further
supported by intranasal delivery of epirubicin or etoposide to the lung (Figure 5j), because
the protective effects as measured by survival are similar to the i.p. administration of those
drugs (Figure 5j).
Epirubicin has a 24 h therapeutic window to protect against sepsis
Finally, we studied the therapeutic window of epirubicin in mice. When given alone,
epirubicin conferred strong protection at the time of the procedure or until 3 h after the
initiation of CLP (Figure 6a). When administered only 6 h after CLP, epirubicin quickly lost
its protective effect (Figure 6a). However, if given in combination with meropenem, even
when this antibiotic is only administered 12 h after CLP, low dose epirubicin conferred
complete protection until at least 24 h after the initial procedure (Figure 6b and 6c). These
results suggest that anthracyclines can be used not only to prevent sepsis, but also that they
can act therapeutically when their administration is combined with a large spectrum
antibiotic.
Discussion
Here we report that epirubicin, and more generally the group of anthracyclines, are very
effective at conferring protection against severe sepsis in mice, even when used up to 24 h
after the onset of infection. This therapeutic window is likely to be sufficient to make these
drugs good candidates as useful therapeutic options in the clinic to reduce the mortality of
sepsis in most patients that are either in the hospital or seek medical attention within the first
few hours of symptoms initiation.
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Although we began our investigation of the use of anthracyclines in sepsis by virtue of their
effects in inhibiting inflammatory cytokine expression in myeloid cells in vitro, our studies
have identified a mode of protection that seems to be much stronger and perhaps completely
independent of such effects, and rather manifests at the level of DNA damage response and
autophagy-induced protection in the lung. Thus, our findings uncover an unexpected role for
these pathways in tissue (lung) tolerance to the pathological consequences of infection.
These findings are especially relevant given that agents discovered in studies over the last
few years targeting various pro-inflammatory cytokines have had limited success in humans.
Our studies suggest a critical role for protecting host tissues thereby conferring protection
against sepsis. Recent studies have highlighted the role of tissue tolerance to infection as an
important aspect of host pathology (Medzhitov et al., 2012).
Interestingly, the protective effect of epirubicin seems to act irrespectively of the host
pathogen burden, revealing that it confers disease tolerance to polymicrobial infection
(Larsen et al., 2010; Raberg et al., 2009; Schneider and Ayres, 2008). This finding reveals
that pharmacologic agents that provide tissue damage control can limit disease severity
irrespectively of pathogen load and represent a promising therapeutic strategy against sepsis.
Moreover, based on our identification of ATM as a major mediator of epirubicin effects, we
propose that this protein and other components of the DNA damage response machinery
constitute novel regulators of tolerance, without affecting pathogen resistance mechanisms.
Recent reports make our findings counter-intuitive as doxorubicin and daunorubicin have
been shown to induce acute inflammation when injected in the abdomen where they induce
cytokine secretion (Krysko et al., 2011; Sauter et al., 2011). However, the concentrations of
anthracyclines utilized in these studies were more than 10-fold higher than those used here.
By using lower concentrations we may reduce the cytotoxicity of these drugs and the
resulting release of pro-inflammatory DAMPs by dying cells and reveal the additional
pharmacological effects mediated by the surviving target cells. Interestingly,
fluoroquinolones that are bacterial type II topoisomerase inhibitors, as opposed to
anthracyclines, which are eukaryotic type II topoisomerase inhibitors, were reported to have
immunomodulatory effects (Dalhoff and Shalit, 2003) when used in supra-therapeutic
concentrations. Fluoroquinolones have been shown to protect against LPS model of septic
shock (Khan et al., 2000). While the molecular mechanisms that explain these effects have
not been elucidated, it has been proposed that higher doses of fluoroquinolones can inhibit
mammalian topoisomerase type II enzymes in addition to their bacterial targets (Dalhoff and
Shalit, 2003), an effect that can be achieved with very low doses of anthracyclines.
The induction of autophagy is a common response to many forms of cellular stress,
including DNA damage (Mizushima and Komatsu, 2011). The rationale for testing the role
of autophagy was based on the knowledge that ATM is a negative regulator of mTOR and
that mTOR is a negative regulator of autophagy(Alexander et al., 2010a; Alexander et al.,
2010b). We therefore reasoned that if epirubicin activates ATM (as we have confirmed),
then it is possible that it induces autophagy. This line of investigation made sense because
several reports(Chien et al., 2011; Nakahira et al., 2010) have suggested a protective role for
autophagy in sepsis. To probe the contribution of autophagy for the protective phenotype
conferred by epirubicin, we have used two different genetic deletions in the autophagy
pathway (LC3b and ATG7) and in both cases the protection normally conferred by
epirubicin is lost. This is considered one of the best and most compelling ways to test the
contribution of autophagy and the direction of autophagic flow (Klionsky et al., 2012).
Chien et al. have previously found that autophagy is transiently induced in the rat liver after
CLP (Chien et al., 2011), and later made similar observations in the rat kidney (Hsiao et al.,
2012). Chien et al. have speculated that the transient induction of autophagy in these organs
Figueiredo et al. Page 7
Immunity. Author manuscript; available in PMC 2014 November 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
could be required for protection and its decline at a later stage could contribute to the
functional failure in liver during polymicrobial sepsis. After we found autophagy induction
by epirubicin, we thought that one reason to explain anthracycline protection against CLP
could be the sustained activation of autophagy in the liver and/or kidney preventing its
decline as observed by Chien et al. Instead we found that both in the liver and in the kidney,
treatment with epirubicin did not change this pattern, but instead transiently induced
autophagy in the lung, a response that was not present in mice subjected to CLP in the
absence of epirubicin treatment. We also report that epirubicin is highly protective when
delivered directly to the lung and that overexpression of ATG7 specifically in the lung
improves survival to CLP. Together, these observations strongly suggest that lung protection
is critical and likely dominant because it prevents failure of additional organs, which makes
our findings all the more relevant as the lung is the organ that often shows the first signs of
dysfunction in septic patients and drives the failure of other target organs particularly the
kidney and later the liver (Hotchkiss and Karl, 2003).
Nakahira et al. demonstrate that depletion of the autophagic proteins LC3b and beclin 1
enhanced the activation of caspase-1 and secretion of IL-1β and IL-18 (Nakahira et al.,
2010). While we also observe inhibition of IL-1β secretion in vitro and in vivo by treatment
with epirubicin, this finding is not dependent on the decreased activation of caspase-1
mediated by autophagy because even low concentrations of epirubicin lead to higher levels
of active caspase-1 (Chora et al., data not shown) but this event is overshadowed by a strong
inhibition of IL-1β, as well as most of pro-inflammatory mediators that are NF-kB
dependent, at the transcriptional level. We have now identified the mechanism: epirubicin
targets the N-terminal region of p65, inhibiting transcription by blocking the DNA-binding
ability of NF-kB (Chora et al., data not shown). The Nakahira et al. report also suggested to
us that severe sepsis could cause DNA lesions capable of activating the inflammasome
leading to chronic inflammation and that the induction of autophagy could block the
inflammasome and prevent excessive inflammation. To address this possibility, we have
used comet assays to look at different types of DNA damage in response to bacterial
challenge in the presence and absence of epirubicin. We did find that E. coli alone triggers a
small but measurable increase of DNA single strand breaks (Neves-Costa et al.,
unpublished). However the presence of epirubicin does not decrease, rather it increases
DNA damage as compared to E. coli alone. Therefore, epirubicin does not decrease the
generation of DNA damaged species that can activate the inflammasome. We conclude that
while the Nakahira et al. work clearly shows that autophagic proteins regulate NALP3-
dependent inflammation by preserving mitochondrial integrity, the autophagy protection
conferred by epirubicin to CLP does not depend on the mechanisms demonstrated in the
Nakahira et al. paper, specifically the negative regulation of IL-1β secretion by autophagy.
Interestingly, the protective phenotype of epirubicin is strikingly similar to that of RIPK3-
deficient mice (Duprez et al., 2011), suggesting that epirubicin-mediated, ATM-dependent,
autophagy induction can possibly prevent TNF-driven necroptosis in such key organs in
sepsis pathology as the lung. In fact, there have been recent works that support the role of
autophagy in the inhibition of necroptosis (Bray et al., 2012; Degenhardt et al., 2006; Lu and
Walsh, 2012; Shen and Codogno, 2012), which could be achieved by targeting key
necroptosis signaling components (such as RIPK1 and RIPK3) for degradation. It is also
possible that autophagy protects against severe sepsis because its activation increases the
degradation of pro-inflammatory mediators with an important role in sepsis, like HMGB1
(Li et al., 2011). In addition, increased effective autophagy can be beneficial in sepsis due to
its critical role in the removal of damaged mitochondria in an ATM-dependent
manner(Valentin-Vega and Kastan, 2012). The molecular mechanisms at the basis of
epirubicin-induced protection in sepsis by autophagy are certainly an interesting topic for
future studies.
Figueiredo et al. Page 8
Immunity. Author manuscript; available in PMC 2014 November 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Experimental Procedures
Animal Model and Anthracycline Treatment
Animal care and experimental procedures were conducted in accordance with Portuguese
and US guidelines and regulations after approval by the respective local committees
(Instituto de Medicina Molecular and Instituto Gulbenkian de Ciência). All mice used were
8–12 weeks old. Mice were bred and maintained under specific pathogen-free (SPF)
conditions. C57BL/6 and C57BL/6 Atm−/− mi ce were obtained from the Instituto
Gulbenkian de Ciência (a kind gift from Dr. Vasco Barreto). C57BL/6 Nrf2−/− mice were
provided originally from the RIKEN BioResource Center (Koyadai, Tsukuba, Ibaraki,
Japan) and subsequently by the Instituto Gulbenkian de Ciência. LC3b−/− (B6129PF2/J
background) and NMRI mice were purchased from Jackson and Charles River laboratories,
respectively. miR-146-deficient mice were generated in the Baltimore’s laboratory (Boldin
et al., 2011). Fancd2−/− mice were generated by the Grompe laboratory (Houghtaling et al.,
2003). Atg7loxP/loxP were generated by Masaaki Komatsu and obtained from the Green
laboratory. AtmloxP/loxP mice were generated and obtained from the F.W. Alt’s laboratory.
CLP was performed as described previously (Rittirsch et al., 2009). The endotoxemia model
was performed by injecting intraperitoneally (i.p.) a single dose of 50 μg/g body weight of
LPS (from E. coli serotype 026:B6; Sigma-Aldrich). Pulmonary monostrain infections were
carried out as described previously (Weber et al., 2011), using intranasal injection of
Klebsiella pneumoniae (ATCC13803) at 8x107 colony-forming units (CFU). Epirubicin
(Sigma-Aldrich), doxorubicin (Sigma-Aldrich), daunorubicin (Sigma-Aldrich) were
dissolved in PBS, etoposide (Sigma-Aldrich) was dissolved in DMSO, aliquoted and stored
at −80°C. Meropenem (AstraZeneca, Lisbon, Portugal). Epirubicin and daunorubicin (0.6μg/
g body weight), doxorubicin (0.5μg/g body weight), etoposide (2μg/g body weight) were
injected intraperitoneally at 0 and 24 h following CLP. Meropenem (20μg/g body weight
b.i.d.) was injected i.p. for 5 consecutive days.
Colony-Forming Units Assay
Blood samples from septic or mock CLP mice were collected by cardiac puncture at
indicated times after surgery. Mice were subsequentially perfused in toto with 10mL ice
cold PBS and spleen, liver and kidneys were surgically removed and homogenized in 5mL
of sterile PBS. Serial dilutions of blood and tissue homogenates were immediately plated on
Trypticase Soy Agar II plates supplemented with 5% Sheep Blood. CFUs were counted after
a 12 h incubation at 37 C.
Serology and Cytokine Measurement
Plasma from blood samples obtained 24 h post-CLP was collected after centrifugation.
LDH, CK, ALT and urea levels were measured using the BioAssay Systems kits (BioAssay
Systems, California) according to company’s protocol. Levels of TNF, IL-1β and IL-6 were
measured using the murine ELISA kits (R&D Systems, Minneapolis) according to
company’s protocol. Levels of HMGB1 were assessed using a murine ELISA kit (Shino
Test Corporation, Tokyo) according to company’s protocol.
Histology
Mice were euthanized, perfused in toto with 10mL ice cold PBS and lungs and livers were
surgically removed. Livers were placed in 10% phosphate buffered formalin for 24 h after
which were embedded in paraffin. Sections were subsequently incubated with a primary
antibody reactive to HMGB1 (Abcam, Cambridge, UK) followed by incubation with
biotinylated secondary antibody and then with biotinylated horseradish peroxidase. Staining
was developed by addition of diaminobenzidine (DAB) substrate (Vector Labs, Burlingame,
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CA) and counterstained with hematoxylin. Lungs were embedded in Tissue-Tek OCT
(Sakura, Alphen aan den Rijn, Netherlands), and snap-frozen in liquid nitrogen. Lung
sections (7 μm) were fixed in 1% paraformaldehyde in PBS for 2 min, followed by methanol
at −20°C for 10 min and then in acetone for 2 min. Detection of LC3b and histone γH2AX
was performed by incubating sections overnight at 4°C with rabbit polyclonal antibodies
specific for, respectively, LC3b (L7543, Sigma Aldrich, USA) and γH2AX (phosphoS139)
(ab2893; Abcam, Cambridge, UK); incubation with a secondary DyLight 488-coupled
antibody (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) was for 1 h at
room temperature. Sections were counterstained with DAPI (0.5 μg/mL) to visualize DNA
and mounted in Vectashield (Vector Laboratories Inc., Burlingame, CA) before confocal
microscopy. Samples were examined with a Zeiss LSM 510 META laser scanning confocal
microscope (Carl Zeiss, Jena, Germany). The acquired images were analyzed using a
MATLAB (Mathworks; Natick, MA) routine developed in-house to perform automatic
threshold segmentation and enumeration of individual cell nuclei stained with DAPI.
In vivo Viral Infection and Viral Titer Assay
Murid herpesvirus-4 infection and viral particle quantification was performed as previously
described (Marques et al., 2008). Briefly, mice were intranasally inoculated with 1000 PFU
of MuHV-4 strain 68 in 20 μLof PBS under light isoflurane anaesthesia. At 6 and 12 days
post-infection, lungs were removed and homogenized in 5mLof Glasgow’s modified Eagle’s
medium (GMEM). Infectious virus titers in freeze-thawed lung homogenates were
determined by serial diluted suspension assay using Baby hamster kidney cells (BHK-21)
cultured in GMEM supplemented with 10% fetal bovine serum, 10% tryptose phosphate
broth, 2 mM glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin (GMEM). Plates
were incubated for four days, fixed with 10% formal saline and counterstained with
toluidine blue. Viral plaques were counted with a plate microscope. Cre-adenovirus were
obtained from the University of Iowa, prepared as a calcium-phosphate coprecipitate and
incubated for 20 min at room temperature. Atg7loxP/loxP and ATMloxP/loxP were subjected to
light isoflurane anesthesia and allowed to inhale 125μLof virus at a concentration of 2.5 ×
107PFU. Additionally, wild -type C57BL/6 mice were included as controls. Mice were
allowed to rest for 5 days after inhalation after which were subjected to CLP.
Stainings and Flow Cytometry
Peritoneal infiltrating leukocytes from either wild-type or LC3b-GFP transgenic animals
were obtained 24 h post CLP by lavage with 5 mL of sterile ice-cold PBS, washed and
blocked with mouse Ab anti-FcγIII/II (clone 93) receptor diluted in PBS containing 2% FCS
(v/v) for 20 min at 4°C. Surface markers were detected by incubating for 30 min at 4°C with
mouse Ab anti-CD4 (clone GK1.5), -CD8 (clone 53–6.7), -CD19 (clone 6D5), -Ly-6G
(clone 1A8) (all Biolegend) and -neutrophil monoclonal antibody (clone 7/4) (Abcam,
Cambridge, UK). Dead cells were excluded by co-staining with propidium iodide. Total cell
number was determined by flow cytometry using a fixed number of latex beads (Beckman
Coulter, CA, USA) co-acquired with a pre-established volume of the cellular suspension.
For phospho-ATM intracellular staining, stimulated THP-1 cells were washed and fixed
with ice-cold methanol. Mouse Ab anti-phosphoATM pS1981, clone 10H11.E12 (IgG1k)
(Rockland, MA, USA) was incubated for 60 min at room temperature followed by an
incubation of secondary Ab conjugated with Alexa 488 (Molecular Probes, CA, USA).
Fluorescence was measured by flow cytometry, and data analyzed using FlowJo software.
Immunoblotting
Mouse phospho-ATM (4526, Cell Signaling, Danvers, MA, 1:1000 dilution), rabbit total
ATM (2873, Cell Signaling, Danvers, MA, 1:1000 dilution), rabbit LC3b (Sigma, 1:1000
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dilution) and the rabbit Fancd2 (Novus Biologicals, CO, USA; 1:1000 dilution) Ab were
used overnight at 4°C. Primary Ab were detected using peroxidase conjugated secondary Ab
(1h; RT) and developed with SuperSignal chemiluminescent detection kit (Pierce,
Carcavelos, Portugal).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Anthracyclines confer strong protection against severe sepsis.
• Anthracyclines act therapeutically by promoting disease tolerance to severe
sepsis.
• DDR and autophagy are required in the lung for anthracycline-induced
protection.
• ATM and FA pathways are required for protection.
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Figure 1. Epirubicin affords protection against severe sepsis
(a) Survival of C57BL/6 wild-type animals subjected to CLP treated with carrier (PBS) or
epirubicin (Epi) (0.6μg/g body weight) at the time of procedure and 24 hours later. (b)
Survival of C57BL/6 wild-type animals subjected to CLP treated with carrier (PBS),
epirubicin (Epi), doxorubicin (Doxo) or daunorubicin (Dauno). Treatment schedule and
doses as in (a). (c) Survival of NMRI mice subjected to CLP and treated with carrier (PBS)
or epirubicin (Epi) as in (a). (d) Survival of C57BL/6 wild-type animals following intranasal
inoculation of Klebsiella pneumoniae and treated with carrier (PBS) or epirubicin (Epi) as in
(a). (e) Quantification of infectious viral MuHV-4 particles in lung of C57BL/6 wild-type
animals previously subjected to mock CLP (S), mock CLP treated with epirubicin (S+E) or
CLP treated with epirubicin (C+E). Epirubicin treatment dose and schedule as in (a). Mice
were intranasally inoculated with 1000 PFU of MuHV-4 on day 3 post CLP and viral
particles quantified by plaque assay at days 6 and 12 post viral infection. Each circle
represents individual animals and horizontal lines indicate arithmetic means ± SEM from
two independent assays. The dashed horizontal line represents the limit of detection of the
assay. ns, not significant; *P<0.05; **P<0.01; ***P<0.001 (log-rank (Mantel-Cox) test for
(a) to (d) and Mann-Whitney test for (e)). See also Figure S1 and Table S1.
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Figure 2. Epirubicin promotes disease tolerance to severe sepsis
(a) Polymicrobial load (CFUs) in blood, lung, liver, kidney and spleen, at indicated time
points, of C57BL/6 animals undergoing CLP and treated with PBS (C+P) or epirubicin (C
+E) (0.6μg/g body weight) at the time of procedure and 24 hours later. Each circle
represents individual animals. Horizontal lines indicate arithmetic means ± SEM. (b) and
(c) Epirubicin counteracts tissue damage and inflammation associated with CLP as assessed
by (b) LDH, CK, ALT, urea and (c) TNF, IL-1β, IL-6 and HMGB1 plasma concentrations in
C57BL/6 wild-type animals 24 hours after mock CLP (S) (n=2) or CLP followed by
treatment with PBS (C+P) (n=5) or epirubicin (C+E) (n=7) as in (a). Results shown
represent arithmetic means ± SEM from duplicate (b) or triplicate (c) readings per animal.
(d) Survival of C57BL/6 wild-type animals following lethal LPS injection and treatment
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with carrier (PBS) or epirubicin (Epi) as in (a). (e) Survival of C57BL/6 wild-type animals
subjected to CLP treated with carrier (PBS), meropenem (40μg/g body weight/day) or
epirubicin (Epi) as in (a). (f) CFUs in blood, at indicated time, of C57BL/6 animals
undergoing mock CLP (S) or CLP followed by treatement with PBS (C+P), epirubicin (C
+E) or meropenem (C+M) as in (a). Each circle represents individual animals. Horizontal
lines indicate arithmetic means ± SEM. (g) IL-1β, TNF and HMGB1 plasma concentrations
in C57BL/6 wild-type animals 24 hours after CLP followed by treatment with PBS (C+P)
(n=4), epirubicin (C+E) (n=5) or meropenem (C+M) (n=5) as in (c). ns, not significant;
*P<0.05; **P<0.01; ***P<0.001 (log-rank (Mantel-Cox) test for (d) and (e), Mann-Whitney
test for (a) and (f), and unpaired t test for (b), (c) and (g)). See also Figure S2.
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Figure 3. The protection afforded by epirubicin against severe sepsis is mediated by ATM
(a) Survival of Atm+/+ and Atm−/− C57BL/6 animals subjected to CLP and treated with PBS
or epirubicin (Epi) with same schedule and dose as in fig 1. (b) LDH, CK, ALT, urea and (c)
TNF, IL-1β and IL-6 plasma concentrations in Atm−/− C57BL/6 animals 24 hours after mock
CLP (S) (n=2) or CLP followed by treatment with PBS (C+P) (n=8) or epirubicin (C+E)
(n=8) as in (a). Results shown represent arithmetic means ± SEM from triplicate readings
per animal. (d) Survival of PBS-, etoposide (Eto)-, and epirubicin (Epi)-treated wild-type
C57BL/6 animals undergoing CLP. Etoposide dose was 2μg/g body weight. Treatment
schedule as in (a). (e) FANCD2 and Ub-FANCD2 protein levels by immunoblotting in
THP-1 cells following E. coli challenge after a pre-incubation (1 hour) with carrier,
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epirubicin or KU-55933 as indicated. (f) Survival of Fancd2+/+ and Fancd2−/− animals
subjected to CLP and treated with PBS or epirubicin (Epi) with same schedule and dose as
in (a). (g) Representative sections of γH2AX staining and percentage of γH2AX+ cells per
field (right panel) in lungs isolated 1 hour after mice were subjected to whole body γ
irradiation (4 Gy). Results shown represent arithmetic means ± SD from 3 fields. (h)
Survival of C57BL/6 wild-type animals subjected to CLP following whole body γ
irradiation (4Gy) or treated with carrier (PBS) or epirubicin (Epi) as in (a). ns, not
significant; *P<0.05; **P<0.01; ***P<0.001 (log-rank (Mantel-Cox) test for (a), (d), (f) and
(h) and unpaired t test for (b), (c) and (g)). See also Figure S3 and Table S2.
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Figure 4. The ATM-dependent protection of epirubicin against severe sepsis relies on the
induction of autophagy
(a) Survival of Lc3b+/+ and Lc3b−/− animals subjected to CLP and treated with PBS or
epirubicin (Epi) with same schedule and dose as in fig 1. (b) LDH, CK, ALT, urea and (c)
TNF, IL-1β and IL-6 plasma concentrations in Lc3b−/− animals 24 hours after mock CLP (S)
(n=2) or CLP followed by treatment with PBS (C+P) (n=4) or epirubicin (C+E) (n=7) as in
(2b). Results shown represent arithmetic means ± SEM from triplicate readings per animal.
ns, not significant; *P<0.05; **P<0.01; ***P<0.001 (log-rank (Mantel-Cox) test for (a),
unpaired t test for (b) and (c)). See also Figure S4.
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Figure 5. The protective effect of epirubicin is dependent on the activation of ATM and the
autophagy pathway in the lung
(a) GFP expression in blood monocytes and neutrophils, isolated from transgenic LC3b-
GFP animals, 24 hours after mice were subjected to mock CLP (S) or CLP followed by
treatment with PBS (C+P) or epirubicin (C+E) (0.6μg/g body weight) at the time of
procedure and 24 hours later. Each circle represents individual animals. Horizontal lines
indicate arithmetic means ± SEM. (b) Survival of Atg7loxP/loxP and Atg7loxP/loxP LysMcre/cre
mice subjected to CLP and treated with PBS or epirubicin (Epi) with same schedule and
dose as in (a). (c) LC3B-I and LC3B-II protein levels by immunoblotting using a specific
antibody against LC3B in lung, liver and kidney, isolated at the indicated times, of naïve
C57BL/6 animals (C) or mice subjected to mock CLP (S) or CLP followed by treatment
with PBS (C+P) or epirubicin (C+E) as in (a). (d) Representative sections of LC3b staining
in lungs, isolated at the indicated times, of mice subjected to CLP followed by treatment
with PBS (C+P) or epirubicin (C+E) as in (a). (e) Survival of wild-type (B6) and
Atg7loxP/loxP animals subjected to CLP and treated with PBS or epirubicin (Epi) with same
schedule and dose as in (b) 5 days after inhalation of adenoviral vector encoding Cre
(AdCre). (f) LDH, CK, ALT and urea plasma concentrations in wild-type (B6 AdCre) and
Atg7loxP/loxP AdCre animals 24 hours after mock CLP (S) (n=2 for B6 AdCre) or CLP
followed by treatment with PBS (C+P) (n=5 for B6 AdCre and n=2 for Atg7loxP/loxP AdCre)
or epirubicin (C+E) (n=6 for B6 AdCre and n=3 for Atg7loxP/loxP AdCre) as in (a). (g)
Survival of wild-type (B6) animals subjected to CLP 4 days after inhalation of adenoviral
vector encoding GFP (AdGFP) or Atg7 (AdATG7). (h) Representative sections of γH2AX
staining and percentage of γH2AX+ cells per field (right panel) in lungs, isolated 6 hours
after mice were subjected to CLP followed by treatment with PBS (C+P) or epirubicin (C
+E) as in (a). Results shown represent arithmetic means ± SD from 10 fields. (i) Survival of
wild-type (B6) and AtmloxP/loxP animals subjected to CLP and treated with PBS or
epirubicin (Epi) with same schedule and dose as in (b) 5 days after inhalation of AdCre. (j)
Survival of C57BL/6 wild-type animals subjected to CLP treated with carrier (PBS),
etoposide (40μg/g body weight/day) or epirubicin (Epi) (0.6μg/g body weight) intranasally,
at the time of procedure and 24 hours later. ns, not significant; *P<0.05; **P<0.01;
***P<0.001 (log-rank (Mantel-Cox) test for (b), (e), (g), (i) and (j), Mann-Whitney test for
(a), and unpaired t-test for (f) and (h) (right panel)). See also Figure S5.
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Figure 6. Epirubicin confers protection against severe sepsis in a therapeutic manner
(a) Survival of C57BL/6 wild-type animals subjected to CLP treated with PBS or epirubicin
(same dose as in Figure 1) at indicated times in the absence of meropenem; (b) with
administration of meropenem (40μg/g body weight/day) starting at the time of the procedure
or (c) with meropenem treatment starting 12 hours after CLP. ns, not significant; *P<0.05;
**P<0.01; ***P<0.001 (log-rank (Mantel-Cox)).
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Original StudyTherapy-Induced Cellular Senescence Induces
Epithelial-to-Mesenchymal Transition and
Increases Invasiveness in Rectal Cancer
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Abstract
We evaluated the effects of the senescence-associated secretome (SAS) in vitro and in clinical samples from
patients with rectal cancer who had undergone neoadjuvant chemoradiotherapy (CRT). The effects of the SASs
on colorectal cancer cells translated into increased invasiveness and induction of epithelial-to-mesenchymal
transition (EMT). In the clinical samples, senescence and EMT co-occurred within a fraction of cancer cell
clusters. These results could have important implications in guiding treatment after CRT.
Introduction: DNA damaging agents and ionizing radiation used in the therapy of human cancers can induce
senescence of cancer cells. Senescent cells exhibit a secretory phenotype (senescence-associated secretome [SAS])
that can affect cancer cell behavior and, eventually, clinical prognosis. We assessed the effects of the SAS on the
induction of epithelial-to-mesenchymal transition (EMT) in vitro and in clinical samples from patients with rectal cancer
who had undergone neoadjuvant chemoradiotherapy (CRT). Materials and Methods: Colorectal cancer cells (HCT
116) were induced into senescence by exposure to either 5-ﬂuorouracil (5-FU) or doxorubicin. The senescent state
was conﬁrmed by staining for senescence-associated b-galactosidase (SA-b-Gal). The paracrine effects of SASs were
assessed on proliferating HCT 116 cells. The quantiﬁed parameters were cell proliferation, invasive capacity, and
induction of EMT. Senescence and EMT in clinical samples were assessed by the expression levels (reverse
transcriptase-quantitative polymerase chain reaction) of genes related to senescence and EMT after laser-assisted
microdissection of cancer cell clusters that stained either positive or negative for SA-b-Gal. Results: We have
shown that cultured colon cancer cells induced into senescence by exposure to 5-FU exhibit a SAS capable of
paracrine induction of EMT in colon and rectal cancer cell lines and increased cell invasion in vitro. Using laser-
assisted microdissection, we found that in rectal cancer samples from patients treated with neoadjuvant CRT, tu-
mor cell niches enriched for senescent cells bookmark regions of increased mRNA expression levels of EMT-related
proteins (Slug, Snail, vimentin) compared with the nearby senescent-null tumor cell niches. Conclusion: We have
provided, ﬁrst-hand, strongly suggestive evidence that senescent cancer cells emerging in the context of neoadjuvant
CRT for rectal cancer inﬂuenced the tumor microenvironment by promoting EMT by way of short-range interactions.
Clinical Colorectal Cancer, Vol. -, No. -, 1-9 ª 2015 Elsevier Inc. All rights reserved.
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Therapy-Induced Cellular Senescence Increases Rectal Cancer Invasivenesschemotherapy with the thymidylate synthase inhibitor 5-
ﬂuorouracil (5-FU) and concomitant radiotherapy (chemo-
radiotherapy [CRT]), followed by surgery.3,4
It has been previously described that chemotherapy, in addition
to its cytotoxic action, can induce a cellular state of irreversible
proliferative arrest because of severe DNA damage, termed “therapy-
induced senescence” (TIS).5,6 Initially considered to be a phe-
nomenon typical of normal somatic cells that lost their ability to
divide and, thereby, termed “replicative senescence,” it is now
known that senescence can also be a response mechanism triggered
by several factors, including oncogenic mutations, oxidative stress,
and DNA damaging agents.7,8
The effect of cellular senescence in the context of cancer is not
completely understood. Cell senescence can play a direct role in
tumor growth inhibition, because it is an important antiproliferative
mechanism.9 In lung and breast cancer, the detection of cell
senescence after neoadjuvant chemotherapy correlated positively
with the response to treatment.10,11 Also, in colorectal cancer, pa-
tients with sporadic senescent cells detected before treatment had
increased susceptibility to TIS and a better response to adjuvant
chemotherapy.12 However, evidence has shown that senescent cells
can also exert deleterious effects on the tissue microenvironment.13
The so-called senescence-associated secretory phenotype (SASP) of
these cells, which includes the secretion of several pro-inﬂammatory
cytokines, epithelial growth factors, and tissue remodeling enzymes,
can induce a more aggressive phenotype in nonsenescent cells in a
paracrine fashion.14 Data from studies of breast, prostate, and
pancreatic cancer showed that senescent ﬁbroblasts promoted tumor
growth and progression by increasing proliferation and invasion and
inducing an epithelial-to-mesenchymal transition (EMT) in pre-
malignant and malignant cells.15-19 It was further shown that
neoadjuvant chemotherapy-induced senescence observed in patients
with malignant pleural mesothelioma or lung cancer was potentially
associated with a poor outcome.20,21 Finally, senescent human
prostate and breast tumor cells also have a SASP, raising the ques-
tion of broader effects of SASPs on tumor behavior.17,22 In the
present study, we assessed the effects of the SASP from
chemotherapy-induced senescence on induction of EMT in vitro
and whether the coupling between cancer cell senescence and EMT
induction was recapitulated in clinical samples from patients with
rectal cancer who had undergone neoadjuvant CRT.
Materials and Methods
Cell Lines and Human Tissue Specimens
The human colon carcinoma cell lines HCT 116 and SW48 and
the human rectal cancer cell line SW837 were obtained from the
American Type Culture Collection (CCL-247, CCL-235, and
CCL-231, respectively). HCT 116 was cultured in McCoy’s 5A
modiﬁed medium (Life Technologies, Carlsbad, CA) supplemented
with 10% fetal bovine serum (Life Technologies), 100 U/mL
penicillin/streptomycin (Life Technologies), 2 mM L-glutamine
(Life Technologies), and 1% nonessential amino acids (Life Tech-
nologies). SW48 and SW837 were cultured in Dulbecco’s modiﬁed
Eagle medium (Life Technologies) supplemented with 10% fetal
bovine serum (Life Technologies) and 100 U/mL penicillin/strep-
tomycin (Life Technologies). All cell lines were kept at 37C in 5%
carbon dioxide. Rectal cancer specimens (n ¼ 19) were collectednical Colorectal Cancer Month 2015during standard of care surgery from patients with rectal cancer who
had or had not (controls) undergone neoadjuvant CRT, included in
OCT compound (Sakura Finetek, Alphen aan den Rijn, The
Netherlands), snapshot frozen in liquid nitrogen within 30 minutes
of collection, and preserved at 80C. The ethics commission of
the Hospital de Santa Maria, Centro Hospitalar Lisboa Norte
(Lisbon, Portugal) approved the study, and all the patients provided
written informed consent.
Induction of Cell Senescence
A total of 4.0  104 HCT 116 cells were seeded in 60-mm
diameter plates and continuously exposed to 5.0 mM 5-FU
(Accord Farmacêutica Ltd, São Paulo, Brazil) or 0.5 mM doxoru-
bicin (Sigma-Aldrich, St Louis, MO), for 7 days or 4 hours,
respectively. The media with and without (controls) drugs were
replaced every 48 hours. After drug removal, the cells were incu-
bated with fresh medium. Conditioned media were collected 72
hours after drug release (senescence-associated secretome [SAS]
medium). Culture media conditioned by exponentially growing
(nonsenescent) cells (non-SAS medium) were collected 72 hours
after seeding. The conditioned media were stored at 4C and used
within 48 hours of storage.
Cellular Assays
The detection of senescence-associated b-galactosidase (SA-b-Gal)
activity in HCT 116 cells and frozen tissues was performed using
the Senescence Cells Histochemical Staining Kit (Sigma-Aldrich),
according to the manufacturer’s instructions, followed by counter-
staining with nuclear fast red (Sigma-Aldrich) and visualized in a
Leica DM2500 bright ﬁeld microscope (Leica Microsystems,
Hannover, Germany).
Cell proliferation was assessed using the alamarBlue assay and
5-bromo-20-deoxyuridine (BrdU) incorporation. The ala-
marBlue assay (Life Technologies) was performed according to
the manufacturer’s instructions. To determine the effect of the
conditioned media on cell proliferation, HCT 116, SW837, and
SW48 cells were plated in 96-well plates (2.0  103, 1.0  104,
and 1.0  104 cells/well, respectively) and incubated for 24
hours in the presence of SAS medium or non-SAS medium. To
test for BrdU incorporation, the cells induced into senescence by
5-FU or untreated control cells were exposed to 10 mM of BrdU
for 24 hours or 1 hour, respectively. The cells were then ﬁxed in
3.7% paraformaldehyde (PFA) for 10 minutes at room tem-
perature. DNA was subsequently depurinated for 30 minutes in
4.0 N HCl, followed by a neutralization step in PBS supple-
mented with Tris buffer (100 mM; pH 8) for another 30 mi-
nutes. The cells were incubated with anti-BrdU antibody (1:50;
clone BMC 9318; Roche, Basel, Switzerland) for 1 hour at
37C, followed by incubation with anti-mouse Cy3 antibody
(1:200; Jackson ImmunoResearch, West Grove, PA). Cover slips
were mounted in VECTASHIELD with 40,6-diamidino-2-
phenylindole (DAPI; Vector Laboratories, Burlingame, CA),
and visualized in a Zeiss Axiovert 200M inverted wide-ﬁeld
ﬂuorescence microscope (Carl Zeiss MicroImaging GmbH,
Jena, Germany). Apoptosis was assessed using the Caspase-Glo
3/7 Assay (Promega, Madison, WI), according to the manu-
facturer’s instructions.
Figure 1 Low-Dose 5-Fluorouracil (5-FU) Induces Cellular Senescence in HCT 116 Colon Cancer Cells. (A) Detection of Senescence-
Associated b-Galactosidase (SA-b-Gal) in HCT 116 Cells Not Exposed to 5-FU (Controls) or Exposed to 5-FU (5 mM) for 7
Days. Note the Increased Staining for SA-b-Gal (Blue Signal) and Enlarged Size of 5-FUeTreated Cells. (B) HCT 116 Cells Not
Treated With 5-FU (Controls) or Treated With 5 mM of 5-FU for 7 Days Were Incubated With 10 mM 5-Bromo-20-deoxyuridine
(BrdU). This Showed That BrdU Incorporation by 5-FUeTreated Cells Was Residual (w6% BrdU-Positive Cells), Even After 24
Hours of BrdU Incorporation Compared With Controls (w58% of BrdU-Positive Cells After 1 Hour of Incorporation). Cells That
Incorporated BrdU Show Nuclear Staining (Red Signal; White Arrows); Nuclei Were Counterstained With 40,6-Diamidino-2-
Phenylindole (DAPI) (Blue Signal); 400 Nuclei Analyzed per Sample. (C) Quantiﬁcation of HCT 116 Cells by AlamarBlue Not
Exposed to 5-FU (Controls) or Exposed to 5 mM of 5-FU for 7 Days. (D) Quantiﬁcation of Apoptosis in HCT 116 Cells Not
Exposed (Controls) or Exposed to 5-FU (5 mM) for 7 Days. Caspase-3 and -7 Activities Were Measured by a Luminescent
Assay (Caspase-Glo 3/7 Assay; Promega; See “Materials and Methods”). Note That the Accumulated Apoptosis Observed
During the Induction of Senescence by 5-FU Was Lower Than in Control Cultures. All Determinations Were Performed in
Triplicate, and Data Are Given as Scatter Plots of the Mean ± Standard Error of Mean. *P < .05; **P < .01; ***P < .001,
Unpaired t Test
Joana Tato-Costa et alImmunoﬂuorescence
The cell lines HCT 116, SW837, and SW48 were seeded on
glass cover slips (2.0  105, 9.0  105, and 9.0  105 cells,
respectively) in 60-mm diameter plates and continuously exposed to
SAS medium or non-SAS medium for 72 hours. Next, the medium
was removed, and the cells were ﬁxed with 3.7% PFA for 10 mi-
nutes at room temperature. The cells were permeabilized with
PBS/0.5% Triton X-100 for 10 minutes and then incubated with
anti-E-cadherin antibody (1:1000; HECD-1, Life Technologies) for
1 hour at 37C, followed by incubation with anti-mouse Cy3
antibody (1:200; Jackson ImmunoResearch) for 45 minutes at
37C. The cover slips were mounted in VECTASHIELD with
DAPI (Vector Laboratories), and visualized in a Zeiss Axiovert
200M inverted wide-ﬁeld ﬂuorescence microscope (Carl Zeiss
MicroImaging GmbH).
Cytokine Proﬁling
The detection and semiquantiﬁcation of cytokines present in the
conditioned media were performed using the Proteome Proﬁler
Array Human XL Cytokine Array Kit (R&D Systems) according to
the manufacturer’s instructions. In brief, the membranes wereincubated with 500 mL of conditioned media (normalized for the
total number of cells and total protein quantiﬁcation, which in this
case corresponded to 8 mg/mL protein, determined using the DC
Protein Assay, Bio-Rad, Hercules, CA). Chemiluminescence
detection was done in ChemiDoc MP (Bio-Rad). Pictures were
acquired using ImageLab software, version 4.1 (Bio-Rad) and im-
ported to ImageJ software, version 1.48 (National Institutes of
Health, Bethesda, MD) for image analysis. The mean pixel density
in each dot was determined by subtracting the same background
value, and the average pixel density of duplicate spots was
calculated.
RNA Isolation and Reverse Transcriptase Quantitative
Polymerase Chain Reaction
The cell lines HCT 116, SW837, and SW48 (3.0  104, 9.0 
105, and 9.0  105 cells, respectively) were seeded in 60-mm
diameter plates and continuously exposed to SAS medium or
non-SAS medium for 72 hours. The RNeasy Mini Kit (Qiagen,
Valencia, CA) for total RNA isolation and DNase I (Promega) were
used in accordance with the manufacturer’s instructions. The RNA
concentration and purity were assessed in a NanoDropClinical Colorectal Cancer Month 2015 - 3
Figure 2 Cytokines Secreted by 5- Fluorouracil (5-FU)eInduced Senescent HCT 116 Colon Cancer Cells. (A) Cytokine Screening Arrays
Incubated With Either Senescence-Associated Secretome (SAS)e or Non-SAS (Control)eConditioned Medium Obtained as
Described in Materials and Methods. Note That Each of the Probed Cytokines Is Detected in Duplicate (Double-Spot) in Each
Array. (B) Proﬁles of Mean Spot Pixel Density, Created Using ImageJ Software. (C) Quantiﬁcation of Interleukin (IL)-8 in
Media Conditioned for 72 Hours by Either Proliferating (Non-SAS Medium; Control) or Senescent (SAS Medium) HCT 116
Cells. Results Represent Mean ± Standard Error of Mean of Triplicate Experiments
Abbreviations: EMMPRIN ¼ extracellular matrix metalloproteinase inducer; FGF-19 ¼ ﬁbroblast growth factor 19; IGFBP2 ¼ insulin-like growth factor binding protein 2; MIC-1 ¼ macrophage
inhibitory cytokine 1; MIF, macrophage migration inhibitory factor; PAI-1 ¼ plasminogen activator inhibitor 1; PDGF-AA ¼ platelet-derived growth factor-AA; TGF-a ¼ transforming growth factor-a;
uPAR ¼ urokinase-type plasminogen activator receptor; VEGF ¼ vascular endothelial growth factor.
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4 - Clispectrophotometer (Thermo Fisher Scientiﬁc, Waltham, MA). RNA
(1 mg per sample) was reverse transcribed using the Superscript III
First-Strand Synthesis System for reverse transcriptase (RT) poly-
merase chain reaction (PCR) with random hexamer primers (Life
Technologies), according to the manufacturer’s instructions. RNA
extraction from the microdissected tissues was performed using the
RNeasy Plus Micro kit (Quiagen) according to the manufacturer’s
instructions. Total RNA was reverse transcribed using the RT2Nano
PreAMP cDNA Synthesis kit (Quiagen) according to the manufac-
turer’s instructions. cDNA was ampliﬁed using semiquantitative real-
time PCR (qPCR) using Power SYBR Green PCR Master Mix
(Applied Biosystems, Carlsbad, CA) and speciﬁc primers in a Rotor
Gene 6000 (Corbett; Quiagen). Speciﬁc primers were used for the
following genes: CDKN2A, which codes for p16INK4a
(PPH00207C); IL-8, coding for IL-8 (PPH00568A; Quiagen); VIM,
coding for vimentin, forward 50- CGAAAACACCCTGCAATCTT-
30, vimentin, reverse 50-TCCTGGATTTCCTCTTCGTG-30; FN1
gene, encoding for ﬁbronectin, forward 50-CAGTGGGA-
GACCTCGAGAAG-30, ﬁbronectin, reverse 50-TCCCTCGGAA-
CATCAGAAAC-30; and CDKN2A, coding p21Waf1/Cip1,nical Colorectal Cancer Month 2015forward 50- CTCAGAGGAGGCGCCATGT-30, p21Waf1/Cip1,
reverse 50-CCATTAGCGCATCACAGTCG-30. The genes SNAI1,
SNAI2, ZEB1, and GAPDH, which encode for Snail, Slug, Zeb1, and
GAPDH proteins, respectively, were ampliﬁed using previously
published primers.23 The relative mRNA expression levels were
determined using the 2DCT method and normalized to the GAPDH
housekeeping gene, using the mean value of 3 replicates.
Invasion Assay
The cell invasion assay was performed using the 24-well BD BioCoat
Tumor Invasion System (BD Biosciences, San Jose, CA), according to
the manufacturer’s instructions. In brief, HCT 116 cells (5.0  104
cells/mL) were plated in the upper chambers, and SAS medium or non-
SAS medium (control) was added to the lower chambers. After 24
hours of incubation at 37C with 5% carbon dioxide, the cells in the
membrane were stained with 4 mg/mL of Calcein-AM (Merck Milli-
pore, Darmstadt, Germany) in Hank’s buffered salt solution (Life
Technologies) at 37C in 5% carbon dioxide for 1 hour. Fluorescence
was quantiﬁed using an Inﬁnite200 Multimode reader (Tecan, Män-
nedorf, Switzerland) at 494/517 nm (excitation/emission).
Figure 3 The Secretome of Senescent HCT 116 Cells Stimulates the Proliferation of Nonsenescent Cells. Quantiﬁcation of HCT 116,
SW48, and SW837 Cells by AlamarBlue After Incubation With Conditioned Media, Either NoneSenescence-Associated
Secretome (SAS) Medium (Controls) or SAS Medium, for 24 Hours. Ratios Between Values Obtained After and Before
Incubation With Conditioned Media Are Presented. All Determinations Were Performed in Triplicate, and Data Are Shown as
Scatter Plots of Mean ± Standard Error of Mean. *P < .05 and **P < .01, an Unpaired t Test
Joana Tato-Costa et alIL-8 Quantiﬁcation
IL-8 in conditioned media was quantiﬁed with the Human IL-8/
CXCL8 Quantikine ELISA (enzyme-linked immunosorbent assay)
kit (R&D Systems), according to the manufacturer’s instructions.
Laser Microdissection
Tumor cells were microdissected in a Laser PALM-Microbeam
4.2 microdissection system (Carl Zeiss MicroImaging GmbH), as
previously described.24 Sequential slides were obtained for the
identiﬁcation of senescent tumor cells (SA-b-Gal activity, as
described) and for laser microdissection.
Statistical Analysis
The assays were performed in triplicate. The data were analyzed
with GraphPad Prism software, version 5.00, for Windows
(GraphPad Software, La Jolla, CA). The data are expressed as the
mean  standard error of the mean. Differences between groups
were analyzed using a 2-tailed unpaired t test and Fisher’s exact test,
as appropriate. The nonparametric Mann-Whitney U test was used
to compare 2 populations with independent observations. The level
of statistical signiﬁcance was set at P < .05.
Results
Low-Dose 5-FU Induces Cellular Senescence in HCT 116
Colorectal Cancer Cells
To address the paracrine effects of the secretome from colorectal
cancer cells on their nonsenescent counterparts, we ﬁrst induced
cellular senescence by exposing HCT 116 colorectal cancer cells to
low-dose 5-FU (5.0 mM) for 7 days. Then, we checked for the
presence of senescent cells by cytochemical detection of the activity
of SA-b-Gal. We observed that > 80% of the cells exposed to 5-FU
displayed high levels of SA-b-Gal compared with that displayed by
the control cells (Figure 1A). In agreement with the senescent state,
5-FUetreated cells displayed residual BrdU incorporation (w6%
BrdU-positive cells) compared with the nontreated controls (w58%BrdU-positive cells; Figure 1B) and reduced proliferation (ala-
marBlue assay; P < .05 to P < .01; Figure 1C). The measurement
of caspase-3 and -7 activities showed that apoptosis contributed
little to the reduced cell numbers observed in the HCT 116 pop-
ulations exposed to low doses of 5-FU (P < .01 to P < .001;
Figure 1D). We concluded that low-dose 5-FU induced HCT 116
cells into a senescent state.
Secretome of Senescent HCT 116 Cells Stimulates
Proliferation of Nonsenescent Cells
To test the paracrine effects of the SAS, we characterized the
cytokine proﬁle of culture media conditioned by HCT 116 cells
induced into senescence by 5-FU, termed “SAS medium.” Controls
were provided by culture media conditioned by exponentially
growing HCT 116 cells (see the “Materials and Methods” section).
This cytokine proﬁle, assessed using a dedicated array, showed SAS
media were enriched in IL-8, TGF-a, VEGF, cystatin C, lipocalin 2
(LCN2), macrophage migration inhibitory factor, extracellular
matrix metalloproteinase inducer, and urokinase-type plasminogen
activator receptor (Figure 2A,B). Because IL-8 is a hallmark of SASs,
we further quantiﬁed this cytokine using ELISA. The results
conﬁrmed a signiﬁcant increase of IL-8 in SAS medium (P < .05;
Figure 2C).
Analyses of cell viability using the alamarBlue assay showed that
after culturingHCT 116 cells for 24 hours in presence of SAS or non-
SASmedia (controls), the SASmedia induced a signiﬁcant increase in
cell proliferation (P < .05; Figure 3), in accordance with previously
published data for other cell types.15,16,18 To checkwhether this effect
was cell type speciﬁc, we also tested the effects of SAS media on
proliferation in a different colon cancer cell line (SW48) and in a rectal
cancer cell line (SW837). These results conﬁrmed the stimulatory
effect of the SAS on the proliferation of these cell lines (Figure 3).
These data suggest that the secretome of HCT 116 cells induced to
senesce by exposure to 5-FU exerts a positive effect on the prolifera-
tion of cycling colorectal and rectal cancer cells.Clinical Colorectal Cancer Month 2015 - 5
Figure 4 The Secretome of Senescent Colon Cancer Cells Induces Epithelial-to-Mesenchymal Transition and Increases Invasiveness.
(A) HCT 116, SW48, and SW837 Cells Incubated With Conditioned Media, Either NoneSenescence-Associated Secretome
(SAS) (Control) or SAS-Enriched, for 72 Hours and Stained by Immunoﬂuorescence With AntieE-Cadherin Antibodies (Red
Signal); Nuclei Were Counterstained With 40,6-Diamidino-2-Phenylindole (DAPI) (Blue Signal). The Cellular Peripheral E-
cadherin Signal Is Either Lost or Signiﬁcantly Reduced in Cells Exposed to SAS Medium. (B) Cells Exposed to Conditioned
Media (Non-SAS [Control] vs. SAS-Enriched) Were Analyzed by Reverse Transcriptase Quantitative Polymerase Chain
Reaction for Expression of Epithelial-to-Mesenchymal Transition-Related Markers (Slug, Zeb1a, Snail, Fibronectin, and
Vimentin). Expression of These Genes Was Normalized for GAPDH Expression. (C) The Chemoattractant Properties of
Conditioned Media (Non-SAS [Control] vs. SAS-Enriched Medium) Were Monitored Using a Standard Invasion Assay (See
“Materials and Methods”). Migrating Cells Were Scored by Quantiﬁcation of Calcein AM-Associated Fluorescence. All
Determinations Were Done in Triplicate, and Data Are Given as Scatter Plots of the Mean ± Standard Error of Mean. *P < .05;
**P < .01; ***P < .001, Unpaired t Test
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6 - CliSecretome of Senescent Colon Cancer Cells Promotes EMT
and Increased Invasiveness
Next, we investigated whether the SAS could affect the epithelial
phenotype of proliferating colon and rectal cancer cells. We found
that in contrast to incubation with non-SAS control medium, in-
cubation with SAS medium induced loss of E-cadherin expression,
as assessed by immunoﬂuorescence with E-cadherinespeciﬁc anti-
bodies (Figure 4A). Moreover, our results showed a signiﬁcant in-
crease (P < .05 to P < .001) in mRNA levels of Slug, ZEB1a, Snail,
ﬁbronectin, and vimentin (Figure 4B), all hallmarks of EMT in
HCT 116, SW48, and SW837 cells. Also, HCT 116 cells exposed
to SAS medium displayed increased invasiveness compared with
control cells exposed to non-SAS conditioned medium (P < .001;
Figure 4C).nical Colorectal Cancer Month 2015Finally, we checked whether the observed effects of the SAS on
stimulation of EMT and invasive behavior were dependent on the
drug used to induce the SAS. Thus, we obtained media conditioned
by HCT 116 cells that were induced into senescence by brief
exposure to doxorubicin (0.5 mM, 4 hours). This treatment resulted
in a proportion of senescent cells (SA-b-Gal staining, w 80%)
similar to that obtained after exposure to 5-FU (data not shown).
Also, within the constraints of the array we used, the cytokine
proﬁle of the SAS obtained from doxorubicin-induced senescent
HCT 116 cells was similar to that obtained from 5-FUeinduced
senescent cells (Supplemental Figure 1AeC; online version).
Similarly, exposure to the doxorubicin-SAS medium also induced
upregulation of EMT-related genes in proliferating HCT 116 cells
(Supplemental Figure 1D; online version). In summary, these data
Table 1 Patient and Tumor Characteristics
Characteristic
Neoadjuvant CRT
Yes (n [ 7) No (n [ 12) P Value
Male gender (%) 57 83 .3047a
Age (years) .7553b
Median 70.8 68.6
Range 50-84 43-89
pT classiﬁcationc
(%)
.3047a
pT2 43 17
pT3 57 83
RLN involvement
(%)
71 50 .6332a
Abbreviations: CRT ¼ chemoradiotherapy; RLN ¼ regional lymph nodes.
aFisher’s exact test.
bStudent’s t test.
cStaging according to American Joint Committee on Cancer Staging Manual, 7th edition.
Joana Tato-Costa et alhave shown that in the presence of senescence-speciﬁc secretomes,
colon and rectal cancer cells are induced into EMT and acquire
increased invasiveness.
Neoadjuvant Chemotherapy Promotes Emergence of
Senescence and EMT in Human Rectal Cancers
The previous data highlighted a relevant set of paracrine effects
exerted by the SAS on target proliferating colon cancer cells (ie,
induction of EMT). We then wondered whether these effects might
be of more broad clinical relevance and, thus, observable in tumors
from patients with rectal cancer.
Because the initial specimens collected for diagnostic purposes
were routinely embedded in parafﬁn and, thus, did not allow for
accurate detection of senescent cancer cells in untreated tumors, an
assessment of the effects of CRT on the induction of cell senescence
in each patient was precluded. We, therefore, selected as a model
system rectal cancer samples collected at surgery from patients who
had or had not undergone neoadjuvant CRT (Table 1). These 2
groups were similar concerning gender distribution, mean age,
pathologic primary tumor classiﬁcation (pT), and regional lymph
node involvement (P ¼ .3047, P ¼ .7553, P ¼ .3047, and
P ¼ .6332, respectively).
In these samples, we tested whether CRT induced senescence in
tumor cells and whether the proximity to senescent cancer cells
correlated with the induction of EMT. Thus, frozen rectal cancer
samples from patients who had either undergone CRT (n¼ 7) or had
not (controls; n ¼ 12) were sectioned, and randomly chosen clusters
of cancer cells were laser microdissected free of stromal components
for quantitative analysis of speciﬁc mRNA using RT-qPCR.
We initially tested for the expression of genes that strongly
correlate with the senescent state (ie, p21Waf1/Cip1, p16INK4a,
and IL-8). Both p21Waf1/Cip1 and IL-8 were upregulated in the
group of patients who had undergone neoadjuvant CRT (P < .05;
Figure 5A) compared with the control (non-CRT) samples, sug-
gesting that CRT induced cellular senescence in these tumors. Next,
we analyzed the expression of the EMT-related markers, Snail, Slug,
and vimentin in the same samples. These genes were signiﬁcantlyupregulated in tumors from patients treated with neoadjuvant CRT
(P < .05; Figure 5A).
Subsequently, in samples from patients who had undergone
neoadjuvant CRT, we obtained serial sections in which every other
section was stained for SA-b-Gal and used to directly assess the
presence of senescent cells in the contiguous sections (stained with
cresyl violet). Staining for SA-b-Gal was detected in discrete regions
of tumor tissue, and cancer cell clusters enriched with senescent cells
were identiﬁed and selected (Supplemental Figure 2A; online
version). These clusters, together with nearby clusters (> 700 mm),
in which senescent cells were absent (controls), were laser micro-
dissected and used for the analysis of expression of p21Waf1/Cip1
and IL-8 and of the EMT markers Snail, Slug and vimentin using
RT-qPCR (Supplemental Figure 2B; online version). As expected,
p21Waf1/Cip1 and IL-8 were upregulated in tumor cell clusters
enriched in senescent cells (Figure 5B). More importantly, Snail,
Slug, and vimentin also showed increased expression in these same
tumor cell clusters, indicating that senescence and EMT co-
occurred within the same microenvironment (Figure 5B). It is
unlikely that senescent cells themselves were the source of increased
expression of genes related to EMT, because this is not part of the
drug-induced senescent phenotype. We found that the expression of
Snail and vimentin was signiﬁcantly lower in HCT 116 cells that
reached senescence by exposure to 5-FU compared with HCT 116
cells induced into EMT (P < .001; Supplemental Figure 3; online
version).
Discussion
Good evidence has shown that the tumor microenvironment has
a role in cancer progression.25 Recently, it was shown that in pa-
tients with rectal cancer receiving neoadjuvant therapy, the patterns
of gene expression of cancer-associated ﬁbroblasts provided predic-
tive power for distant recurrence and prognosis. This ﬁnding sup-
ports a role for the microenvironment in rectal cancer behavior.26
Also, the treatment of patients with cancer using DNA-damaging
agents, in both neoadjuvant and curative settings, was shown to
induce epithelial cancer cells into accelerated forms of senescence.14
Senescent cells derived from either nontransformed cells or cancer
cells are associated with SASs.17 Despite the powerful paracrine
effects exerted by SASs in vitro,15-19 to what extent senescent cancer
cells present within tumors inﬂuence the microenvironment and,
eventually, cancer progression has remained elusive.12,20,21
We initially interrogated the cytokine composition of the SAS
from colon cancer cells (HCT 116) induced to senesce by exposure
to either 5-FU, which targets cells in the S phase and interferes with
DNA repair, or to doxorubicin, a DNA-damaging drug. We have
presented evidence that senescent colon cancer cells are able to
consistently secrete several cytokines to high levels (eg, IL-8), irre-
spectively of whether senescence was induced by 5-FU or doxoru-
bicin. In addition, we have provided evidence, for the ﬁrst time, that
CD147, cystatin C, LCN2, and TGF-a are also SAS-related mol-
ecules. As previously described for other cell types,16,17,19 in 2
different colon cancer cell lines (HCT 116 and SW48) and 1 rectal
cancer cell line (SW837), the paracrine effects of the SAS included
increased proliferation and invasiveness and the induction of EMT,
all of which correlate with aggressive cell behavior.Clinical Colorectal Cancer Month 2015 - 7
Figure 5 Neoadjuvant (Neo.) Chemotherapy Promotes Emergence of Senescence and Epithelial-to-Mesenchymal Transition (EMT) in
Human Rectal Cancers. (A) Total RNA Was Extracted From Microdissected Clusters of Cancer Cells From Human Rectal
Cancer Samples Obtained From Patients Who Had Either Received Neoadjuvant Chemoradiotherapy (Neo. CRTD; n[ 7) or
Not (Neo. CRTL [Controls]; n[ 12) Before Surgery. Speciﬁed mRNA Were Quantiﬁed by Reverse Transcriptase Quantitative
Polymerase Chain Reaction (RT-qPCR) and Normalized to GAPDH Expression. (B) In Rectal Cancer Samples From Patients
Subjected to Neoadjuvant Chemoradiotherapy (n [ 4), Cancer Cell Clusters Enriched in Senescent Cells and Clusters
Located Nearby (> 700 mm) and Certiﬁed as Devoid of Senescent Cells (Controls) Were Laser Microdissected and Used for
Quantiﬁcation of Speciﬁc mRNA by RT-qPCR. Note the Increase in Both Senescence (p21Waf1/Cip1, Interleukin-8) and EMT
Markers (Snail, Slug, Vimentin) in Tumor Areas Enriched for Senescent Cells. Whiskers Represent the Minimum and
Maximum Across the Data. *P < .05, Mann-Whitney U Test
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8 - CliOur data also showed that, in contrast to cells undergoing EMT,
senescent cells express relatively low mRNA levels of EMT markers
such as Snail and vimentin, thus allowing a distinction between
these 2 cellular outcomes using gene expression criteria. Given the
consistent induction of EMT by SASs and the known relevance of
EMT in cancer behavior, we addressed whether the paracrine effects
of senescent cells, by way of the SAS, on EMT induction seen
in vitro might be recapitulated in vivo, in the clinical setting. Our
data showed that in tumor sections obtained from patients with
rectal cancer, the senescent cells, identiﬁed by their strong staining
for SA-b-Gal, were present within discrete clusters of cancer cells.
Laser microdissection of these clusters and of nearby clusters devoid
of senescent cells was performed and followed by RT-qPCR analysis
of the senescence and EMT markers, p21Waf1/Cip1 and IL-8 and
Snail, Slug, and vimentin, respectively. This showed that these ge-
netic markers were coexpressed at greater levels in the cancer
cell clusters enriched for senescent cells relative to the nearby clus-
ters (> 700 mm) devoid of senescent cells. These data stronglynical Colorectal Cancer Month 2015suggest the co-occurrence of senescence and EMT within the same
cell clusters. They are also consistent with the inﬂuence of senescent
cancer cells on the induction of EMT being relatively short range
and not affecting nearby niches of cancer cells.
Tumor recurrence after preoperative CRT followed by surgery
with curative intent remains a major problem to successful cancer
treatment, affecting 15% to 20% of patients diagnosed with locally
advanced rectal cancer.1,2 Tumor regression after neoadjuvant CRT
has been used to evaluate the treatment response and prognosis.27,28
However, the results of neoadjuvant therapy have ranged from a
lack of effectiveness to complete pathologic remission. Clearly, the
identiﬁcation of novel predictive biomarkers of disease progression
is crucial to improve adjuvant therapeutic agents and follow-up
strategies.
Conclusion
Both 5-FU and doxorubicin robustly induced senescence and
SASs in cultured HCT 116 cells. The effects of the SASs on the
Joana Tato-Costa et alproliferating colon and rectal cells translated into increased prolif-
eration, invasiveness, and induction of EMT. In clinical samples
from patients who had undergone neoadjuvant CRT, senescence
and EMT co-occurred within a fraction of cancer cell clusters.
Future studies are needed to determine whether after neoadjuvant
therapy for rectal cancer, the presence of senescent cells and EMT-
related changes in their microenvironment add prognostic power
regarding cancer recurrence and patient survival.
Clinical Practice Points
 In patients with rectal cancer, locoregional relapse and distant
metastasis are major events leading to death.
 Senescent cells exhibit a secretory phenotype that can affect
cancer cell behavior and, eventually, clinical prognosis.
 We focused on therapy-induced cancer cell senescence and on
the effects exerted by senescent cells on cancer cell behavior and
the tumor microenvironment.
 We found that, in vitro, the secretomes of senescent cells induce
invasion and EMT.
 The effects of senescent cancer cells on EMT appear to be
recapitulated in clinical samples from patients with rectal cancer
who had undergone neoadjuvant CRT.
 CRT induced cancer cell senescence, and senescence and EMT
coexisted within the same cancer cell niches.
 The results of the present study have provided ﬁrst-hand evidence
that senescent cells can alter the tumor microenvironment and
raises the possibility that the combined assessment of senescence
and EMT could be useful in guiding treatment after CRT.Acknowledgments
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Supplemental Figure 1 Cytokine Screening Array and Epithelial-to-Mesenchymal Transition (EMT) Induction by Senescence-
Associated Secretome (SAS) Medium Obtained From Doxorubicin-Induced Senescent HCT 116 Colon Cancer
Cells. (A) Cytokine Screening Arrays Incubated With Either SAS or Non-SAS (Controls) Media. SAS Media Were
Conditioned by HCT 116 Cells Induced Into Senescence by Doxorubicin. Each of the Probed Cytokines Was
Detected in Duplicate. (B) Proﬁles of Mean Spot Pixel Density Were Created Using ImageJ Software. (C) SAS
Medium Conditioned by Senescent HCT 116 cells (Doxorubicin-Induced Senescence) Was Enriched in
Interleukin (IL)-8 Relative to Control (Non-SAS) Medium. Quantiﬁcations Were Performed by Enzyme-Linked
Immunosorbent Assay. (D) Expression Levels of mRNA From EMT-Related Genes in Proliferating HCT 116 cells
Incubated for 72 Hours With Either SAS Medium or Non-SAS Medium (Controls). Gene Expression Was
Assessed by Reverse Transcriptase Quantitative Polymerase Chain Reaction and Normalized to GAPDH
Expression. All Determinations Were Done in Triplicate, and Data Are Presented as Scatter Plots of the Mean
± Standard Error of the Mean. *P < .05, Unpaired t Test
Abbreviations: EMMPRIN ¼ extracellular matrix metalloproteinase inducer; FGF-19 ¼ ﬁbroblast growth factor 19; IGFBP2, insulin-like growth factor binding protein 2; MIC-1 ¼ macrophage inhibitory
cytokine 1; MIF ¼ migration inhibitory factor; PAI-1 ¼ plasminogen activator inhibitor 1; PDGF-AA ¼ platelet-derived growth factor-AA; TGF-a ¼ transforming growth factor-a; uPAR ¼ urokinase-
type plasminogen activator receptor; VEGF ¼ vascular endothelial growth factor.
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Supplemental Figure 2 Representative Sequential Frozen Sections of Human Rectal Cancer Tissue Selected for Isolation of
Senescent-Positive and Senescent-Negative Epithelial Cell Populations by Laser Microdissection. (A) Section
Stained for Senescence-Associated b-Galactosidase (SA-b-Gal) Activity to Identify Clusters of Cancer Cells
Harboring Senescent Cells (Blue Staining; Upper Inset, Left; Arrows, Top Right) and Nearby Clusters Devoid of
SA-b-Gal Staining (Lower Inset, Left; Bottom Right). Counterstaining Was With Nuclear Fast Red. (B)
Contiguous Section Stained With Cresyl Violet in Which Areas Selected for Microdissection Are Delineated
(Senescent-Positive, Blue Lines; Senescent-Negative, Already Laser-Ablated, Red Lines).
Magniﬁcation, 3100 (A, left) and 3200 (A, Right; B)
Joana Tato-Costa et al
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Supplemental Figure 3 Epithelial-to-Mesenchymal Transition
(EMT)-Related Genes Are Poorly
Expressed in Senescent Cells.
Expression of Vimentin and Snail Were
Assessed by Reverse Transcriptase
Quantitative Polymerase Chain
Reaction in HCT 116 Cells, Either
Senescent or Induced Into EMT by
Exposure to SAS-Enriched Medium.
All Determinations Were Done in
Triplicate, and Data Are Given as
Scatter Plots of the Mean ± Standard
Error of the Mean. ***P < .001,
Unpaired t Test
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